RECOMBINANT VESICULOVIRUSES AND THEIR USES

Abstract: The present invention provides recombinant replicable vesiculoviruses. The invention provides a method which, for the first time, successfully allows the production and recovery of replicable vesiculoviruses, as well as recombinant replicable vesiculoviruses, from cloned DNA, by a method comprising expression of the full-length positive-strand vesiculovirus antigenomic RNA in host cells. The recombinant vesiculoviruses do not cause serious pathology in humans, can be obtained in high titers, and have use as vaccines. The recombinant vesiculoviruses can also be inactivated for use as killed vaccines.

Description: RECOMBINANT VESICULOVIRUSES AND THEIR USES This invention was made with government support under grant number R37 AI243245 awarded by the National Institutes of Health. The government has certain rights in the invention. 1. INTRODUCTION The present invention relates to recombinant vesiculoviruses which are replicable and capable of expressing foreign nucleic acid contained in their genome. Also provided are inactivated forms of the recombinant viruses. The vesiculoviruses are useful in vaccine formulations to prevent or treat various diseases and disorders. 2. BACKGROUND OF THE INVENTION 2.1. RHABDOVIRUSES Rhabdoviruses are membrane-enveloped viruses that are widely distributed in nature where they infect vertebrates, invertebrates, and plants. There are two distinct genera within the rhabdoviruses, the Lyssavirus genus and the Vesiculovirus genus. Rhabdoviruses have single, negative-strand RNA genomes of 11-12,000 nucleotides (Rose and Schubert, 1987, Rhabdovirus genomes and their products, in The Viruses : The Rhabdoviruses , Plenum Publishing Corp. , NY, pp. 129-166) . The virus particles contain a helical, nucleocapsid core composed of the genomic RNA and protein. Generally, three proteins, termed N (nucleocapsid) , P (formerly termed NS, originally indicating nonstructural) , and L (large) are found to be associated with the nucleocapsid. An additional matrix (M) protein lies within the membrane envelope, perhaps interacting both with the membrane and the nucleocapsid core. A single glycoprotein (G) species spans the membrane and forms the spikes on the surface of the virus particle. Because the genome is the negative sense [i.e., complementary to the RNA sequence (positive sense) that functions as mRNA to directly produce encoded protein] , rhabdoviruses must encode and package an RNA-dependent RNA polymerase in the virion (Baltimore et al., 1970, Proc. Natl. Acad. Sci. USA 66: 572-576) , composed of the P and L proteins. This enzyme transcribes genomic RNA to make subgenomic MRNAS encoding the 5-6 viral proteins and also replicates full-length positive and negative sense RNAs. The genes are transcribed sequentially, starting at the 3' end of the genomes. The same basic genetic system is also employed by the paramyxoviruses and filoviruses. The prototype rhabdovirus, vesicular stomatitis virus (VSV) , grows to very high titers in most animal cells and can be prepared in large quantities. As a result, VSV has been widely used as a model system for studying the replication and assembly of enveloped RNA viruses. The study of VSV and related negative strand viruses has been limited by the inability to perform direct genetic manipulation of the virus using recombinant DNA technology. The difficulty in generating VSV from DNA is that neither the full-length genomic nor antigenomic RNAs are infectious. The minimal infectious unit is the genomic RNA tightly bound to 1,250 subunits of the nucleocapsid (N) protein (Thomas et al., 1985, J. Virol. 54:598-607) and smaller amounts of the two virally encoded polymerase subunits, L and P. To reconstitute infectious virus from the viral RNA, it is necessary first to assemble the N protein-RNA complex that serves as the template for transcription and replication by the VSV polymerase. Although smaller negative-strand RNA segments of the influenza virus genome can be packaged into nucleocapsids in vitro , and then rescued in influenza infected cells (Enami et al., 1990, Proc. Natl. Acad. Sci. USA 87:3802-3805; Luytjes et al., 1989, Cell 59:1107-1113), systems for packaging the much larger rhabdoviral genomic RNAs in vitro are not yet available. Recently, systems for replication and transcription of DNA-derived minigenomes or small defective RNAs from rhabdoviruses (Conzelmann and Schnell, 1994, J. Virol. 68:713-719; Pattnaik et al., 1992, Cell 69:1011-1120) and paramyxoviruses (Calain et al., 1992, Virology 191:62-71; Collins et al., 1991, Proc. Natl. Acad. Sci. USA 88:9663-9667; Collins et al., 1993, Virology 195:252-256; De and Banerjee, 1993, Virology 196:344-348; Dimock and Collins, 1993, J. Virol. 67:2772-2778; Park et al., 1991, Proc. Natl. Acad. Sci. USA 88:5537-5541) have been described. In these systems, RNAs are assembled into nucleocapsids within cells that express the viral N protein and polymerase proteins. Although these systems have been very useful, they do not allow genetic manipulation of the full-length genome of infectious viruses. The recovery of rabies virus from a complete cDNA clone was published recently (Schnell et al., 1994, EMBO J. 13:4195-4203). The infectious cycle was initiated by expressing the antigenomic (full-length positive strand) RNA in cells expressing the viral N, P, and L proteins. Although rabies virus is a rhabdovirus, it is structurally and functionally different from the vesiculoviruses. Rabies virus is a Lyssavirus, not a Vesiculovirus. Lyssaviruses invade the central nervous system. Vesiculoviruses invade epithelial cells, predominantly those of the tongue, to produce vesicles. Rabies virus causes encephalitis in a variety of animals and in humans, while VSV causes an epidemic but self-limiting disease in cattle. In sharp contrast to VSV-infected cells, rabies virus produces little or no cytopathic effect in infected cell culture, replicates less efficiently than VSV in cell culture, and causes little depression of cellular DNA, RNA or protein synthesis in infected cell cultures (see Baer et al., 1990, in Virology, 2d ed. , Fields et al. (eds.), Raven Press, Ltd., NY, pp. 883, 887) . Indeed, there is no cross-hybridization observed between the genomes of rabies virus and VSV, and sequence " homology between the two genomes is generally discernable only with the aid of computer run homology programs. The differences between vesiculoviruses and rabies virus, and the extremely rare nature of rabies virus recovery from cDNA (~10 8 cells are transfected to yield one infectious cell) , renders it unpredictable whether the strategy used with rabies virus would be successful for viruses of a different genus, i.e., the vesiculoviruses. The recovery of infectious measles virus, another negative strand RNA virus, from cloned cDNA has been attempted, without success (see Ballart et al., 1990, EMBO J. 9(2):379-384 and the retraction thereof by Eschle et al., 1991, EMBO J. 10(11) :3558) . 2.2. VACCINES The development of vaccines for the prevention of viral, bacterial, or parasitic diseases is the focus of much research effort. Traditional ways of preparing vaccines include the use of inactivated or attenuated pathogens. A suitable inactivation of the pathogenic microorganism renders it harmless as a biological agent but does not destroy its immunogenicity. Injection of these "killed" particles into a host will then elicit an immune response capable of preventing a future infection with a live microorganism. However, a major concern in the use of killed vaccines (using inactivated pathogen) is failure to inactivate all the microorganism particles. Even when this is accomplished, since killed pathogens do not multiply in their host, or for other unknown reasons, the immunity achieved is often incomplete, short lived and requires multiple immunizations. Finally, the inactivation process may alter the microorganism's antigens, rendering them less effective as immunogens. Attenuation refers to the production of strains of pathogenic microorganisms which have essentially lost their disease-producing ability. One way to accomplish this is to subject the microorganism to unusual growth conditions and/or frequent passage in cell culture. Mutants are then selected which have lost virulence but yet are capable of eliciting an immune response. Attenuated pathogens often make good immunogens as they actually replicate in the host cell and elicit long lasting immunity. However, several problems are encountered with the use of live vaccines, the most worrisome being insufficient attenuation and the risk of reversion to virulence. An alternative to the above methods is the use of subunit vaccines. This involves immunization only with those components which contain the relevant immunological material. Vaccines are often formulated and inoculated with various adjuvants. The adjuvants aid in attaining a more durable and higher level of immunity using small amounts of antigen or fewer doses than if the immunogen were administered alone. The mechanism of adjuvant action is complex and not completely understood. However, it may involve the stimulation of cytokine production, phagocytosis and other activities of the reticuloendothelial system as well as a delayed release and degradation of the antigen. Examples of adjuvants include Freund's adjuvant (complete or incomplete) , Adjuvant 65 (containing peanut oil, mannide monooleate and aluminum monostearate) , the pluronic polyol L-121, Avridine, and mineral gels such as aluminum hydroxide, aluminum phosphate, etc. Freund's adjuvant is no longer used in vaccine formulations for humans because it contains nonmetabolizable mineral oil and is a potential carcinogen. 3. SUMMARY OF THE INVENTION The present invention provides recombinant replicable vesiculoviruses. The prior art has unsuccessfully attempted to produce replicable vesiculoviruses from cloned DNA. In contrast, the invention provides a method which, for the first time, has successfully allowed the production and recovery of replicable vesiculoviruses, as well as recombinant replicable vesiculoviruses, from cloned DNA. The vesiculoviruses of the invention are produced by providing in an appropriate host cell: (a) DNA that can be transcribed to yield (encodes) vesiculovirus antigenomic (+) RNA (complementary to the vesiculovirus genome) , (b) a recombinant source of vesiculovirus N protein, (c) a recombinant source of vesiculovirus P protein, and (d) a recombinant source of vesiculovirus L protein; under conditions such that the DNA is transcribed to produce the antigenomic RNA, and a vesiculovirus is produced that contains genomic RNA complementary to the antigenomic RNA produced from the DNA. The invention provides an infectious recombinant vesiculovirus capable of replication in an animal into which the recombinant vesiculovirus is introduced, in which the genome of the vesiculovirus comprises foreign RNA which is not naturally a part of the vesiculovirus genome. The recombinant vesiculovirus is formed by producing vesiculoviruses according to the method of the invention, in which regions of the DNA encoding vesiculovirus antigenomic (+) RNA that are nonessential for viral replication have been inserted into or replaced with foreign DNA. In a preferred embodiment, the foreign RNA contained within the genome of the recombinant vesiculovirus (originally encoded by the foreign DNA) , upon expression in an appropriate host cell, produces a protein or peptide that is antigenic or immunogenic. The recombinant vesiculoviruses of the invention have use as vaccines. In one embodiment, where the foreign RNA directs production of an antigen that induces an immune response against a pathogen, the vaccines of the invention have use in the treatment or prevention of infections by such a pathogen (particularly a pathogenic microorganism) , and its clinical manifestations, i.e., infectious disease. In a preferred embodiment, such an antigen displays the antigenicity or immunogenicity of an envelope glycoprotein of a virus other than a vesiculovirus, and the antigen is incorporated into the vesiculovirus envelope. The recombinant vesiculoviruses also have uses in diagnosis, and monitoring progression of infectious disorders, including response to vaccination and/or therapy. In another embodiment, where the foreign RNA directs production of an antigen that induces an immune response against a tumor, the recombinant viruses of the invention have uses in cancer immunoprophylaxis, immunotherapy, and diagnosis, and monitoring of tumor progression or regression. The recombinant vesiculoviruses can be used as live vaccines, or can be inactivated for use as killed vaccines. The recombinant viruses can also be used to produce large quantities of readily purified antigen, e . g. , for use in subunit vaccines. The invention also provides vaccine formulations, kits, and recombinant host cells. 4. DESCRIPTION OF THE FIGURES Figure l. Nucleotide sequence of plasmid pVSVFL(+) , showing the complete DNA sequence that is transcribed to produce VSV antigenomic (+) RNA, and predicted sequences of the encoded VSV proteins. [N protein: SEQ ID NO:2; P protein: SEQ ID NO:3; M protein: SEQ ID NO:4; G protein: SEQ ID NO:5; L protein: SEQ ID NO:6] The noncoding and intergenic regions are observable. The upper line of sequence (SEQ ID NO:l) is the VSV antigenomic positive strand; lower line = SEQ ID NO:7. Restriction sites are indicated. The transmembrane and cytoplasmic domains of the G protein are also indicated. The sequences of the first T7 RNA polymerase promoter (SEQ ID NO:8), the second T7 RNA polymerase promoter (SEQ ID N0:9); leader sequence (SEQ ID NO: 10), T7 RNA polymerase transcription termination signal (SEQ ID NO: 11), and the sequence that is transcribed to produce the HDV ribozyme (SEQ ID NO: 12) are shown. Figure 2. Nucleotide sequence of a portion of plasmid pVSVSSl, showing the synthetic DNA insert containing the polylinker region inserted between the G and L coding regions (3' of G and 5' of L) containing unique restriction enzyme recognition sites, namely, Xmal, NotI, and Smal. Upper line of sequence: SEQ ID NO:13; lower line of sequence: SEQ ID NO:14. Figure 3. Gene junctions of VSV. The nucleotide sequences at the 3' end of the leader RNA and the 5' and 3' ends of each mRNA are shown along with the corresponding genomic sequences (vRNA) (SEQ ID NO:15-31). The intergenic dinucleotides are indicated by bold letters. From Rose and Schubert, 1987, in The Viruses : The Rhabdoviruses , Plenum Press, NY, pp. 129-166, at p. 136. Figure 4. Plasmid DNA construction. A. The diagram illustrates the cloned VSV genomic sequence and the four DNA fragments (numbered 1-4) that were used to generate the plasmid pVSVFL(- ) . The horizontal arrows represent PCR primers used to generate fragments 1 and 3. B. Diagram of the plasmid pVSVFL(+) that gives rise to infectious VSV. The locations of the VSV genes encoding the five proteins N, P, M, G, and L are shown. The stippled region from Sac I to Xho I represents the pBSSK + vector sequence, and the hatched segments represent the regions of the VSV genome generated by PCR. Transcription from the T7 promoter generates the complete (+) strand VSV RNA. Figure 5. Proteins present in wild-type and recombinant VSVs. Proteins from 1% of the virus recovered from approximately 5 x 10 6 infected BHK cells were separated by SDS-PAGE (10% acrylamide) and visualized by staining with Coomassie brilliant blue. Positions of the five VSV proteins are indicated. Figure 6. Identification of a restriction enzyme recognition sequence in the recombinant VSV. A 620 nucleotide segment of genomic RNA isolated from wildtype and recombinant VSV was amplified by reverse transcription and PCR using the primers 5'-CATTCAAGACGCTGCTTCGCAACTTCC (SEQ ID NO:32) and 5'-CATGAATGTTAACATCTCAAGA (SEQ ID NO:33). Controls in which reverse transcriptase was omitted from the reaction are indicated. DNA samples were either digested with Nhe I or left undigested prior to electrophoresis on a 6% polyacrylamide gel as indicated. DNA was detected by staining with ethidium bromide. Sizes of DNA markers are indicated on the left. Figure 7. Autoradiogram showing the sequence of genomic RNA from recombinant VSV. RNA prepared from recombinant VSV was sequenced by the dideoxy method using reverse transcriptase. The written sequence corresponds to nucleotides 1563-1593 in the G mRNA (Rose and Gallione, 1981, J. Virol. 39:519-528) . The underlined sequence represents the four nucleotides that were changed to generate the Nhe I site. Figure 8. Protein analysis of recombinant VSV expressing the glycoprotein from the New Jersey serotype. Proteins from 1% of the virus pelleted from the medium of approximately 5 x 10 6 BHK cells infected for 24 hours with wildtype VSV, (lane 1) , recombinant "VSV mjG (lane 2) or wildtype VSV NJ (lane 3) were separated by SDS-PAGE (10% acrylamide) . The proteins were visualized by staining with Coomassie brilliant blue. Positions of viral proteins are indicated. 5. DETAILED DESCRIPTION OF THE INVENTION The present invention provides recombinant replicable vesiculoviruses. The prior art has unsuccessfully attempted to produce replicable vesiculoviruses from cloned DNA. In contrast, the invention provides a method which, for the first time, has successfully allowed the production and recovery of replicable vesiculoviruses, as well as recombinant replicable vesiculoviruses, from cloned DNA. Expression of the full-length positive-strand vesiculovirus RNA in host cells has successfully allowed the generation of recombinant vesiculoviruses from DNA, providing recombinant viruses that do not cause serious pathology in humans and that can be obtained in high titers, that have use as vaccines. The vesiculoviruses of the invention are produced by providing in an appropriate host cell: (a) DNA that can be transcribed to yield (encodes) vesiculovirus antigenomic (+) RNA (complementary to the vesiculovirus genome) , (b) a recombinant source of vesiculovirus N protein, (c) a recombinant source of vesiculovirus P protein, and (d) a recombinant source of vesiculovirus L protein; under conditions such that the DNA is transcribed to produce the antigenomic RNA, and a vesiculovirus is produced that contains genomic RNA complementary to the antigenomic RNA produced from the DNA. The invention provides an infectious recombinant vesiculovirus capable of replication in an animal into which the recombinant vesiculovirus is introduced, in which the genome of the vesiculovirus comprises foreign RNA which is not naturally a part of the vesiculovirus genome. The recombinant vesiculovirus is formed by producing vesiculoviruses according to the method of the invention, in which regions of the DNA encoding vesiculovirus antigenomic (+) RNA that are nonessential for viral replication have been inserted into or replaced with foreign DNA. Since the viruses are replicable (i.e., not replication-defective) , they encode all the vesiculovirus machinery necessary for replication in a cell upon infection by the virus. In a preferred embodiment, the recombinant vesiculovirus is a recombinant vesicular stomatitis virus (VSV) . In another preferred embodiment, the foreign RNA contained within the genome of the recombinant vesiculovirus (originally encoded by the foreign DNA) , upon expression in an appropriate host cell, produces a protein or peptide that is antigenic or immunogenic. Such an antigenic or immunogenic protein or peptide whose expression is directed by the foreign RNA (present in the negative sense) within the vesiculovirus genome (by expression from the (+) antigenomic message) shall be referred to hereinafter as the "Antigen." Appropriate Antigens include but are not limited to known antigens of pathogenic microorganisms or of tumors, as well as fragments or derivatives of such antigens displaying the antigenicity or immunogenicity of such antigens. A protein displays the antigenicity of an antigen when the protein is capable of being immunospecifically bound by an antibody to the antigen. A protein displays the immunogenicity of an antigen when it elicits an immune response to the antigen (e.g., when immunization with the protein elicits production of an antibody that immunospecifically binds the antigen or elicits a cell-mediated immune response directed against the antigen) . The recombinant vesiculoviruses of the invention have use as vaccines. In one embodiment, where the foreign RNA directs production of an Antigen (originally encoded by the foreign DNA used to produce the recombinant vesiculovirus or its predecessor) that induces an immune response against a pathogen, the vaccines of the invention have use in the treatment or prevention of infections by such a pathogen (particularly a pathogenic microorganism) , and its clinical manifestations, i.e., infectious disease. The invention thus provides methods of prevention or treatment of infection and infectious disease comprising administering to a subject in which such treatment or prevention is desired one or more of the recombinant vesiculoviruses of the invention. The recombinant vesiculoviruses also have uses in diagnosis, and monitoring progression of infectious disorders, including response to vaccination and/or therapy. In another embodiment, where the Antigen induces an immune response against a tumor, the recombinant viruses of the invention have uses in cancer immunoprophylaxis, immunotherapy, and diagnosis, and monitoring of tumor progression or regression. The recombinant vesiculoviruses can be used as live vaccines, or can be inactivated for use as killed vaccines. The recombinant viruses can also be used to produce large quantities of readily purified antigen, e . g . , for use in subunit vaccines. In a specific embodiment, the foreign DNA used initially for production of the recombinant vesiculoviruses can also comprise a sequence encoding a detectable marker, e . g . , /3-galactosidase, /3-glucuronidase, β-qeo (Friedrich & Soriano, 1991, Genes Dev. 5:1513-1523) . In another specific embodiment, the foreign DNA can also comprise a sequence encoding a cytokine capable of stimulating an immune response. Such cytokines include but are not limited to, interleukin-2, interleukin-6, interleukin-12 , interferons, and granulocyte-macrophage colony stimulating factors. In a preferred aspect, upon infection with a recombinant vesiculovirus of the invention, the Antigen is expressed as a nonfusion protein. In a less preferred embodiment, the Antigen is expressed as a fusion protein, e . g . , to the viral G protein. "Fusion protein," as used herein, refers to a protein comprising an amino acid sequence from a first protein covalently linked via a peptide bond at its carboxy terminus to the amino terminus of an amino acid sequence from a second, different protein. In one embodiment, a vaccine formulation of the invention contains a single type of recombinant vesiculovirus of the invention. In another embodiment, a vaccine formulation comprises a mixture of two or more recombinant viruses of the invention. The vaccine formulations of the invention provide one or more of the following benefits: stability for long periods without refrigeration; ease of production; low cost and high titer of production; ability to be administered by local workers without advanced medical training; and involving administration of a microorganism that is known not to cause serious disease in humans. The present invention also provides a host cell infected with a recombinant vesiculovirus capable of replication. In one embodiment, the host cell is a mammalian cell. Preferably, the mammalian cell is a hamster kidney cell. 5.1. DNA THAT CAN BE TRANSCRIBED TO PRODUCE VESICULOVIRUS ANTIGENOMIC (+) RNA Many vesiculoviruses are known in the art and can be made recombinant according to the methods of the invention. Examples of such vesiculoviruses are listed in Table I. TABLE I MEMBERS OF THE VESICULOVIRUS GENUS Virus Source of virus in nature VSV-New Jersey Mammals, mosquitoes, midges, blackflies, houseflies VSV-Indiana Mammals, mosquitoes, sandflies Alagoas Mammals, sandflies Cocal Mammals, mosquitoes, mites Jurona Mosquitoes Carajas Sandflies Maraba Sandflies Piry Mammals Calchaqui Mosquitoes Yug Bogdanovac Sandflies Isfahan Sandflies, ticks Chandipura Mammals, sandflies Perinct Mosquitoes, sandflies Porton-S Mosquitoes Any DNA that can be transcribed to produce vesiculovirus antigenomic (+) RNA (complementary to the VSV genome) can be used for the construction of a recombinant DNA containing foreign DNA encoding an Antigen, for use in producing the recombinant vesiculoviruses of the invention. DNA that can be transcribed to produce vesiculovirus antigenomic (+) RNA (such DNA being referred to herein as "vesiculovirus (-) DNA") is available in the art and/or can be obtained by standard methods. In particular, plasmid pVSVFL(- ) , containing VSV (-) DNA that is preferred for use in the present invention, has been deposited with the ATCC and assigned accession no. 97134. In a preferred aspect, DNA that can be transcribed to produce VSV (+) RNA, [i.e., VSV (-) DNA], is used. VSV (-) DNA for any serotype or strain known in the art, e . g. , the New Jersey or Indiana serotypes of VSV, can be used. The complete nucleotide and deduced protein sequence of the VSV genome is known, and is available as Genbank VSVCG, Accession No. J02428; NCBI Seq ID 335873; and is published in Rose and Schubert, 1987, in The Viruses: The Rhabdoviruses , Plenum Press, NY, pp. 129-166. Partial sequences of other vesiculovirus genomes have been published and are available in the art. The complete sequence of the VSV(-) DNA that is used in a preferred embodiment is contained in plasmid pVSVFL(+) and is shown in Figure 1; also shown are with the predicted sequences of the VSV proteins (this sequence contains several sequence corrections relative to that obtainable from Genbank) . Vesiculovirus (-) DNA, if not already available, can be prepared by standard methods, as follows: If vesiculoviral cDNA is not already available, vesiculovirus genomic RNA can be purified from virus preparations, and reverse transcription with long distance polymerase chain reaction used to generate the vesiculovirus (-) DNA. Alternatively, after purification of genomic RNA, VSV mRNA can be synthesized in vitro , and cDNA prepared by standard methods, followed by insertion into cloning vectors (see, e . g . , Rose and Gallione, 1981, J. Virol. 39 (2) :519-528) . Individual cDNA clones of vesiculovirus RNA can be joined by use of small DNA fragments covering the gene junctions, generated by use of reverse transcription and polymerase chain reaction (RT-PCR) (Mullis and Faloona, 1987, Meth. Enzymol. 155:335-350) from VSV genomic RNA (see Section 6, infra) . Vesiculoviruses are available in the art. For example, VSV can be obtained from the American Type Culture Collection. In a preferred embodiment, one or more, preferably unique, restriction sites (e.g., in a polylinker) are introduced into the vesiculovirus (-) DNA, in intergenic regions, or 5' of the sequence complementary to the 3' end of the vesiculovirus genome, or 3' of the sequence complementary to the 5' end of the vesiculovirus genome, to facilitate insertion of the foreign DNA. In a preferred method of the invention, the vesiculovirus (-) DNA is constructed so as to have a promoter operatively linked thereto. The promoter should be capable of initiating transcription of the (-) DNA in an animal or insect cell in which it is desired to produce the recombinant vesiculovirus. Promoters which may be used include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3* long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); heat shock promoters (e.g., hsp70 for use in Drosophila S2 cells) ; the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122) , immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1- antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta- globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712); and myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286). Preferably, the promoter is an RNA polymerase promoter, preferably a bacteriophage or viral or insect RNA polymerase promoter, including but not limited to the promoters for T7 RNA polymerase, SP6 RNA polymerase, and T3 RNA polymerase. If an RNA polymerase promoter is used in which the RNA polymerase is not endogenously produced by the host cell in which it is desired to produce the recombinant vesiculovirus, a recombinant source of the RNA polymerase must also be provided in the host cell. The vesiculovirus (-) DNA can be operably linked to a promoter before or after insertion of foreign DNA encoding an Antigen. Preferably, a transcriptional terminator is situated downstream of the vesiculovirus (-) DNA. In another preferred embodiment, a DNA sequence that can be transcribed to produce a ribozyme sequence is situated at the immediate 3' end of the vesiculovirus (-) DNA, prior to the transcriptional termination signal, so that upon transcription a self-cleaving ribozyme sequence is produced at the 3' end of the antigenomic RNA, which ribozyme sequence will autolytically cleave (after a U) this fusion transcript to release the exact 3' end of the vesiculovirus antigenomic (+) RNA. Any ribozyme sequence known in the art may be used, as long as the correct sequence is recognized and cleaved. (It is noted that hammerhead ribozyme is probably not suitable for use.) In a preferred aspect, hepatitis delta virus (HDV) ribozyme is used (Perrotta and Been, 1991, Nature 350:434-436; Pattnaik et al., 1992, Cell 69:1011-1020) . A preferred VSV(-) DNA for use, for insertion of foreign DNA, is that shown in Fig. 1 and contained in plasmid pVSVFL(- ) , in which a T7 RNA polymerase promoter is present 5' of the sequence complementary to the 3' end of the VSV genome. Plasmid pVSVFL(+) thus comprises (in 5' to 3' order) the following operably linked components: the T7 RNA polymerase promoter, VSV (-) DNA, a DNA sequence that is transcribed to produce an HDV ribozyme sequence (immediately downstream of the VSV (-) DNA) , and a T7 RNA polymerase transcription termination site. A plasmid that can also be made and used is plasmid pVSVSSl, a portion of the sequence of which is shown in Fig. 2, in which a synthetic DNA polylinker, facilitating insertion of foreign DNA, has been inserted into pVSVFL(+) between the G and L coding regions. The polylinker was synthesized on a DNA synthesizer so as to have ends compatible for ligation into an Nhel site, and to contain the unique restriction enzyme recognition sites Xmal, S al, and NotI, facilitating insertion of foreign DNA generated by cleavage with one of these enzymes or ligated to a linker containing a recognition site for one of these enzymes (which is then subjected to cleavage prior to insertion) . The foreign DNA encoding an Antigen is inserted into any region, or replaces any region, of the vesiculovirus (-) DNA that is not essential for vesiculovirus replication. In a preferred embodiment, the foreign DNA is thus inserted into an intergenic region, or a portion of the vesiculovirus (-) DNA that is transcribed to form the noncoding region of a viral mRNA. In a preferred embodiment, the invention provides a nucleic acid comprising the DNA sequence of plasmid pVSVFL(- ) as depicted in Figure 1 from nucleotide numbers 623-12088 (a portion of SEQ ID NO:l), in which a region nonessential for vesiculovirus replication has been inserted into or replaced by foreign DNA. Vesiculoviruses have a defined intergenic structure. Extensive homologies are found around the intergenic dinucleotides (Fig. 3) . These regions have the common structure (3' )AUACUUUUUUUNAJUGUCNNUAG(5 ' ) (SEQ ID NO:34), in which N indicates any nucleotide (thus three variable positions are present) and the intergenic dinucleotide is underlined. These dinucleotide spacers are GA, except at the NS-M junction, where the dinucleotide is CA. The first 11 nucleotides of the common sequence are complementary to the sequence (5') . . . UAUGAAAAAAA . . . (3') (SEQ ID NO:35) that occurs at the mRNA-polyadenylate[poly(A) ] junction in each mRNA including L. Reiterative copying of the U residues by the VSV polymerase presumably generates the poly(A) tail on each mRNA (McGeoch, 1979, Cell 17:3199; Rose, 1980, Cell 19:415; Schubert et al., 1980, J. Virol. 34:550). The sequence complementary to the 5' end of the mRNA follows the intergenic dinucleotide. The L m NA also terminates with the sequence UAUG-poly(A) encoded by the sequence (3' )AUACUUUUUUU (SEQ ID NO:36) and is presumably also polyadenylated by a polymerase "slippage" mechanism (Schubert et al., 1980, J. Virol. 34:550; Schubert and Lazarini, 1981, J. Virol. 38:256) . Thus, intergenic regions in vesiculovirus (-) DNA consist of three parts, triggering transcriptional termination and reinitiation present both 5' and 3' to each gene (presented as the 5' to 3' sequence of the positive sense strand of vesiculovirus (-) DNA) : (a) TATGAAAAAAA (SEQ ID NO:37), followed by (b) the dinucleotide GT or CT, followed by (c) AACAG. Therefore, in a preferred aspect, foreign DNA encoding an Antigen can readily be expressed as a nonfusion protein from intergenic regions, simply by ensuring that this three-part intergenic region is reconstituted — i.e., that this intergenic region appears 5' and 3' to the foreign DNA and also 5' and 3' to the adjacent genes. For example, in a preferred embodiment, DNA consisting of (a) this three-part intergenic region, fused to (b) foreign DNA coding for a desired Antigen (preferably including the Antigen gene's native start and stop codons for initiation), is inserted into a portion of the vesiculovirus (-) DNA that is transcribed to form the 3 ' noncoding region of any vesiculovirus mRNA. In a particularly preferred aspect, the foreign DNA is inserted in the noncoding region between G and L. In an alternative embodiment, the foreign DNA can be inserted into the G gene, so as to encode a fusion protein with G, for resultant surface display of the Antigen on the vesiculovirus particle. Selection should be undertaken to ensure that the foreign DNA insertion does not disrupt G protein function. In a preferred embodiment, an Antigen expressed by a recombinant vesiculovirus is all or a portion of an envelope glycoprotein of a virus other than a vesiculovirus. Such an Antigen can replace the endogenous vesiculovirus G protein in the vesiculovirus, or can be expressed as a fusion with the endogenous G protein, or can be expressed in addition to the endogenous G protein either as a fusion or nonfusion protein. In a specific embodiment, such an Antigen forms a part of the vesiculovirus envelope and thus is surface-displayed in the vesiculovirus particle. By way of example, gpl60 or a fragment thereof of Human Immunodeficiency Virus can be the Antigen, which is cleaved to produce gpl20 and gp41 (see Owens and Rose, 1993, J. Virol. 67(1) :360-365) . In a specific embodiment, the G gene of VSV in the VSV (-) DNA of plasmid pVSVFL(+) can be easily excised and replaced, by cleavage at the Nhel and Mlul sites flanking the G gene and insertion of the desired sequence. In another specific embodiment, the Antigen is a foreign envelope glycoprotein or portion thereof that is expressed as a fusion protein comprising the cytoplasmic domain (and, optionally, also the transmembrane region) of the native vesiculovirus G protein (see Owens and Rose, 1993, J. Virol. 67(1) :360-365) . Such a fusion protein can replace or be expressed in addition to the endogenous vesiculovirus G protein. As shown by way of example in Section 6 below, the entire native G coding sequence can be replaced by a coding sequence of a different G to produce recombinant replicable vesiculoviruses that express a non-native glycoprotein. While recombinant vesiculoviruses that express and display epitope(s) of envelope glycoproteins of other viruses can be used as live vaccines, such vesiculoviruses also are particularly useful as killed vaccines, as well as in the production of subunit vaccines containing the vesiculovirus- produced protein comprising such epitope(s) . In a specific embodiment, a recombinant vesiculovirus of the invention expresses in a host to which it is administered one or more Antigens. In one embodiment, a multiplicity of Antigens are expressed, each displaying different antigenicity or immunogenicity. 5.2. DNA SEQUENCES ENCODING ANTIGENS The invention provides recombinant vesiculoviruses capable of replication that have a foreign RNA sequence inserted into or replacing a site of the genome nonessential for replication, wherein the foreign RNA sequence (which is in the negative sense) directs the production of an Antigen capable of being expressed in a host infected by the recombinant virus. This recombinant genome is originally produced by insertion of foreign DNA encoding the Antigen into the vesiculovirus (-) DNA. Any DNA sequence which encodes an immunogenic (capable of provoking an immune response) Antigen, which produces prophylactic or therapeutic immunity against a disease or disorder, when expressed as a fusion or, preferably, nonfusion protein in a recombinant vesiculovirus of the invention, alone or in combination with other Antigens expressed by the same or a different vesiculovirus recombinant, can be isolated for use in the vaccine formulations of the present invention. In a preferred embodiment, expression of an Antigen by a recombinant vesiculovirus induces an immune response against a pathogenic microorganism. For example, an Antigen may display the immunogenicity or antigenicity of an antigen found on bacteria, parasites, viruses, or fungi which are causative agents of diseases or disorders. In a preferred embodiment. Antigens displaying the antigenicity or immunogenicity of antigens of animal viruses of veterinary importance (for example, which cause diseases or disorders in non-human animals such as domestic or farm animals, e . g . , cows, chickens, horses, dogs, cats, etc.) are used. In another embodiment, Antigens displaying the antigenicity or immunogenicity of an antigen of a human pathogen are used. To determine immunogenicity or antigenicity by detecting binding to antibody, various im unoassays known in the art can be used, including but not limited to competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay) , "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example) , western blots, immunoprecipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays) , complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labelled. Many means are known in the art for detecting binding in an immunoassay and are envisioned for use. In one embodiment for detecting immunogenicity, T cell-mediated responses can be assayed by standard methods, e . g . , in vitro cytoxicity assays or in vivo delayed-type hypersensitivity assays. Parasites and bacteria expressing epitopes (antigenic determinants) that can be expressed by recombinant vesiculoviruses (wherein the foreign RNA directs the production of an antigen of the parasite or bacteria or a derivative thereof containing an epitope thereof) include but are not limited to those listed in Table II. TABLE II PARASITES AND BACTERIA EXPRESSING EPITOPES THAT CAN BE EXPRESSED BY RECOMBINANT VESICULOVIRUSES PARASITES: Plasmodium spp. Eimeria spp. BACTERIA: Vibrio cholerae Streptococcus pneumoniae Neisseria mennigitidis Neisseria gonorrhoeae Corynebacteria diphtheriae Clostridium tetani Bordetella pertussis Haemophiluε spp. (e . g. , influenzae) Chlamydia spp. Enterotoxigenic Eεcherichia coli In another embodiment, the Antigen comprises an epitope of an antigen of a nematode, to protect against disorders caused by such worms. In another specific embodiment, any DNA sequence which encodes a Plasmodium epitope, which when expressed by a recombinant vesiculovirus, is immunogenic in a vertebrate host, can be isolated for insertion into vesiculovirus (-) DNA according to the present invention. The species of Plasmodium which can serve as DNA sources include but are not limited to the human malaria parasites P. falciparum , P. malariae , P . ovale , P. vivax, and the animal malaria parasites P. berghei , P . yoelii, P . knowlesi , and P. cynomolgi . In a particular embodiment, the epitope to be expressed is an epitope of the circumsporozoite (CS) protein of a species of Plasmodium (Miller et al., 1986, Science 234:1349) . In yet another embodiment, the Antigen comprises a peptide of the β subunit of Cholera toxin (Jacob et al., 1983, Proc. Natl. Acad. Sci. USA 80:7611). 0 Viruses expressing epitopes (antigenic determinants) that can be expressed by recombinant vesiculoviruses (wherein the foreign RNA directs the production of an antigen of the virus or a derivative thereof comprising an epitope thereof) include but are not limited to 5 those listed in Table III, which lists such viruses by family for purposes of convenience and not limitation (see 1990, Fields Virology, 2d ed. , Fields and Knipe (eds.). Raven Press, NY) . 0 TABLE III VIRUSES EXPRESSING EPITOPES THAT CAN BE EXPRESSED BY RECOMBINANT VESICULOVIRUSES I. Picornaviridae 5 Enteroviruses Poliovirus Coxsackievirus Echovirus Rhinoviruses Hepatitis A Virus _ II. Caliciviridae Norwalk group of viruses III. Togaviridae and Flaviviridae Togaviruses (e.g., Dengue virus) Alphaviruses Flaviviruses (e.g., Hepatitis C virus) Rubella virus 5 IV. Coronaviridae Coronaviruses V. Rhabdoviridae Rabies virus VI. Filoviridae Marburg viruses Ebola viruses VII. Paramyxoviridae Parainfluenza virus Mumps virus Measles virus Respiratory syncytial virus VIII. Orthomyxoviridae Orthomyxoviruses (e.g., Influenza virus) IX. Bunyaviridae Bunyaviruses X. Arenaviridae Arenaviruses XI. Reoviridae Reoviruses Rotaviruses Orbiviruses XII. Retroviridae Human T Cell Leukemia Virus type I Human T Cell Leukemia Virus type II Human Immunodeficiency Viruses (e.g., type I and type II) Simian Immunodeficiency Virus Lentiviruses XIII. Papoviridae Polyomaviruses Papillomaviruses Adenoviruses XIV. Parvoviridae Parvoviruses XV. Herpesviridae Herpes Simplex Viruses Epstein-Barr virus Cytomegalovirus Varicella-Zoster virus Human Herpesvirus-6 Cercopithecine Herpes Virus 1 (B virus) XVI. Poxviridae Poxviruses XVIII. Hepadnaviridae Hepatitis B virus In specific embodiments, the Antigen encoded by the foreign sequences that is expressed upon infection of a host by the recombinant vesiculovirus, displays the antigenicity or immunogenicity of an influenza virus hemagglutinin (Genbank accession no. J02132; Air, 1981, Proc. Natl. Acad. Sci. USA 78:7639-7643; Newton et al. , 1983, Virology 128:495-501); human respiratory syncytial virus G glycoprotein (Genbank accession no. Z33429; Garcia et al., 1994, J. Virol.; Collins et al., 1984, Proc. Natl. Acad. Sci. USA 81:7683) ; core protein, matrix protein or other protein of Dengue virus (Genbank accession no. M19197; Hahn et al., 1988, Virology 162:167-180), measles virus hemagglutinin (Genbank accession no. M81899; Rota et al., 1992, Virology 188:135-142); and herpes simplex virus type 2 glycoprotein gB (Genbank accession no. M14923; Bzik et al., 1986, Virology 155:322-333). In another embodiment, one or more epitopes of the fusion protein of respiratory synctyial virus (RSV) can be expressed as an Antigen. Other Antigens that can be expressed by a recombinant vesiculovirus include but are not limited to those displaying the antigenicity or immunogenicity of the following antigens: Poliovirus I VP1 (Emini et al., 1983, Nature 304:699); envelope glycoproteins of HIV I (Putney et al., 1986, Science 234:1392-1395); Hepatitis B surface antigen (Itoh et al., 1986, Nature 308:19; Neurath et al., 1986, Vaccine 4:34); Diptheria toxin (Audibert et al., 1981, Nature 289:543); streptococcus 24M epitope (Beachey, 1985, Adv. Exp. Med. Biol. 185:193); and gonococcal pilin (Rothbard and Schoolnik, 1985, Adv. Exp. Med. Biol. 185:247). In other embodiments, the Antigen expressed by the recombinant vesiculovirus displays the antigenicity or immunogenicity of pseudorabies virus g50 (gpD) , pseudorabies virus II (gpB) , pseudorabies virus gill (gpC) , pseudorabies virus glycoprotein H, pseudorabies virus glycoprotein E, transmissible gastroenteritis glycoprotein 195, transmissible gastroenteritis matrix protein, swine rotavirus glycoprotein 38, swine parvovirus capsid protein, Serpulina hydodysenteriae protective antigen, Bovine Viral Diarrhea glycoprotein 55, Newcastle Disease Virus he agglutinin- neuraminidase, swine flu hemagglutinin, or swine flu neuraminidase. In various embodiments, the Antigen expressed by the recombinant vesiculovirus displays the antigenicity or immunogenicity of an antigen derived from Serpulina hyodysenteriae , Foot and Mouth Disease Virus, Hog Colera Virus, swine influenza virus, African Swine Fever Virus, Mycoplasma hyopneumoniae , infectious bovine rhinotracheitis virus (e.g., infectious bovine rhinotracheitis virus glycoprotein E or glycoprotein G) , or infectious laryngotracheitis virus (e.g., infectious laryngotracheitis virus glycoprotein G or glycoprotein I) . In another embodiment, the Antigen displays the antigenicity or immunogenicity of a glycoprotein of La Crosse Virus (Gonzales-Scarano et al., 1982, Virology 120:42), Neonatal Calf Diarrhea Virus (Matsuno and Inouye, 1983, Infection and Immunity 39:155), Venezuelan Equine Encephalomyelitis Virus (Mathews and Roehrig, 1982, J. Immunol. 129:2763), Punta Toro Virus (Dalrymple et al., 1981, in Replication of Negative Strand Viruses, Bishop and Compans (eds.), Elsevier, NY, p. 167), Murine Leukemia Virus (Steeves et al., 1974, J. Virol. 14:187), or Mouse Mammary Tumor Virus (Massey and Schochetman, 1981, Virology 115:20). In another embodiment, the Antigen displays the antigenicity or immunogenicity of an antigen of a human pathogen, including but not limited to human herpesvirus, herpes simplex virus-1, herpes simplex virus-2, human cytomegalovirus, Epstein-Barr virus, Varicella-Zoster virus, human herpesvirus-6, human herpesvirus-7, human influenza virus, human immunodeficiency virus, rabies virus, measles virus, hepatitis B virus, hepatitis C virus, Plasmodium falciparum, and Bordetella pertussis . In a specific embodiment of the invention, a recombinant vesiculovirus expresses hepatitis B virus core protein and/or hepatitis B virus surface antigen or a fragment or derivative thereof (see, e.g., U.K. Patent Publication No. GB 2034323A published June 4, 1980; Ganem and Varmus, 1987, Ann. Rev. Biochem. 56:651-693; Tiollais et al., 1985, Nature 317:489-495). The HBV genome (subtype adw) is contained in plasmid pAM6 (Moriarty et al., 1981, Proc. Natl. Acad. Sci. USA 78:2606-2610, available from the American Type Culture Collection (ATCC) , Accession No. 45020), a pBR322-based vector that is replicable in E . coli . In another embodiment, the Antigen expressed by the recombinant vesiculovirus displays the antigenicity or immunogenicity of an antigen of equine influenza virus or equine herpesvirus. Examples of such antigens are equine influenza virus type A/Alaska 91 neuraminidase, equine influenza virus type A/Miami 63 neuraminidase, equine influenza virus type A/Kentucky 81 neuraminidase equine herpesvirus type 1 glycoprotein B, and equine herpesvirus type 1 glycoprotein D. In another embodiment, the Antigen displays the antigenicity or immunogenicity of an antigen of bovine respiratory syncytial virus or bovine parainfluenza virus. For example, such antigens include but are not limited to bovine respiratory syncytial virus attachment protein (BRSV G) , bovine respiratory syncytial virus fusion protein (BRSV F) , bovine respiratory syncytial virus nucleocapsid protein (BRSV N) , bovine parainfluenza virus type 3 fusion protein, and the bovine parainfluenza virus type 3 hemagglutinin neuraminidase. In another embodiment, the Antigen displays the antigenicity or immunogenicity of bovine viral diarrhea virus glycoprotein 48 or glycoprotein 53. In another embodiment, the Antigen displays the antigenicity or immunogenicity of an antigen of infectious bursal disease virus. Examples of such antigens are infectious bursal disease virus polyprotein and VP2. 5 Potentially useful antigens or derivatives thereof for use as Antigens expressed by recombinant vesiculoviruses can be identified by various criteria, such as the antigen's involvement in neutralization of a pathogen's infectivity (Norrby, 1985, Summary, n Vaccines85, Lerner et al. (eds.), 10 Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 388-389) , type or group specificity, recognition by patients' antisera or immune cells, and/or the demonstration of protective effects of antisera or immune cells specific for the antigen. In addition, the antigen's encoded epitope 15 should preferably display a small or no degree of antigenic variation in time or amongst different isolates of the same pathogen. In a preferred embodiment, the foreign DNA inserted into the vesiculovirus (-) DNA encodes an immunopotent 20 dominant epitope of a pathogen. Foreign DNA encoding epitopes which are reactive with antibody although incapable of eliciting immune responses, still have potential uses in immunoassays (see Section 5.8, infra) . In another embodiment, foreign RNA of the 25 recombinant vesiculovirus directs the production of an Antigen comprising an epitope, which when the recombinant vesiculovirus is introduced into a desired host, induces an immune response that protects against a condition or disorder caused by an entity containing the epitope. For example, the 30 Antigen can be a tumor specific antigen or tumor-associated antigen, for induction of a protective immune response against a tumor (e.g., a malignant tumor) . Such tumor- specific or tumor-associated antigens include but are not limited to KS 1/4 pan-carcinoma antigen (Perez and Walker, 35 1990, J. Immunol. 142:3662-3667; Bu al, 1988, Hybridoma 7 (4) :407-415) ; ovarian carcinoma antigen (CA125) (Yu et al., 1991, Cancer Res. 51(2) :468-475) ; prostatic acid phosphate (Tailor et al., 1990, Nucl. Acids Res. 18(16) :4928) ; prostate specific antigen (Henttu and Vihko, 1989, Biochem. Biophys. Res. Comm. 160(2) :903-910; Israeli et al., 1993, Cancer Res. 53:227-230; melanoma-associated antigen p97 (Estin et al., 1989, J. Natl. Cancer Instit. 81(6) :445-446) ; melanoma antigen gp75 (Vijayasardahl et al., 1990, J. Exp. Med. 171(4) :1375-1380) ; high molecular weight melanoma antigen (Natali et al., 1987, Cancer 59:55-63); and prostate specific membrane antigen. In another embodiment of the invention, the Antigen expressed by the recombinant vesiculovirus comprises large regions of proteins which contain several B cell epitopes (i.e., epitopes capable of enticing a humoral immune response) and T cell epitopes (i.e., epitopes capable of inducing a cell-mediated immune response) . Peptides or proteins which are known to contain antigenic determinants can be used as the Antigen. If specific desired antigens are unknown, identification and characterization of immunoreactive sequences can be carried out. One way in which to accomplish this is through the use of monoclonal antibodies generated to the surface or other molecules of a pathogen or tumor, as the case may be. The peptide sequences capable of being recognized by the antibodies are defined epitopes. Alternatively, small synthetic peptides conjugated to carrier molecules can be tested for generation of monoclonal antibodies that bind to the sites corresponding to the peptide, on the intact molecule (see, e.g., Wilson et al., 1984, Cell 37:767). In a specific embodiment, appropriate Antigens, including fragments or derivatives of known antigens, can be identified by virtue of their hydrophilicity, by carrying out a hydrophilicity analysis (Hopp and Woods, 1981, Proc. Natl. Acad. Sci. USA 78:3824) to generate a hydrophilicity profile. A hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of a protein and the corresponding regions of the gene sequence which encode such proteins. Hydrophilic regions are predicted to be immunogenic/antigenic. Other methods known in the art which may be employed for the identification and characterization of antigenic determinants are also within the scope of the invention. The foreign DNA encoding the Antigen, that is inserted into a non-essential site of the vesiculovirus (-) DNA, optionally can further comprise a foreign DNA sequence encoding a cytokine capable of being expressed and stimulating an immune response in a host infected by the recombinant vesiculovirus. For example, such cytokines include but are not limited to interleukin-2, interleukin-6, interleukin-12, interferons, granulocyte-macrophage colony stimulating factors, and interleukin receptors. The foreign DNA optionally can further comprise a sequence encoding and capable of expressing a detectable marker (e.g., β galactosidase) . 5.3. CONSTRUCTION OF VESICULOVIRUS (-) DNA CONTAINING FOREIGN DNA For initial production of a recombinant vesiculovirus, the foreign DNA comprising a sequence encoding the desired antigen is inserted into and/or replaces a region of the vesiculovirus (-) DNA nonessential for replication. Many strategies known in the art can be used in the construction of the vesiculovirus (-) DNA containing the foreign DNA. For example, the relevant sequences of the foreign DNA and of the vesiculovirus (-) DNA can, by techniques known in the art, be cleaved at appropriate sites with restriction endonuclease(s) , isolated, and ligated in vitro . If cohesive termini are generated by restriction endonuclease digestion, no further modification of DNA before ligation may be needed. If, however, cohesive termini of the DNA are not available for generation by restriction endonuclease digestion, or different sites other than those available are preferred, any of numerous techniques known in the art may be used to accomplish ligation of the heterologous DNA at the desired sites. In a preferred embodiment, a desired restriction enzyme site is readily introduced into the desired DNA by amplification of the DNA by use of PCR with primers containing the restriction enzyme site. By way of another example, cleavage with a restriction enzyme can be followed by modification to create blunt ends by digesting back or filling in single-stranded DNA termini before ligation. Alternatively, the cleaved ends of the vesiculovirus (-) DNA or foreign DNA can be "chewed back" using a nuclease such as nuclease Bal 31, exonuclease III, lambda exonuclease, mung bean nuclease, or T4 DNA polymerase exonuclease activity, to name but a few, in order to remove portions of the sequence. To facilitate insertion of the foreign DNA, an oligonucleotide sequence (a linker) which encodes one or more restriction sites can be inserted in a region of the vesiculovirus (-) DNA (see, e.g., the polylinker in pVSVSSl, Fig. 2) by ligation to DNA termini. A linker may also be used to generate suitable restriction sites in the foreign DNA sequence. Additionally, vesiculovirus (-) DNA or foreign DNA sequences can be mutated in vitro or in vivo in order to form new restriction endonuclease sites or destroy preexisting ones, to facilitate in vitro ligation procedures. Any technique for mutagenesis known in the art can be used, including but not limited to, in vitro site-directed mutagenesis (Hutchinson et al., 1978, J. Biol. Chem. 253:6551), chemical mutagenesis, etc. Sequences of the vesiculovirus (-) DNA that have been undesirably modified by such in vitro manipulations can be "restored," if desired, by introduction of appropriate sequences at the desired sites. The particular strategy for inserting the foreign DNA will depend on the specific vesiculovirus (-) DNA site to be replaced or inserted into, as well as the foreign DNA to be inserted. The sequences encoding the immunogenic peptides or proteins are preferably present in single copies, but can also be present in multiple copies within the virus genome. Formation of the desired vesiculovirus (-) DNA containing the foreign DNA can be confirmed by standard methods such as DNA sequence analysis, hybridization analysis, and/or restriction mapping, using methods well known in the art. Foreign DNA encoding a desired antigen can be obtained from any of numerous sources such as cloned DNA, genomic DNA, or cDNA made from RNA of the desired pathogen or tumor, as the case may be, or chemically synthesized DNA, and manipulated by recombinant DNA methodology well known in the art (see Sambrook et al., 1991, Molecular Cloning, A Laboratory Manual, 2d ed. , Cold Spring Harbor Laboratory Press, New York) . In a preferred embodiment, polymerase chain reaction (PCR) is used to amplify the desired fragment of foreign DNA from among a crude preparation of DNA or a small sample of the DNA, by standard methods. Appropriate primers for use in PCR can be readily deduced based on published sequences. In order to generate appropriate DNA fragments, the DNA (e.g., from the pathogen or tumor of interest) may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNasel in the presence of manganese, or mung bean nuclease (McCutchan et al., 1984, Science 225:626), to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including, but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography. PCR amplification of DNA fragments containing the desired epitope(s) is most preferably carried out, in which the PCR primers contain and thus introduce into the amplified DNA a desired restriction enzyme recognition site. Alternatively, any restriction enzyme or combination of restriction enzymes may be used to generate DNA fragment(s) containing the desired epitope(s), provided the enzymes do not destroy the im unopotency of the encoded product. Consequently, many restriction enzyme combinations may be used to generate DNA fragments which, when inserted into the vesiculovirus (-) DNA, are capable of producing recombinant vesiculoviruses that direct the production of the peptide containing the epitope(s) . Once the DNA fragments are generated, identification of the specific fragment containing the desired sequence may be accomplished in a number of ways. For example, if a small amount of the desired DNA sequence or a homologous sequence is previously available, it can be used as a labeled probe (e.g., nick translated) to detect the DNA fragment containing the desired sequence, by nucleic acid hybridization. Alternatively, if the sequence of the derived gene or gene fragment is known, isolated fragments or portions thereof can be sequenced by methods known in the art, and identified by a comparison of the derived sequence to that of the known DNA or protein sequence. Alternatively, the desired fragment can be identified by techniques including but not limited to mRNA selection, making cDNA to the identified mRNA, chemically synthesizing the gene sequence (provided the sequence is known) , or selection on the basis of expression of the encoded protein (e.g., by antibody binding) after "shotgun cloning" of various DNA fragments into an expression system. The sequences encoding peptides to be expressed in recombinant vesiculoviruses according to the present invention, whether produced by recombinant DNA methods, chemical synthesis, or purification techniques, include but are not limited to sequences encoding all or part (fragments) of the amino acid sequences of pathogen-specific and tumor-specific antigens, as well as other derivatives and analogs thereof displaying the antigenicity or immunogenicity thereof. Derivatives or analogs of antigens can be tested for the desired activity by procedures known in the art, including but not limited to standard immunoassays. In particular, antigen derivatives can be made by altering the encoding antigen nucleotide sequences by substitutions, additions or deletions that do not destroy the antigenicity or immunogenicity of the antigen. For example, due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a native antigen gene or portion thereof may be used in the practice of the present invention. Other examples may include but are not limited to nucleotide sequences comprising all or portions of genes or cDNAs which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine, and histidine. The negatively charged (acidic) amino acids include aspartic and glutamic acid. The antigen derivatives and analogs can be produced by various methods known in the art. For example, a cloned gene sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) . The sequence can be cleaved at appropriate sites with restriction endonuclease(s) , followed by further enzymatic modification if desired, isolated, and ligated in vitro . In the production of the gene encoding a derivative or analog of an antigen, care should be taken to ensure that the modified gene remains within the same translational reading frame as the antigen, uninterrupted by translational stop signals, in the gene region where the desired epitope(s) are encoded. Additionally, the antigen-encoding nucleic acid sequence can be mutated in vitro or in vivo , to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification. Any technique for mutagenesis known in the art can be used, including but not limited to, in vitro site- directed mutagenesis (Hutchinson, C . , et al., 1978, J. Biol. Chem 253:6551), use of TAB® linkers (Pharmacia), etc. In another specific embodiment, the encoded antigen derivative is a chimeric, or fusion, protein comprising a first protein or fragment thereof fused to a second, different amino acid sequence. Such a chimeric protein is encoded by a chimeric nucleic acid in which the two coding sequences are joined inframe. Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame. In a specific embodiment, a fusion protein is produced in which the first protein sequence contains an epitope of an antigen, and the second protein sequence contains an epitope of a different antigen. Derivatives and fragments of known antigens can be readily tested by standard immunoassay techniques to ascertain if they display the desired immunogenicity or antigenicity, rendering a DNA sequence encoding such a fragment or derivative suitable for insertion into the vesiculovirus (-) DNA. A DNA sequence encoding an epitope that is a hapten, i.e., a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response when administered without adjuvants or carrier proteins, can also be isolated for use, since it is envisioned that, in particular embodiments, presentation by the vesiculoviruses of the invention can confer immunogenicity to the hapten expressed by the virus. Once identified and isolated, the foreign DNA containing the sequence(s) of interest is then inserted into the vesiculovirus (-) DNA, for production of a recombinant vesiculovirus. 5.4. PRODUCTION OF RECOMBINANT VESICULOVIRUSES The recombinant vesiculoviruses of the invention are produced by providing in an appropriate host cell: vesiculovirus (-) DNA, in which regions nonessential for replication have been inserted into or replaced by foreign DNA comprising a sequence encoding an Antigen, and recombinant sources of vesiculovirus N protein, P protein, and L protein. The production is preferably in vitro , in cell culture. The host cell used for recombinant vesiculovirus production can be any cell in which vesiculoviruses grow, e.g., mammalian cells and some insect (e.g., Drosophila) cells. Primary cells, or more preferably, cell lines can be used. A vast number of cell lines commonly known in the art are available for use. By way of example, such cell lines include but are not limited to BHK (baby hamster kidney) cells, CHO (Chinese hamster ovary) cells, HeLA (human) cells, mouse L cells, Vero (monkey) cells, ESK-4, PK-15, EMSK cells, MDCK (Madin-Darby canine kidney) cells, MDBK (Madin-Darby bovine kidney) cells, 293 (human) cells, and Hep-2 cells. The sources of N, P, and L proteins can be the same or different recombinant nucleic acid(s) , encoding and capable of expressing the N, P and L proteins in the host cell in which it is desired to produce recombinant vesiculovirus. The nucleic acids encoding the N, P and L proteins are obtained by any means available in the art. The N, P and L nucleic acid sequences have been disclosed and can be used. For example, see Genbank accession no. J02428; Rose and Schubert, 1987, in The Viruses : The Rhabdoviruses , Plenum Press, NY, pp. 129-166. The sequences encoding the N, P and L genes can also be obtained from plasmid pVSVFL(+) , deposited with the ATCC and assigned accession no. 97134, e.g., by PCR amplification of the desired gene (PCR; U.S. Patent Nos. 4,683,202, 4,683,195 and 4,889,818; Gyllenstein et al., 1988, Proc. Natl. Acad. Sci. USA 85:7652-7656; Ochman et al., 1988, Genetics 120:621-623; Loh et al., 1989, Science 243:217-220). If a nucleic acid clone of any of the N, P or L genes is not already available, the clone can be obtained by use of standard recombinant DNA methodology. For example, the DNA may be obtained by standard procedures known in the art by purification of RNA from vesiculoviruses followed by reverse transcription and polymerase chain reaction (Mullis and Faloona, 1987, Methods in Enzymology 155:335-350). Alternatives to isolating an N, P or L gene include, but are not limited to, chemically synthesizing the gene sequence itself. Other methods are possible and within the scope of the invention. If desired, the identified and isolated gene can then optimally be inserted into an appropriate cloning vector prior to transfer to an expression vector. Nucleic acids that encode derivatives (including fragments) and analogs of native N, P and L genes, as well as derivatives and analogs of the vesiculovirus (-) DNA can also be used in the present invention, as long as such derivatives and analogs retain function, as exemplified by the ability when used according to the invention to produce a replicable vesiculovirus containing a genomic RNA containing foreign RNA. In particular, derivatives can be made by altering sequences by substitutions, additions, or deletions that provide for functionally active molecules. Furthermore, due to the inherent degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be used in the practice of the methods of the invention. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved. The desired N/P/L-encoding nucleic acid is then preferably inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence in the host in which it is desired to produce recombinant vesiculovirus, to create a vector that functions to direct the synthesis of the N/P/L protein that will subsequently assemble with the vesiculovirus genomic RNA containing the foreign sequence (produced in the host cell from antigenomic vesiculovirus (+) RNA produced by transcription of the vesiculovirus (-) DNA) . A variety of vector systems may be utilized to express the N, P and L-coding sequences, as well as to transcribe the vesiculovirus (-) DNA containing the foreign DNA, as long as the vector is functional in the host and compatible with any other vector present. Such vectors include but are not limited to bacteriophages, plasmids, or cosmids. In a preferred aspect, a plasmid expression vector is used. The expression elements of vectors vary in their strengths and specificities. Any one of a number of suitable transcription and translation elements may be used, as long as they are functional in the host. Standard recombinant DNA methods may be used to construct expression vectors containing DNA encoding the N, P, and L proteins, and the vesiculovirus (-) DNA containing the foreign DNA, comprising appropriate transcriptional/ translational control signals (see, e.g., Sambrook et al., 1989, supra , and methods described hereinabove) . (Translational control signals are not needed for transcription of the vesiculovirus (-) DNA, and thus may be omitted from a vector containing the vesiculovirus (-) DNA, although such signals may be present in the vector and operably linked to other sequences encoding a protein which it is desired to express) . Expression may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control expression can be constitutive or inducible. In a specific embodiment, the promoter is an RNA polymerase promoter. Transcription termination signals (downstream of the gene) , and selectable markers are preferably also included in a plasmid expression vector. In addition to promoter sequences, expression vectors for the N, P, and L proteins preferably contain specific initiation signals for efficient translation of inserted N/P/L sequences, e.g., a ribosome binding site. Specific initiation signals are required for efficient translation of inserted protein coding sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where the entire N, P, or L gene including its own initiation codon and adjacent sequences are inserted into the appropriate vectors, no additional translational control signals may be needed. However, in cases where only a portion of the gene sequence is inserted, exogenous translational control signals, including the ATG initiation codon, must be provided. The initiation codon must furthermore be in phase with the reading frame of the protein coding sequences to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. In a specific embodiment, a recombinant expression vector provided by the invention, encoding an N, P, and/or L protein or functional derivative thereof, comprises the following operatively linked components: a promoter which controls the expression of the N, P, or L protein or functional derivative thereof, a translation initiation signal, a DNA sequence encoding the N, P or L protein or functional derivative thereof, and a transcription termination signal. In a preferred aspect, the above components are present in 5' to 3' order as listed above. In another specific embodiment, the gene encoding the N, P, or L protein is inserted downstream of the T7 RNA polymerase promoter from phage T7 gene 10, situated with an A in the -3 position. A T7 RNA polymerase terminator and a replicon are also included in the expression vector. In this embodiment, T7 RNA polymerase is provided to transcribe the N/P/L sequence. The T7 RNA polymerase can be produced from a chromosomally integrated sequence or episomally, and is most preferably provided by intracellular expression from a recombinant vaccinia virus encoding the T7 RNA polymerase (see infra) . Preferably, the N, P, and L proteins are each encoded by a DNA sequence operably linked to a promoter in an expression plasmid, containing the necessary regulatory signals for transcription and translation of the N, P, and L proteins. Such an expression plasmid preferably includes a promoter, the coding sequence, and a transcription termination/polyadenylation signal, and optionally, a selectable marker (e.g., β-galactosidase) . The N, P and L proteins can be encoded by the same or different plasmids, or a combination thereof, and preferably are in different plasmids. Less preferably, one or more of the N, P, and L proteins can be expressed intrachromosomally. The cloned sequences comprising the vesiculovirus (-) DNA containing the foreign DNA, and the cloned sequences comprising sequences encoding the N, P, and L proteins can be introduced into the desired host cell by any method known in the art, e.g., transfection, electroporation, infection (when the sequences are contained in, e.g., a viral vector), microinjection, etc. In a preferred embodiment, DNA comprising vesiculovirus (-) DNA containing foreign DNA encoding an Antigen, operably linked to an RNA polymerase promoter (preferably a bacteriophage RNA polymerase promoter) ; DNA encoding N, operably linked to the same RNA polymerase promoter; DNA encoding P, operably linked to the same polymerase promoter; and DNA encoding L, operably linked to the same polymerase promoter; are all introduced (preferably by transfection) into the same host cell, in which host cell the RNA polymerase has been cytoplasmically provided. The RNA polymerase is cytoplasmically provided preferably by expression from a recombinant virus that replicates in the cytoplasm and expresses the RNA polymerase, most preferably a vaccinia virus (see the section hereinbelow) , that has been introduced (e.g., by infection) into the same host cell. Cytoplasmic provision of RNA polymerase is preferred, since this will result in cytoplasmic transcription and processing, of the VSV (-) DNA comprising the foreign DNA and of the N, P and L proteins, avoiding splicing machinery in the cell nucleus, and thus maximizing proper processing and production of N, P and L proteins, and resulting assembly of the recombinant vesiculovirus. For example, vaccinia virus also cytoplasmically provides enzymes for processing (capping and polyadenylation) of mRNA, facilitating proper translation. In a most preferred aspect, T7 RNA polymerase promoters are employed, and a cytoplasmic source of T7 RNA polymerase is provided by also introducing into the host cell a recombinant vaccinia virus encoding T7 RNA polymerase into the host cell. Such vaccinia viruses can be obtained by well known methods (see section 5.5, infra) . In a preferred aspect, a recombinant vaccinia virus such as vTF7-3 (Fuerst et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:8122-8126) can be used. In a most preferred aspect, the DNA comprising vesiculovirus (-) DNA containing foreign DNA is plasmid pVSVSSl in which foreign DNA has been inserted into the polylinker region. Alternatively, but less preferably, the RNA polymerase (e.g., T7 RNA polymerase) can be provided by use of a host cell that expresses T7 RNA polymerase from a chromosomally integrated sequence (e.g., originally inserted into the chromosome by homologous recombination) , preferably constitutively, or that expresses T7 RNA polymerase episomally, from a plasmid. In another, less preferred, embodiment, the VSV (-) DNA encoding an Antigen, operably linked to a promoter, can be transfected into a host cell that stably recombinantly expresses the N, P, and L proteins from chromosomally integrated sequences. The cells are cultured and recombinant vesiculovirus is recovered, by standard methods. For example, and not by limitation, after approximately 24 hours, cells and medium are collected, freeze-thawed, and the lysates clarified to yield virus preparations. Alternatively, the cells and medium are collected and simply cleared of cells and debris by low-speed centrifugation. Confirmation that the appropriate foreign sequence is present in the genome of the recombinant vesiculovirus and directs the production of the desired protein(s) in an infected cell, is then preferably carried out. Standard procedures known in the art can be used for this purpose. For example, genomic RNA is obtained from the vesiculovirus by SDS phenol extraction from virus preparations, and can be subjected to reverse transcription (and PCR, if desired) , followed by sequencing, Southern hybridization using a probe specific to the foreign DNA, or restriction enzyme mapping, etc. The virus can be used to infect host cells, which can then be assayed for expression of the desired protein by standard im unoassay techniques using an antibody to the protein, or by assays based on functional activity of the protein. Other techniques are known in the art and can be used. The invention also provides kits for production of recombinant vesiculoviruses. In one embodiment, the kit comprises in one or more (and most preferably, in separate) containers: (a) a first recombinant DNA that can be transcribed in a suitable host cell to produce a vesiculovirus antigenomic (+) RNA in which a portion of the RNA nonessential for replication of the vesiculovirus has been inserted into or replaced by a foreign RNA sequence; (b) a second recombinant DNA comprising a sequence encoding a vesiculovirus N protein; (c) a third recombinant DNA comprising a sequence encoding a vesiculovirus L protein; and (d) a fourth recombinant DNA comprising a sequence encoding a vesiculovirus P protein. The second, third and fourth recombinant DNAs can be part of the same or different DNA molecules. In a preferred embodiment, the sequences encoding the N, L, and P proteins are each operably linked to a promoter that controls expression of the N, L, and P proteins, respectively, in the suitable host cell. In various embodiments, the kit can contain the various nucleic acids, e.g., plasmid expression vectors, described hereinabove for use in production of recombinant vesiculoviruses. In another embodiment, a kit of the invention comprises (a) a first recombinant DNA that can be transcribed in a suitable host cell to produce a vesiculovirus antigenomic DNA in which a portion of the RNA nonessential for replication of the vesiculovirus has been inserted into or replaced by a foreign RNA sequence; and (b) a host cell that recombinantly expresses vesiculovirus N, P and L proteins. In a preferred embodiment, a kit of the invention comprises in separate containers: (a) a first plasmid comprising the following operatively linked components: (i) a bacteriophage RNA polymerase promoter, (ii) a DNA comprising a sequence capable of being transcribed in a suitable host cell to produce an RNA molecule comprising a vesiculovirus antigenomic RNA in which a portion of the RNA nonessential for replication of the vesiculovirus has been inserted into or replaced by a foreign RNA sequence, and in which the 3' end of the antigenomic RNA is immediately adjacent to a ribozyme sequence that cleaves at the 3 ' end of the antigenomic RNA, and (iii) a transcriptional termination signal for the bacteriophage RNA polymerase; and (b) a second plasmid comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter, (ii) a DNA comprising a sequence encoding the vesiculovirus N protein, and (ii) a transcriptional termination signal for the bacteriophage RNA polymerase; and (c) a third plasmid comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter, (ii) a DNA comprising a sequence encoding the vesiculovirus P protein, and (ii) a transcriptional termination signal for the bacteriophage RNA polymerase; and (d) a fourth plasmid comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter, (ii) a DNA comprising a sequence encoding the vesiculovirus L protein, and (ii) a transcriptional termination signal for the bacteriophage RNA polymerase. In another embodiment, a kit of the invention further comprises in a separate container a recombinant vaccinia virus encoding and capable of expressing the bacteriophage RNA polymerase. In a preferred embodiment, the components in the containers are in purified form. 5.4.1. RECOMBINANT VACCINIA VIRUSES ENCODING AND CAPABLE OF EXPRESSING FOREIGN RNA POLYMERASES In a preferred aspect of the invention, transcription of the vesiculovirus (-) DNA containing the foreign DNA encoding an Antigen, and/or transcription of the DNA encoding the N, P, and L proteins in the host cell, is controlled by an RNA polymerase promoter (preferably one in which the RNA polymerase is not endogenous to the host cell) , and the RNA polymerase (that initiates transcription from the promoter) is recombinantly provided in the host cell by expression from a recombinant vaccinia virus. DNA sequences encoding RNA polymerases are well known and available in the art and can be used. For example, phage DNA can be obtained and PCR used to amplify the desired polymerase gene. Insertion of the desired recombinant DNA sequence encoding and capable of expressing the RNA polymerase into a vaccinia virus for expression by the vaccinia virus is preferably accomplished by first inserting the DNA sequence into a plasmid vector which is capable of subsequent transfer to a vaccinia virus genome by homologous recombination. Thus, in a preferred aspect of the invention for constructing the recombinant vaccinia viruses, the desired DNA sequence encoding the polymerase is inserted, using recombinant DNA methodology (see Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) into an insertion (preferably, plasmid) vector flanked by (preferably) nonessential vaccinia DNA sequences, thus providing for subsequent transfer of its chimeric gene(s) into vaccinia virus by homologous recombination. The sequences are placed in the vector such that they can be expressed under the control of a promoter functional in vaccinia virus. Expression of foreign DNA in recombinant vaccinia viruses requires the positioning of promoters functional in vaccinia so as to direct the expression of the protein-coding polymerase DNA sequences. Plasmid insertion vectors have been constructed to insert chimeric genes into vaccinia virus for expression therein. Examples of such vectors are described by Mackett (Mackett et al., 1984. J. Virol. 49:857- 864) . The DNA encoding the polymerase is inserted into a suitable restriction endonuclease cloning site. In addition to plasmid insertion vectors, insertion vectors based on single-stranded M13 bacteriophage DNA (Wilson et al., 1986, Gene 49:207-213) can be used. The inserted polymerase DNA should preferably not contain introns, and insertion should preferably be so as to place the coding sequences in close proximity to the promoter, with no other start codons in between the initiator ATG and the 5' end of the transcript. The plasmid insertion vector should contain transcriptional and translational regulatory elements that are active in vaccinia virus. The plasmid should be configured so that the polymerase sequences are under the control of a promoter active in vaccinia virus. Promoters which can be used in the insertion vectors include but are not limited to the vaccinia virus thymidine kinase (TK) promoter, the 7.5K promoter (Cochran et al., 1985, J. Virol. 54:30-37), the UK promoter (European Patent Publication 0198328), the F promoter (Paoletti et al., 1984, Proc. Natl. Acad. Sci. USA 81:193-197), and various early and late vaccinia promoters (see Moss, 1990, Virology, 2d ed. , ch. 74, Fields et al., eds., Raven Press, Ltd., New York, pp. 2079- 2111) . In a specific embodiment, the plasmid insertion vector contains (for eventual transfer into vaccinia virus) a T7 RNA polymerase coding sequence under the control of a promoter active in vaccinia virus. In another specific embodiment, a plasmid insertion vector contains a co- expression system consisting of divergently oriented promoters, one directing transcription of the polymerase sequences, the other directing transcription of a reporter gene or selectable marker, to facilitate detection or selection of the eventual recombinant vaccinia virus (see, e.g., Fuerst et al., 1987, Mol. Cell. Biol. 5:1918-1924). As described supra , the plasmid insertion vector contains at least one set of polymerase coding sequences operatively linked to a promoter, flanked by sequences preferably nonessential for vaccinia viral replication. Such nonessential sequences include but are not limited to the TK gene (Mackett et al., 1984, J. Virol. 49:857-864), the vaccinia Hindlll-F DNA fragment (Paoletti et al., 1984, Proc. Natl. Acad. Sci. USA 81:193-197), the vaccinia growth factor gene situated within both terminal repeats (Buller et al., 1988, J. Virol. 62:866-874), the N2 and Ml genes (Tamin et al., 1988, Virology 165:141-150), the Ml subunit of the ribonucleotide reductase gene in the vaccinia HindIII-I DNA fragment (Child et al., 1990, Virology 174:625-629), the vaccinia hemagglutinin (Shida et al., 1988, J. Virol. 62:4474-4480), vaccinia 14 kD fusion protein gene (Rodriguez et al., 1989, Proc. Natl. Acad. Sci. USA 86:1287-1291), etc. (see also Buller and Palumbo, 1991, Microbiol. Rev. 55(1) :80- 122) . TK sequences are preferred for use; use of such sequences results in the generation of TK- recombinant viruses. Recombinant vaccinia viruses are preferably produced by transfection of the recombinant insertion vectors containing the polymerase sequences into cells previously infected with vaccinia virus. Alternatively, transfection can take place prior to infection with vaccinia virus. Homologous recombination takes place within the infected cells and results in the insertion of the foreign gene into the viral genome, in the region corresponding to the insertion vector flanking regions. The infected cells can be screened using a variety of procedures such as immunological techniques, DNA plaque hybridization, or genetic selection for recombinant viruses which subsequently can be isolated. These vaccinia recombinants preferably retain their essential functions and infectivity and can be constructed to accommodate up to approximately 35 kilobases of foreign DNA. Transfections may be performed by procedures known in the art, for example, a calcium chloride-mediated procedure (Mackett et al., 1985, The construction and characterization of vaccinia virus recombinants expressing foreign genes, in DNA Cloning, Vol. II, Rickwood and Hames (eds.), IRL Press, Oxford-Washington, D.C.) or a liposome-mediated procedure (Rose et al., 1991, Biotechniques 10:520-525) . Where, as is preferred, flanking TK sequences are used to promote homologous recombination, the resulting recombinant viruses thus have a disrupted TK region, permitting them to grow on a TK ~ host cell line such as Rat2 (ATCC Accession No. CRL 1764) in the presence of 5-bromo-2 '-deoxyuridine (BUDR) , under which conditions non-recombinant (TK + ) viruses will not grow. In another embodiment, recombinant vaccinia viruses of the invention can be made by in vitro cloning, and then packaging with a poxvirus sensitive to a selection condition, rather than by homologous recombination (see International Publication No. WO 94/12617 dated June 9, 1994). For example, the HBV DNA sequences can be inserted into vaccinia genomic DNA using standard recombinant DNA techniques in vitro ; this recombinant DNA can then be packaged in the presence of a "helper" poxvirus such as a temperature sensitive vaccinia virus mutant or a fowlpox virus which can be selected against under the appropriate conditions. Various vaccinia virus strains known in the art can be used to generate the recombinant viruses of the invention. A preferred vaccinia virus is the New York City Department of Health Laboratories strain, prepared by Wyeth (available from the American Type Culture Collection (ATCC) , Accession No. VR-325) . Other vaccinia strains include but are not limited to the Elstree and Moscow strains, the strain of Rivers (CV-1 and CV-2) , and the LCl6m8 strain of Hashizume. Selection of the recombinant vaccinia virus can be by any method known in the art, including hybridization techniques (e.g., using polymerase DNA sequences as a hybridization probe), immunological techniques (e.g., assay for binding to antibodies recognizing the encoded polymerase epitope(s)), etc. In a preferred aspect where TK flanking sequences are used in the insertion vector, selection is for TK- recombinants, as described above; screening for the correct recombinant can then be carried out by standard molecular analyses. In many preferred aspects, the method of choice for selection is dictated by the selectable marker in an insertion vector used to generate the recombinant viruses. The selected recombinant vaccinia virus is then generally plaque-purified, and preferably subjected to standard nucleic acid and protein analyses to verify its identity and purity, and expression of the inserted polymerase. 5.5. LARGE SCALE GROWTH AND PURIFICATION OF RECOMBINANT REPLICABLE VESICULOVIRUSES The recovered recombinant vesiculovirus, after plaque-purification, can then be grown to large numbers, by way of example, as follows. Virus from a single plaque (~10 6 pfu) is recovered and used to infect -10 7 cells (e.g., BHK cells) , to yield, typically, 10 ml at a titer of 10 9 -10 10 pfu/ml for a total of approximately 10 n pfu. Infection of -10 12 cells can then be carried out (with a multiplicity of infection of 0.1), and the cells can be grown in suspension culture, large dishes, or roller bottles by standard methods. It is noted that recombinant vesiculoviruses which no longer express the extracellular region of the vesiculovirus G protein (which determine host range) and which, instead, express an envelope glycoprotein of a different virus will need to be grown in cells which are susceptible to infection by the different virus (and which cells thus express a receptor promoting infection by a virus expressing the envelope glycoprotein of the different virus) . Thus, for example, where the recombinant vesiculovirus expresses the HIV envelope glycoprotein, the virus is grown in CD4 + cells (e.g., CD4 + lymphoid cells). Virus for vaccine preparations can then be collected from culture supernatants, and the supernatants clarified to remove cellular debris. If desired, one method of isolating and concentrating the virus that can be employed is by passage of the supernatant through a tangential flow membrane concentration. The harvest can be further reduced in volume by pelleting through a glycerol cushion and by concentration on a sucrose step gradient. An alternate method of concentration is affinity column purification (Daniel et al., 1988, Int. J. Cancer 41:601-608). However, other methods can also be used for purification (see, e . g . , Arthur et al., 1986, J. Cell. Biochem. Suppl. 10A:226), and any possible modifications of the above procedure will be readily recognized by one skilled in the art. Purification should be as gentle as possible, so as to maintain the integrity of the virus particle. 5.6. RECOMBINANT REPLICABLE VESICULOVIRUSES FOR USE AS LIVE VACCINES In one embodiment of the invention, the recombinant replicable vesiculoviruses that express an immunogenic Antigen are used as live vaccines. The recombinant vesiculoviruses for use as therapeutic or prophylactic live vaccines according to the invention are preferably somewhat attenuated. Most available strains e.g., laboratory strains of VSV, may be sufficiently attenuated for use. Should additional attenuation be desired, e.g., based on pathogenicity testing in animals, attenuation is most preferably achieved simply by laboratory passage of the recombinant vesiculovirus (e.g., in BHK or any other suitable cell line) . Generally, attenuated viruses are obtainable by numerous methods known in the art including but not limited to chemical mutagenesis, genetic insertion, deletion (Miller, 1972, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) or recombination using recombinant DNA methodology (Maniatis et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) , laboratory selection of natural mutants, etc. In this embodiment of the invention, a vaccine is formulated in which the immunogen is one or several recombinant vesiculovirus(es) , in which the foreign RNA in the genome directs the production of an Antigen in a host so as to elicit an immune (humoral and/or cell mediated) response in the host that is prophylactic or therapeutic. In an embodiment wherein the Antigen displays the antigenicity or immunogenicity of an antigen of a pathogen, administration of the vaccine is carried out to prevent or treat an infection by the pathogen and/or the resultant infectious disorder and/or other undesirable correlates of infection. In an embodiment wherein the Antigen is a tumor antigen, administration of the vaccine is carried out to prevent or treat tumors (particularly, cancer) . In a preferred specific embodiment, the recombinant vesiculoviruses are administered prophylactically, to prevent/protect against infection and/or infectious diseases or tumor (e.g., cancer) formation. In a specific embodiment directed to therapeutics, the recombinant vesiculoviruses of the invention, encoding immunogenic epitope(s), are administered therapeutically, for the treatment of infection or tumor formation. Administration of such viruses, e .g. , to neonates and other human subjects, can be used as a method of immunostimulation, to boost the host's immune system, enhancing cell-mediated and/or humoral immunity, and facilitating the clearance of infectious agents or tumors. The viruses of the invention can be administered alone or in combination with other therapies (examples of anti-viral therapies, including but not limited to α-interferon and vidarabine phosphate; examples of tumor therapy including but not limited to radiation and cancer chemotherapy) . 5.7. INACTIVATED RECOMBINANT VESICULOVIRUSES FOR VACCINE USE In a specific embodiment, the recombinant replicable vesiculoviruses of the invention are inactivated (i.e., killed, rendered nonreplicable) prior to vaccine use, to provide a killed vaccine. Since the vesiculovirus envelope is highly immunogenic, in an embodiment wherein one or more foreign proteins (e.g., an envelope glycoprotein of a virus other than a vesiculovirus) is incorporated into the vesiculovirus envelope, such a virus, even in killed form, can be effective to provide an immune response against said foreign protein(s) in a host to which it is administered. In a specific embodiment, a multiplicity of Antigens, each displaying the immunogenicity or antigenicity of an envelope glycoprotein of a different virus, are present in the recombinant vesiculovirus particle. The inactivated recombinant viruses of the invention differ from defective interfering particles in that, prior to inactivation the virus is replicable (i.e., it encodes all the vesiculovirus proteins necessary to enable it to replicate in an infected cell) . Thus, since the virus is originally in a replicable state, it can be easily propagated and grown to large amounts prior to inactivation, to provide a large amount of killed virus for use in vaccines, or for purification of the expressed antigen for use in a subunit vaccine (see Section 5.8, infra) . Various methods are known in the art and can be used to inactivate the recombinant replicable vesiculoviruses of the invention, for use as killed vaccines. Such methods include but are not limited to inactivation by use of formalin, betapropiolactone, gamma irradiation, and psoralen plus ultraviolet light. In a specific embodiment, recombinant vesiculovirus can be readily inactivated by resuspension of purified virions in a suitable concentration of formaldehyde. While 0.8 formaldehyde may be sufficient, verification of the optimum concentration of formaldehyde can be readily determined for a particular virus by titration of serial dilutions of formaldehyde with infectious virus to determine the inactivation curve of formalin for that virus. This technique has been described in detail by Salk and Gori, 1960, Ann. N.Y. Acad. Sci. 83:609-637). By extrapolation to zero, the concentration expected to inactivate the last infectious particle can be estimated. By utilizing a substantially higher concentration, e.g., 4-fold greater than the estimated concentration, complete inactivation can be assured. Although formalin inactivation alone has proven to be effective, it may be desirable, for safety and regulatory purposes, to kill the virus twice or more, using one or more of the numerous other methods currently known for virus inactivation. Thus, although not essential, it is contemplated that the virus used in the final formulation will be often inactivated by a second agent after treatment with formalin. 5.8. USE OF RECOMBINANT REPLICABLE VESICULOVIRUSES IN THE PRODUCTION OF SUBUNIT VACCINES Since the recombinant vesiculoviruses of the invention can be propagated and grown to large amounts, where the recombinant vesiculoviruses express an Antigen, growth of such vesiculoviruses provides a method for large scale production and ready purification of the expressed Antigen, particularly when the Antigen is incorporated into the envelope of the recombinant vesiculovirus. In a specific embodiment, the Antigen is all or a portion of an envelope glycoprotein of another virus, e.g., HIV gpl60, expressed as a nonfusion protein, or expressed as a fusion to the cytoplasmic domain of a vesiculovirus G protein. The Antigens thus produced and purified have use in subunit vaccines. The recombinant vesiculoviruses that express an Antigen can also be used to recombinantly produce the Antigen in infected cells in vitro , to provide a source of 'Antigen for use in immunoassays, e . g. , to detect or measure in a sample of body fluid from a vaccinated subject the presence of antibodies to the Antigen, and thus to diagnose infection or the presence of a tumor and/or monitor immune response of the subject subsequent to vaccination. 5.9. DETERMINATION OF VACCINE EFFICACY Immunopotency of the one or more Antigen(s) in its live or inactivated vesiculovirus vaccine formulation, or in is subunit vaccine formulation, can be determined by monitoring the immune response of test animals following immunization with the recombinant vesiculovirus(es) expressing the Antigen(s) or with the subunit vaccine containing the Antigen, by use of any immunoassay known in the art. Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects. Methods of introduction of the vaccine may include oral, intracerebral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization. The immune response of the test subjects can be analyzed by various approaches such as: the reactivity of the resultant immune serum to the Antigen, as assayed by known techniques, e.g., enzyme linked immunosorbent assay (ELISA) , im unoblots, radioimmunoprecipitations, etc.; or, in the case where the Antigen displays the antigenicity or immunogenicity of a pathogen's antigen, by protection of immunized hosts from infection by the pathogen and/or attenuation of symptoms due to infection by the pathogen in immunized hosts; or, in the case where the antigen displays the antigenicity or immunogenicity of a tumor antigen, by prevention of tumor formation or prevention of metastasis, or by regression, or by inhibition of tumor progression, in immunized hosts. As one example of suitable animal testing of a live vaccine, live vaccines of the invention may be tested in rabbits for the ability to induce an antibody response to the Antigens. Male specific-pathogen-free (SPF) young adult New Zealand White rabbits may be used. The test group of rabbits each receives approximately 5 x 10 8 pfu (plaque forming units) of the vaccine. A control group of rabbits receives an injection in 1 mM Tris-HCl pH 9.0 of a non-recombinant vesiculovirus or of a recombinant vesiculovirus which does not express the same Antigen. Blood samples may be drawn from the rabbits every one or two weeks, and serum analyzed for antibodies to the Antigen(s) . The presence of antibodies specific for the Antigen(s) may be assayed, e.g., using an ELISA. Animals may also be used to test vaccine efficacy (e.g., challenge experiments). For example, in a specific embodiment regarding a live vaccine formulation, monkeys each receive intradermally approximately 5 x 10 8 pfu of recombinant vesiculovirus. A control monkey receives (control) non- recombinant virus intradermally. Blood is drawn weekly for 12 weeks, and serum is analyzed for antibodies to the Antigen(s) . 5.10. VACCINE FORMULATION AND ADMINISTRATION The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one Antigen, from the same or different recombinant viruses. Many methods may be used to introduce the vaccine formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle). The patient to which the vaccine is administered is preferably a mammal, most preferably a human, but can also be a non-human animal including but not limited to cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats. In the use of a live vesiculovirus vaccine, the patient can be any animal in which vesiculovirus replicates (for example, the above-listed animals) . The virus vaccine formulations of the invention comprise an effective immunizing amount of one or more recombinant vesiculoviruses (live or inactivated, as the case may be) and a pharmaceutically acceptable carrier or excipient. Subunit vaccines comprise an effective immunizing amount of one or more Antigens and a pharmaceutically acceptable carrier or excipient. Pharmaceutically acceptable carriers are well known in the art and include but are not limited to saline, buffered saline, dextrose, water, glycerol, sterile isotonic aqueous buffer, and combinations thereof. One example of such an acceptable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc. The carrier is preferably sterile. The formulation should suit the mode of administration. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration. In a specific embodiment, a lyophilized recombinant vesiculovirus of the invention is provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green). The precise dose of virus, or subunit vaccine, to be employed in the formulation will also depend on the route of administration, and the nature of the patient, and should be decided according to the judgment of the practitioner and each patient's circumstances according to standard clinical techniques. An effective immunizing amount is that amount sufficient to produce an immune response to the Antigen in the host to which the recombinant vesiculovirus, or subunit vaccine, is administered. In a specific embodiment, an effective immunizing amount of a live recombinant vesiculovirus of the present invention is within the range of 10 3 to 10 9 pfu/dose, more preferably 10 6 to 10 9 pfu/dose. Boosting is possible but not preferred. If boosting is desired, one optionally may boost with the Antigen in purified form rather than using a recombinant vesiculovirus of the invention. For inactivated recombinant vesiculovirus vaccines, the vaccine formulation comprises an effective immunizing amount of the inactivated virus, preferably in combination with an immunostimulant; and a pharmaceutically acceptable carrier. As used in the present context, "immunostimulant" is intended to encompass any compound or composition which has the ability to enhance the activity of the immune system, whether it be a specific potentiating effect in combination with a specific antigen, or simply an independent effect upon the activity of one or more elements of the immune response. Some of the more commonly utilized immunostimulant compounds in vaccine compositions are the adjuvants alum or muramyl dipeptide (MDP) and its analogues. Methods of utilizing these materials are known in the art, and it is well within the ability of the skilled artisan to determine an optimum amount of stimulant for a given virus vaccine. It may also be desired to use more than one immunostimulant in a given formulation. The exact amount of inactivated virus utilized in a given preparation is not critical, provided that the minimum amount of virus necessary to provoke an immune response is given. A dosage range of as little as about 10 μq , up to amount a milligram or more, is contemplated. As one example, in a specific embodiment, individual dosages may range from about 50-650 μq per immunization. Use of purified Antigens as subunit vaccines can be carried out by standard methods. For example, the purified protein(s) should be adjusted to an appropriate concentration, formulated with any suitable vaccine adjuvant and packaged for use. Suitable adjuvants may include, but are not limited to: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, and MDP. The immunogen may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers for use in a vaccine formulation. In instances where the recombinant Antigen is a hapten, i.e., a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine. Effective doses (immunizing amounts) of the vaccines of the invention may also be extrapolated from dose- response curves derived from animal model test systems. The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the vaccine formulations of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. The present invention thus provides a method of immunizing an animal, or treating or preventing various diseases or disorders in an animal, comprising administering to the animal an effective immunizing dose of a vaccine of the present invention. 5.11. USE OF ANTIBODIES GENERATED BY THE VACCINES OF THE INVENTION The antibodies generated against the Antigen by immunization with the recombinant viruses of the present invention also have potential uses in diagnostic immunoassays, passive immunotherapy, and generation of antiidiotypic antibodies. The generated antibodies may be isolated by standard techniques known in the art (e.g., immunoaffinity chromatography, centrifugation, precipitation, etc.) and used in diagnostic immunoassays. The antibodies may also be used to monitor treatment and/or disease progression. Any immunoassay system known in the art, such as those listed supra , may be used for this purpose including but not limited to competitive and noncompetitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme-linked immunosorbent assays) , "sandwich" immunoassays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement- fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays and immunoelectrophoresis assays, to name but a few. The vaccine formulations of the present invention can also be used to produce antibodies for use in passive immunotherapy, in which short-term protection of a host is achieved by the administration of pre-formed antibody directed against a heterologous organism. The antibodies generated by the vaccine formulations of the present invention can also be used in the production of antiidiotypic antibody. The antiidiotypic antibody can then in turn be used for immunization, in order to produce a subpopulation of antibodies that bind the initial antigen of the pathogenic microorganism (Jerne, 1974, Ann. Immunol. (Paris) 125c:373; Jerne, et al., 1982, EMBO J. 1:234) . 6. RECOMBINANT VESICULAR STOMATITIS VIRUSES FROM DNA We assembled a DNA clone containing the 11,161 nucleotide sequence of the prototype rhabdovirus, vesicular stomatitis virus (VSV) , such that it could be transcribed by the bacteriophage T7 RNA polymerase to yield a full-length positive strand RNA complementary to the VSV genome. Expression of this RNA in cells also expressing the VSV nucleocapsid protein and the two VSV polymerase subunits resulted in production of VSV with the growth characteristics of wild-type VSV. Recovery of virus from DNA was verified by: 1) the presence of two genetic tags 5 generating novel restriction sites in DNA derived from the genome; 2) direct sequencing of the genomic RNA of the recovered virus, and 3) , production of a VSV recombinant in which the glycoprotein was derived from a second serotype. The ability to generate VSV from DNA opens numerous 10 possibilities for the genetic analysis of VSV replication. In addition, because VSV can be grown to very high titers and in large quantities with relative ease, one can genetically engineer recombinant VSVs displaying novel antigens. Such modified viruses can be used as vaccines conferring 15 protection against other viruses or pathogenic microorganisms, or to produce immunity in general against an encoded foreign antigen. 6.1. MATERIALS AND METHODS 20 Plasmid Construction. The plasmid pVSVFL(+) expressing the 11,161 nucleotide positive strand (antigenomic) VSV RNA sequence was constructed from four DNA fragments cloned into pBluescript SK + (Stratagene) . The starting plasmid for the construction, pVSVFL(-) , expressed 25 the complete negative sense VSV genomic RNA (Indiana serotype) from a T7 promoter. This plasmid was generated in a nine step cloning procedure that involved joining the five original cDNA clones of the VSV mRNAs (Gallione et al., 1981, J. Virol. 39:529-535; Rose and Gallione, 1981, J. Virol. 30 39:519-528; Schubert et al., 1985, Proc. Natl. Acad. Sci. USA 82:7984-7988) with gene junction fragments and terminal fragments. These fragments were generated by reverse transcription and polymerase chain reaction (RT-PCR) (Mullis and Faloona, 1987, Methods in Enzymology 155:335-350) from 35 VSV genomic RNA (M.A. Whitt, R. Burdine, E.A. Stillman and J.K. Rose, manuscript in preparation) . To facilitate engineering of the VSV genome and to provide genetic tags, unique Mlu I and Nhe I restriction enzyme sites were introduced by oligonucleotide-directed mutagenesis into the 5 ' and 3 ' non-coding regions flanking the VSV glycoprotein gene prior to construction of the full length genome. In the initial step of constructing pVSVFL(+) we used the primers (5'CCGGCTCGAGTTGTAATACGACTCACTATAGGGACGAAGACAAACAAACCATTATTAT C-3') (SEQ ID NO:38) and (5'GAACTCTCCTCTAGATGAGAAC-3') (SEQ ID NO:39) to amplify (Mullis and Faloona, 1987, Methods in Enzymology 155:335-350) a 2,124 nucleotide fragment from pVSVFL(-) (# 1, Fig. 4A) . This fragment corresponds to the 3' end of the VSV genome. The first primer introduced an Xho I site and a T7 promoter (underlined) immediately preceding the sequence complementary to the 3' end of the VSV genome. The second primer covered a unique Xba I site present in the VSV P gene. The PCR product was digested with Xho I and Xba I and cloned into pBluescript SK + (Stratagene) that had been digested with Xho I and Xba I. The resulting plasmid carrying the sequence corresponding to the 3' end of the VSV genome preceded by a T7 promoter was designated pBSXX. Note that an additional T7 promoter is also present upstream of the Xho I site in the vector. Next we generated the sequence corresponding to the 5' end of the VSV genome and part of the hepatitis delta virus (HDV) ribozyme (Pattnaik et al., 1992, Cell 69:1011-1120; Perrotta and Been, 1991, Nature 350:434-436) . A 147 nucleotide PCR product (#3, Fig. 4A) was amplified from pVSVFL(-) with primers (5'AGGTCGGACCGCGAGGAGGTGGAGATGCCATGCCGACCCACGAAGACCACAAAACCAG -3') (SEQ ID NO:40) and (5ΑTGTTGAAGAGTGACCTACACG-3' ) (SEQ ID NO:41). The first primer contained 39 nucleotides of the sequence encoding the HDV ribozyme (underlined) followed by 19 nucleotides complementary to the 3' end of the VSV antigenomic RNA. The second primer hybridized within the L gene (Fig. 4A) . The PCR product was digested with Afl II and Rsr II and the 80 nucleotide Afl II-Rsr II fragment was ligated to a 225 nucleotide Rsr II-Sac I fragment (#4, Fig. 4A) derived from a plasmid designated pBS-GMG (Stillman et al., manuscript submitted). Fragment 4 contained the T7 terminator sequence and the remainder of the sequence encoding the HDV ribozyme. Ligated products were digested with Afl II and Sac I and the 305 nucleotide Afl II-Sac I product was cloned into the Afl II and Sac I sites of a modified pBSXX vector that contained an Afl II site inserted at the unique Not I site within the polylinker. This plasmid containing the Afl II-Sac I fragment was designated pBXXAS. To complete the construction, a 10,077 nucleotide Bst 1107 I to Afl II fragment (#2, Fig. 4A) containing 90% of the VSV sequences from pVSVFL(-) was inserted into the unique Bst 1107 I and Aflll sites of pBXXAS. The final plasmid was designated pVSVFL(+) . The sequences in this plasmid generated by PCR (hatched sequences, Fig. 4B) were determined and contained no errors. We also prepared a plasmid in which the sequence of the VSV Indiana serotype G gene (Mlul-Nhel) was replaced with the G gene from the New Jersey serotype of VSV (Gallione and Rose, 1983, J. Virol. 46:162-169) . This plasmid is called pVSVFL(+) miC and has only a single T7 promoter. Transfection and recovery of recombinant VSV. Baby hamster kidney cells (BHK-21, ATCC) were maintained in DME (Dulbecco's modified Eagle's medium) supplemented with 5% fetal bovine serum (FBS) . Cells on 10 cm dishes ( " 70% confluent) were infected at a multiplicity of 10 with VTF7-3 (Fuerst et al., 1986, Proc. Natl. Acad. Sci. USA 83:8122-8126). After 30 min, plasmids encoding the VSV antigenomic RNA and the N, P, and L proteins were transfected into the cells using a calcium phosphate transfection kit according to directions supplied (Stratagene) . The coding regions for N, P, and L proteins were each expressed in pBluescript SK(+) from the T7 promoter. Plasmid amounts were 10 μq pVSVFL(+), 5 μq pBS-N, 4 μg pBS-P, and 2 μq pBS-L. After 24-48 h incubation at 37°C in 3% C0 2 , cells were scraped from the dish and subjected to three rounds of freeze-thawing (-70°C, 37°C) to release cell-associated virus. Debris was pelleted from the cell lysates by centrifugation at 1,250 x g for 5 min. Five ml of this lysate was added to approximately 10 6 BHK cells on a 10 cm plate in 10 ml of DME + 5% FBS. After 48 h the medium was clarified by centrifugation at 1,250 x g for 10 min, and passed through a filter to remove the majority of the vaccinia virus (0.2 μm pore size, Gelman Sciences). One ml was then added directly to BHK cells that had been plated on a coverslip in a 35 mm dish. After four hours, the cells were fixed in 3% paraformaldehyde and stained with monoclonal antibody II to the VSV G,protein (Lefrancois and Lyles, 1982, Virology 121:168-174) or 9B5 (Bricker et al., 1987, Virology 161:533-540) to the VSV G NJ protein followed by goat anti-mouse rhodamine conjugated antibody (Jackson Research) . Cells were then examined by indirect immunofluorescence using a Nikon Microphot-FX microscope equipped with a 4Ox planapochromat objective. When VSV recovery was successful, 100% of the cells showed the typical bright stain for G protein characteristic of a VSV infection. Preparation and analysis of VSV RNA and protein. Recombinant VSV and wild-type VSV isolated from single plaques (~10 5 plaque forming units) were used to infect a monolayer of BHK cells (~80% confluent) on a 10 cm dish in 10 ml DME plus 5% FBS. After 24 h, cell debris and nuclei were removed by centrifugation at 1,250 x g for 5 min, and virus was then pelleted from the medium at 35,000 RPM in a Beckman SW41 rotor for one hour. Virus pellets were resuspended in 0.5 ml 10 mM Tris-HCl, pH 7.4 for protein analysis. For RNA isolation, virus was resuspended in 0.2 ml of 0.5% SDS/0.2M sodium acetate, pH 8.0, followed by extraction with phenol/CHCl 3 . RNA was precipitated with 95% ethanol and 5 μg carrier tRNA. RNA was pelleted by centrifugation at 12,000 x g for 15 min and resuspended in water with 1 unit RNasin (Promega) . For analysis of RNA by RT-PCR, primer pairs flanking either the novel Nhe I or Mlu I sites were used. The first strand DNA synthesis reaction was carried out in 50 μl of PCR buffer (Promega) containing 5 mM MgCl 2 , 1 mM dNTPs, 1 unit RNAs in (Promega) , l unit avian myeloblastosis virus reverse transcriptase (AMV RT; Promega) 0.75 μM primer and approximately 0.25 μg of VSV genomic RNA. Incubation was at 42°C for 15 min followed by 5 min at 99°C and 5 min at 5°C. PCR was carried out by addition of 0.5 U Taq polymerase, adjustment of MgCl 2 concentration to 1.25 mM, and addition of the second primer (0.75 μM) . The reaction was subjected to 20 thermal cycles: 95°C, 1 min; 60°C 1.5 min. The reaction was then incubated at 60°C for 7 min. Direct sequencing of VSV genomic RNA was performed according to a previously described protocol based on the dideoxy chain termination method (Mierendorf and Pfeffer, 1987, Methods in Enzymology 152:563-566) except that [α- 33 P]dATP (Amersham, Inc.) was used. Each reaction included approximately 0.25 μg of VSV genomic RNA. 6.2. RESULTS To construct a cDNA clone encoding the entire 11,161 VSV genome, individual cDNA clones of the VSV mRNAs were initially joined using small DNA fragments generated by RT-PCR that covered the four gene junctions. Correct genomic terminal sequences were also generated by RT-PCR of the VSV genome, and these were joined to the other DNAs using restriction sites. This initial clone was constructed with a T7 promoter directing synthesis of the full-length negative strand VSV RNA. Despite numerous attempts, we were unable to recover VSV from cells expressing the VSV genomic RNA and the VSV N, P, and L proteins. The VSV constructed was thus redesigned to express the VSV antigenomic DNA. The construction strategy is described in Materials and Methods and in Fig. 4A-B. The entire VSV sequence as well as a T7 promoter, terminator and HDV ribozyme sequence were cloned in pBluescript SK+ between the Xho I and Sac I sites (Fig. 4B; Fig. 1) . An additional T7 promoter is also present upstream of the Xho I site in the plasmid. A slightly different cloning strategy was used to generate plasmids lacking the upstream T7 promoter and VSV has also been recovered from these constructs. Recovery of VSV from DNA. To determine if we could recover VSV from plasmid DNA, we infected cells with vaccinia VTF7-3 (Fuerst et al., 1986, Proc. Natl. Acad. Sci. USA 83:8122-8126) to provide cytoplasmic T7 RNA polymerase. These cells were then transfected with pVSVFL(+) , which expresses the antigenomic VSV RNA from a T7 promoter, and three other plasmids which express the VSV N, P, and L proteins. Expression of the N protein was required to assemble nascent VSV antigenomic RNA into nucleocapsids. Once formed, these nucleocapsids should serve as templates for synthesis of minus strand RNA by the L/P polymerase complex. Encapsidated minus strand RNA should then be a template for transcription, initiating the VSV infectious cycle. The initial recovery experiment employed two 10 cm plates of BHK cells (~5 x 10 6 cells each) . At 24 hours after the infection with VTF7-3 and transfection with the four plasmids, cells and medium were frozen and thawed to release any cell-associated VSV, and the clarified lysates were added to fresh BHK cells. After 48 hours, both plates showed severe cytopathic effects that could have been due either to vaccinia virus or to recovered VSV. One ml of each supernatant was then added to small dishes of BHK cells on coverslips. After two hours, one of these coverslips showed rounded cells characteristic of a VSV infection, while the other did not. After 4 hours, cells on both coverslips were fixed, stained with appropriate antibodies, and examined by indirect immunofluorescence microscopy to detect the VSV G protein. All cells on the coverslip showing rounded cells revealed intense fluorescence characteristic of G protein expression during VSV infection (data not shown) . Subsequent passaging and analysis described below showed that VSV had been recovered from the transfection. The other coverslip showed no G expression, and no VSV could be recovered after passaging. Based on the frequency with which rabies virus (Schnell et al., 1994, EMBO J. 13:4195-4203) and VSV minigenomes (Stillman et al., manuscript submitted) were recovered, we anticipated that recovery of complete VSV, if obtainable, would be a rare event. The initial recovery of VSV from only one of two transfections suggested the possibility that the initial titer in the positive lysate was very low. To examine this titer, we infected BHK cells on coverslips with one tenth of the lysate (1 ml) derived from each initial transfection. After eight hours, the cells were examined for expression of G protein by indirect immunofluorescence. A scan of the entire coverslip revealed no VSV infection from the negative lysate, and only five small areas of infection (2-6 cells each) from the lysate that gave rise to VSV G expression on subsequent passaging. The initial titer was therefore very low as we suspected, and likely represented a total of about 50 infectious particles, probably derived from a VSV infection initiated in only one cell out of 2 x 10 7 transfected. This low rate of recovery of infectious VSV is typical of that observed in several experiments. Analysis of viral proteins. Subsequent passages and plaque assays of VSV recovered in three independent experiments revealed plaques that were detectable in less than 16 hours and titers up to 2 x 10 9 pfu/ml characteristic of VSV. For further verification that VSV had been recovered, the proteins in virus pelleted from the medium were examined by SDS polyacrylamide gel electrophoresis (PAGE) . Fig. 5 shows the Coomassie stained gel of proteins of VSV recovered from recombinant DNA (rVSV) and wildtype VSV. The mobilities and relative amounts of the five viral proteins were indistinguishable in the wildtype and recombinant virus. Identification of sequence tags. In pVSVFL(+) , the VSV nucleotide sequence was altered by oligonucleotide- directed mutagenesis to generate unique Mlu I and Nhe I restriction enzyme sites in the 5' and 3' non-coding regions of the glycoprotein gene. To verify that these sites were present in recovered virus, we carried out reverse transcription of genomic RNA purified from wild-type or recombinant virions using primers upstream of each restriction site. The reverse transcription products were then amplified by PCR using an additional primer downstream of each restriction site. The presence of the genetic tag in the recombinant virus was verified by digestion of the PCR products with the appropriate restriction enzymes. Using this method, the presence of both the Mlu I and Nhe I sequences in the recovered virus RNA was verified, and the results for the Nhe I site are shown in Fig. 6. Sequences from wild-type VSV and recombinant VSV were amplified in parallel and a 620 nucleotide fragment was obtained in both cases (lanes 3 and 5) . No product was obtained when reverse transcriptase was omitted from the reactions prior to PCR (lanes 1 and 2) , indicating that the PCR product was derived from RNA, not from contaminating DNA. After digestion with Nhe I, expected fragments of 273 and 347 base pairs were obtained from recombinant VSV RNA, while the DNA derived from the wildtype RNA remained undigested (lanes 4 and 6) . Direct sequencing of tagged genomic RNA. The presence of new restriction sites in the DNA generated by PCR provided strong evidence that VSV had been recovered from DNA. To ensure that identification of the genetic tags by PCR had not resulted from inadvertent contamination by plasmid DNA, we carried out direct sequence analysis of the genomic RNA using reverse transcriptase and a primer hybridizing upstream of the Nhe I site. The sequence from the autoradiogram shown in Fig. 7 is in exact agreement with the published sequence of the VSV G mRNA (Rose and Gallione, 1981, J. Virol. 39:519-528) except that the four nucleotide changes used to generate the Nhe I site (GCACAA to GCTAGC) are present. These results show unequivocally that the sequence tag is present in the genomic RNA. Recombinant VSV Indiana virus carrying the glycoprotein of the New Jersey serotype. There are two serotypes of VSV designated Indiana and New Jersey. The glycoproteins of the two serotypes share approximately 50% sequence identity (Gallione and Rose, 1983, J. Virol. 46:162-169). In earlier studies we found that the glycoprotein of the New Jersey serotype could complement a mutant of the VSV, serotype that makes a defective glycoprotein (Whitt et al., 1989, J. Virol. 63:3569-3578). It therefore seemed likely that a recombinant VSV in which the Indiana glycoprotein (G,) gene was replaced by the New Jersey glycoprotein (G NJ ) gene would be viable despite the extensive sequence divergence. To generate such a recombinant, the G NJ cDNA was amplified by PCR using primers that introduced Mlu I and Nhe I sites within the 5' and 3' non-coding regions at each end of the gene. The amplified DNA was cloned into pBluescript and the G NJ protein was expressed in BHK cells using the vaccinia-T7 system. The protein expressed was shown to have membrane fusion activity below pH 6.0 indicating that it was functional (data not shown) . This G NJ cDNA was then cloned into the unique Mlu I and Nhe I sites of the full-length construct after removal of sequences encoding G, Recombinant VSV was recovered essentially as described above except that the initial transfection was allowed to proceed for 48 hours before the freeze-thaw step. After the first passage, expression of the G NJ protein was verified by indirect immunofluorescence using a monoclonal antibody specific to G NJ (Bricker et al., 1987, Virology 161:533-540). The virus was then plaque purified and grown. To examine the proteins present in the recombinant virus, virus recovered from cells infected with VSV, , VSV NJ , and the recombinant VSV mJC was analyzed by SDS- PAGE followed by Coo assie staining. The VSV, G, N, P, and M proteins each have mobilities distinct from their VSV NJ counterparts (Fig. 8, lanes 1 and 3). The recombinant VSV^ Q shows the mobility difference in only the G protein as expected (lane 2) . The presence of the novel Nhe I and Mlu I sites in the recombinant was also verified (data not shown) . 6.3. DISCUSSION The results presented here establish that infectious VSV can be recovered from recombinant DNA. We believe that expressing the positive strand, antigenomic RNA in the presence of the N, P and L proteins was critical to our success because we have not recovered virus starting with an equivalent construct encoding the genomic RNA. Why is the initial event of generating VSV so rare, apparently occurring in only 1 in 10 7 to 10 8 transfected cells? One possibility is that our clone contains a sequence error that is only corrected by a rare mutational event. We believe this is not the case because the clone was completely sequenced prior to assembly and differences from published sequences were corrected, or the proteins were shown to be functional in complementation assays. Also, the frequency of recovery is actually higher than expected based on our observations with minigenomes encoding one or two VSV proteins (Stillman et al., manuscript submitted). In these cases we found that a transcribing and replicating minigenome (~2kb RNA) was recovered in about 1 in 10 2 transfected cells expressing the RNA with the N,P and L proteins. Addition of a second cistron (0.85 kb additional RNA) encoding the M protein dropped the recovery rate to approximately 1 in 10 3 transfected cells. If there is a ten-fold drop in recovery rate for each additional kilobase of RNA added, one can easily rationalize an even lower frequency of recovery for the 11, 161 kb genome than we observed. Although these minigenomes encode negative sense RNAs, the comparison of the frequency of recovery to that of the full length plus construct is probably valid because expression of the N, P and L mRNAs would not generate mRNAs complementary to the minigenome. Although the rate limiting step in generation of infectious VSV is not known, it is likely to be at the level of synthesis and encapsidation of the large antigenomic RNA, which must occur prior to replication and transcription. The complete encapsidation with N protein probably has to occur on the nascent RNA to protect it from degradation, and the cells in which this occurs must also produce appropriate amounts of L and P proteins to initiate replication. Once this has occurred, however, the transcription and translation of the genome should generate additional N, P, and L proteins as well as the G and M proteins required for budding of infectious virus. The recovery of VSV from DNA opens numerous aspects of the viral life cycle to genetic analysis. The studies of the genetic signals involved in transcription and replication have so far been confined to analysis of defective RNAs that do not encode viral proteins (Pattnaik et al., 1992, Cell 69:1011-1120; Wertz et al., 1994, Proc. Natl. Acad. Sci. USA 91:8587-8591). These and other signals can be now examined in the context of a VSV infection occurring in the absence of a vaccinia virus infection. The system we have described also provides an opportunity to study the roles of individual viral protein domains and modifications in viral assembly and replication. Previously these analyses have been confined to in vitro systems or to analysis employing the complementation of naturally occurring mutants where synthesis of the mutant protein can complicate the analysis. Perhaps even more exciting is the ability to use VSV as a vector to express other proteins. The experiment in which we recovered VSV Indiana carrying the glycoprotein from the New Jersey serotype (Fig. 8) illustrates that viable recombinants can be made. For reasons that are unclear the titers of recombinant virus were at least ten-fold lower than those obtained with either parent. The lower titer apparently did not result from a defect in viral assembly because the amounts of proteins in wildtype and recombinant virions at the end of the infection were comparable (Fig. 8) . Our previous experiments showed that a foreign glycoprotein carrying the appropriate cytoplasmic tail signal could be incorporated into the VSV envelope (Owens and Rose, 1993, J. Virol. 67:360-365). This suggests that one may generate recombinant VSVs carrying novel proteins in their envelopes. If these were appropriately attenuated, they can be used as vaccines against other viral diseases. The truncated genomes of defective interfering particles are replicated and packaged very well, thus we suspect that there will be flexibility in the maximum length of the genome that can be packaged as well. Presumably a longer nucleocapsid can be packaged as a longer bullet-shaped particle. Because of the modular nature of the VSV genome, with conserved gene end and start sequences at the gene junctions (Rose and Schubert, 1987, in The Viruses: The Rhabdoviruses, Plenum Publishing Corp., NY, pp. 129-166), it should be relatively easy to engineer additional genes into VSV. 7. DEPOSIT OF MICROORGANISMS Plasmid pVSVFL(+) was deposited on May 2, 1995 with the American Type Culture Collection (ATCC) , 1201 Parklawn Drive, Rockville, Maryland 20852, under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and assigned accession no. 97134. The present invention is not to be limited in scope by the microorganism deposited or the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims. Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Rose, John K. (ii) TITLE OF INVENTION: RECOMBINANT VESICULOVIRUSES AND THEIR USES (iii) NUMBER OF SEQUENCES: 41 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: PENNIE & EDMONDS (B) STREET: 1155 Avenue of the Americas (C) CITY: New York (D) STATE: New York (E) COUNTRY: USA (F) ZIP: 10036-2711 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: To Be Assigned (B) FILING DATE: On Even Date Herewith (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Misrock, S. Leslie (B) REGISTRATION NUMBER: 18,872 (C) REFERENCE/DOCKET NUMBER: 6523-009-228 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 790-9090 (B) TELEFAX: (212) 869-9741/8864 (C) TELEX: 66141 PENNIE (2) INFORMATION FOR SEQ ID NO:1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14311 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 760..2025 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2092..2886 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2946..3632 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 3774..5306 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 5429..11755 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 : CACCTAAATT GTAAGCGTTA ATATTTTGTT AAAATTCGCG TTAAATTTTT GTTAAATCAG 60 CTCATTTTTT AACCAATAGG CCGAAATCGG CAAAATCCCT TATAAATCAA AAGAATAGAC 120 CGAGATAGGG TTGAGTGTTG TTCCAGTTTG GAACAAGAGT CCACTATTAA AGAACGTGGA 180 CTCCAACGTC AAAGGGCGAA AAACCGTCTA TCAGGGCGAT GGCCCACTAC GTGAACCATC 240 ACCCTAATCA AGTTTTTTGG GGTCGAGGTG CCGTAAAGCA CTAAATCGGA ACCCTAAAGG 300 GAGCCCCCGA TTTAGAGCTT GACGGGGAAA GCCGGCGAAC GTGGCGAGAA AGGAAGGGAA 360 GAAAGCGAAA GGAGCGGGCG CTAGGGCGCT GGCAAGTGTA GCGGTCACGC TGCGCGTAAC 420 CACCACACCC GCCGCGCTTA ATGCGCCGCT ACAGGGCGCG TCCCATTCGC CATTCAGGCT 480 GCGCAACTGT TGGGAAGGGC GATCGGTGCG GGCCTCTTCG CTATTACGCC AGCTGGCGAA 540 AGGGGGATGT GCTGCAAGGC GATTAAGTTG GGTAACGCCA GGGTTTTCCC AGTCACGACG 600 TTGTAAAACG ACGGCCAGTG AATTGTAATA CGACTCACTA TAGGGCGAAT TGGGTACCGG 660 GCCCCCCCTC GAGTTGTAAT ACGACTCACT ATAGGGACGA AGACAAACAA ACCATTATTA 720 TCATTAAAAG GCTCAGGAGA AACTTTAACA GTAATCAAA ATG TCT GTT ACA GTC 774 Met Ser Val Thr Val 1 5 AAG AGA ATC ATT GAC AAC ACA GTC ATA GTT CCA AAA CTT CCT GCA AAT 822 Lys Arg lie lie Asp Asn Thr Val lie Val Pro Lys Leu Pro Ala Asn 10 15 20 GAG GAT CCA GTG GAA TAC CCG GCA GAT TAC TTC AGA AAA TCA AAG GAG 870 Glu Asp Pro Val Glu Tyr Pro Ala Asp Tyr Phe Arg Lys Ser Lys Glu 25 30 35 ATT CCT CTT TAC ATC AAT ACT ACA AAA AGT TTG TCA GAT CTA AGA GGA 918 lie Pro Leu Tyr lie Asn Thr Thr Lys Ser Leu Ser Asp Leu Arg Gly 40 45 50 TAT GTC TAC CAA GGC CTC AAA TCC GGA AAT GTA TCA ATC ATA CAT GTC 966 Tyr Val Tyr Gin Gly Leu Lys Ser Gly Asn Val Ser lie lie His Val 55 60 65 AAC AGC TAC TTG TAT GGA GCA TTA AAG GAC ATC CGG GGT AAG TTG GAT 1014 Asn Ser Tyr Leu Tyr Gly Ala Leu Lys Asp lie Arg Gly Lys Leu Asp 70 75 80 85 AAA GAT TGG TCA AGT TTC GGA ATA AAC ATC GGG AAA GCA GGG GAT ACA 1062 Lys Asp Trp Ser Ser Phe Gly lie Asn lie Gly Lys Ala Gly Asp Thr 90 95 100 ATC GGA ATA TTT GAC CTT GTA TCC TTG AAA GCC CTG GAC GGC GTA CTT 1110 lie Gly lie Phe Asp Leu Val Ser Leu Lys Ala Leu Asp Gly Val Leu 105 110 115 CCA GAT GGA GTA TCG GAT GCT TCC AGA ACC AGC GCA GAT GAC AAA TGG 1158 Pro Asp Gly Val Ser Asp Ala Ser Arg Thr Ser Ala Asp Asp Lys Trp 120 125 130 TTG CCT TTG TAT CTA CTT GGC TTA TAC AGA GTG GGC AGA ACA CAA ATG 1206 Leu Pro Leu Tyr Leu Leu Gly Leu Tyr Arg Val Gly Arg Thr Gin Met 135 140 145 CCT GAA TAC AGA AAA AAG CTC ATG GAT GGG CTG ACA AAT CAA TGC AAA 1254 Pro Glu Tyr Arg Lys Lys Leu Met Asp Gly Leu Thr Asn Gin Cys Lys 150 155 160 165 ATG ATC AAT GAA CAG TTT GAA CCT CTT GTG CCA GAA GGT CGT GAC ATT 1302 Met lie Asn Glu Gin Phe Glu Pro Leu Val Pro Glu Gly Arg Asp lie 170 175 180 TTT GAT GTG TGG GGA AAT GAC AGT AAT TAC ACA AAA ATT GTC GCT GCA 1350 Phe Asp Val Trp Gly Asn Asp Ser Asn Tyr Thr Lys lie Val Ala Ala 185 190 195 GTG GAC ATG TTC TTC CAC ATG TTC AAA AAA CAT GAA TGT GCC TCG TTC 1398 Val Asp Met Phe Phe His Met Phe Lys Lys His Glu Cys Ala Ser Phe 200 205 210 AGA TAC GGA ACT ATT GTT TCC AGA TTC AAA GAT TGT GCT GCA TTG GCA 1446 Arg Tyr Gly Thr lie Val Ser Arg Phe Lys Asp Cys Ala Ala Leu Ala 215 220 225 ACA TTT GGA CAC CTC TGC AAA ATA ACC GGA ATG TCT ACA GAA GAT GTA 1494 Thr Phe Gly His Leu Cys Lys lie Thr Gly Met Ser Thr Glu Asp Val 230 235 240 245 ACG ACC TGG ATC TTG AAC CGA GAA GTT GCA GAT GAA ATG GTC CAA ATG 1542 Thr Thr Trp lie Leu Asn Arg Glu Val Ala Asp Glu Met Val Gin Met 250 255 260 ATG CTT CCA GGC CAA GAA ATT GAC AAG GCC GAT TCA TAC ATG CCT TAT 1590 Met Leu Pro Gly Gin Glu lie Asp Lys Ala Asp Ser Tyr Met Pro Tyr 265 270 275 TTG ATC GAC TTT GGA TTG TCT TCT AAG TCT CCA TAT TCT TCC GTC AAA 1638 Leu lie Asp Phe Gly Leu Ser Ser Lys Ser Pro Tyr Ser Ser Val Lys 280 285 290 AAC CCT GCC TTC CAC TTC TGG GGG CAA TTG ACA GCT CTT CTG CTC AGA 1686 Asn Pro Ala Phe His Phe Trp Gly Gin Leu Thr Ala Leu Leu Leu Arg 295 300 305 TCC ACC AGA GCA AGG AAT GCC CGA CAG CCT GAT GAC ATT GAG TAT ACA 1734 Ser Thr Arg Ala Arg Asn Ala Arg Gin Pro Asp Asp lie Glu Tyr Thr 310 315 320 325 TCT CTT ACT ACA GCA GGT TTG TTG TAC GCT TAT GCA GTA GGA TCC TCT 1782 Ser Leu Thr Thr Ala Gly Leu Leu Tyr Ala Tyr Ala Val Gly Ser Ser 330 335 340 GCC GAC TTG GCA CAA CAG TTT TGT GTT GGA GAT AAC AAA TAC ACT CCA 1830 Ala Asp Leu Ala Gin Gin Phe Cys Val Gly Asp Asn Lys Tyr Thr Pro 345 350 355 GAT GAT AGT ACC GGA GGA TTG ACG ACT AAT GCA CCG CCA CAA GGC AGA 1878 Asp Asp Ser Thr Gly Gly Leu Thr Thr Asn Ala Pro Pro Gin Gly Arg 360 365 370 GAT GTG GTC GAA TGG CTC GGA TGG TTT GAA GAT CAA AAC AGA AAA CCG 1926 Asp Val Val Glu Trp Leu Gly Trp Phe Glu Asp Gin Asn Arg Lys Pro 375 380 385 ACT CCT GAT ATG ATG CAG TAT GCG AAA AGA GCA GTC ATG TCA CTG CAA 1974 Thr Pro Asp Met Met Gin Tyr Ala Lys Arg Ala Val Met Ser Leu Gin 390 395 400 405 GGC CTA AGA GAG AAG ACA ATT GGC AAG TAT GCT AAG TCA GAA TTT GAC 2022 Gly Leu Arg Glu Lys Thr lie Gly Lys Tyr Ala Lys Ser Glu Phe Asp 410 415 420 AAA TGA CCCTATAATT CTCAGATCAC CTATTATATA TTATGCTACA TATGAAAAAA 2078 Lys ACTAACAGAT ATC ATG GAT AAT CTC ACA AAA GTT CGT GAG TAT CTC AAG 2127 Met Asp Asn Leu Thr Lys Val Arg Glu Tyr Leu Lys 1 5 10 TCC TAT TCT CGT CTG GAT CAG GCG GTA GGA GAG ATA GAT GAG ATC GAA 2175 Ser Tyr Ser Arg Leu Asp Gin Ala Val Gly Glu lie Asp Glu lie Glu 15 20 . 25 GCA CAA CGA GCT GAA AAG TCC AAT TAT GAG TTG TTC CAA GAG GAT GGA 2223 Ala Gin Arg Ala Glu Lys Ser Asn Tyr Glu Leu Phe Gin Glu Asp Gly 30 35 40 GTG GAA GAG CAT ACT AAG CCC TCT TAT TTT CAG GCA GCA GAT GAT TCT 2271 Val Glu Glu His Thr Lys Pro Ser Tyr Phe Gin Ala Ala Asp Asp Ser 45 50 55 60 GAC ACA GAA TCT GAA CCA GAA ATT GAA GAC AAT CAA GGT TTG TAT GCA 2319 Asp Thr Glu Ser Glu Pro Glu lie Glu Asp Asn Gin Gly Leu Tyr Ala 65 70 75 CCA GAT CCA GAA GCT GAG CAA GTT GAA GGC TTT ATA CAG GGG CCT TTA 2367 Pro Asp Pro Glu Ala Glu Gin Val Glu Gly Phe lie Gin Gly Pro Leu 80 85 90 GAT GAC TAT GCA GAT GAG GAA GTG GAT GTT GTA TTT ACT TCG GAC TGG 2415 Asp Asp Tyr Ala Asp Glu Glu Val Asp Val Val Phe Thr Ser Asp Trp 95 100 105 AAA CAG CCT GAG CTT GAA TCT GAC GAG CAT GGA AAG ACC TTA CGG TTG 2463 Lys Gin Pro Glu Leu Glu Ser Asp Glu His Gly Lys Thr Leu Arg Leu 110 115 120 ACA TCG CCA GAG GGT TTA AGT GGA GAG CAG AAA TCC CAG TGG CTT TCG 2511 Thr Ser Pro Glu Gly Leu Ser Gly Glu Gin Lys Ser Gin Trp Leu Ser 125 130 135 140 ACG ATT AAA GCA GTC GTG CAA AGT GCC AAA TAC TGG AAT CTG GCA GAG 2559 Thr lie Lys Ala Val Val Gin Ser Ala Lys Tyr Trp Asn Leu Ala Glu 145 150 155 TGC ACA TTT GAA GCA TCG GGA GAA GGG GTC ATT ATG AAG GAG CGC CAG 2607 Cys Thr Phe Glu Ala Ser Gly Glu Gly Val He Met Lys Glu Arg Gin 160 165 170 ATA ACT CCG GAT GTA TAT AAG GTC ACT CCA GTG ATG AAC ACA CAT CCG 2655 He Thr Pro Asp Val Tyr Lys Val Thr Pro Val Met Asn Thr His Pro 175 180 185 TCC CAA TCA GAA GCA GTA TCA GAT GTT TGG TCT CTC TCA AAG ACA TCC 2703 Ser Gin Ser Glu Ala Val Ser Asp Val Trp Ser Leu Ser Lys Thr Ser 190 195 200 ATG ACT TTC CAA CCC AAG AAA GCA AGT CTT CAG CCT CTC ACC ATA TCC 2751 Met Thr Phe Gin Pro Lys Lys Ala Ser Leu Gin Pro Leu Thr He Ser 205 210 215 220 TTG GAT GAA TTG TTC TCA TCT AGA GGA GAG TTC ATC TCT GTC GGA GGT 2799 Leu Asp Glu Leu Phe Ser Ser Arg Gly Glu Phe He Ser Val Gly Gly 225 230 235 GAC GGA CGA ATG TCT CAT AAA GAG GCC ATC CTG CTC GGC CTG AGA TAC 2847 Asp Gly Arg Met Ser His Lys Glu Ala He Leu Leu Gly Leu Arg Tyr 240 245 250 AAA AAG TTG TAC AAT CAG GCG AGA GTC AAA TAT TCT CTG TAG 2889 Lys Lys Leu Tyr Asn Gin Ala Arg Val Lys Tyr Ser Leu 255 260 265 ACTATGAAAA AAAGTAACAG ATATCACGAT CTAAGTGTTA TCCCAATCCA TTCATC 2945 ATG AGT TCC TTA AAG AAG ATT CTC GGT CTG AAG GGG AAA GGT AAG AAA 2993 Met Ser Ser Leu Lys Lys He Leu Gly Leu Lys Gly Lys Gly Lys Lys 1 5 10 15 TCT AAG AAA TTA GGG ATC GCA CCA CCC CCT TAT GAA GAG GAC ACT AGC 3041 Ser Lys Lys Leu Gly He Ala Pro Pro Pro Tyr Glu Glu Asp Thr Ser 20 25 30 ATG GAG TAT GCT CCG AGC GCT CCA ATT GAC AAA TCC TAT TTT GGA GTT 3089 Met Glu Tyr Ala Pro Ser Ala Pro He Asp Lys Ser Tyr Phe Gly Val 35 40 45 GAC GAG ATG GAC ACC TAT GAT CCG AAT CAA TTA AGA TAT GAG AAA TTC 3137 Asp Glu Met Asp Thr Tyr Asp Pro Asn Gin Leu Arg Tyr Glu Lys Phe 50 55 60 TTC TTT ACA GTG AAA ATG ACG GTT AGA TCT AAT CGT CCG TTC AGA ACA 3185 Phe Phe Thr Val Lys Met Thr Val Arg Ser Asn Arg Pro Phe Arg Thr 65 70 75 80 TAC TCA GAT GTG GCA GCC GCT GTA TCC CAT TGG GAT CAC ATG TAC ATC 3233 Tyr Ser Asp Val Ala Ala Ala Val Ser His Trp Asp His Met Tyr He 85 90 95 GGA ATG GCA GGG AAA CGT CCC TTC TAC AAA ATC TTG GCT TTT TTG GGT 3281 Gly Met Ala Gly Lys Arg Pro Phe Tyr Lys He Leu Ala Phe Leu Gly 100 105 110 TCT TCT AAT CTA AAG GCC ACT CCA GCG GTA TTG GCA GAT CAA GGT CAA 3329 Ser Ser Asn Leu Lys Ala Thr Pro Ala Val Leu Ala Asp Gin Gly Gin 115 120 125 CCA GAG TAT CAC ACT CAC TGC GAA GGC AGG GCT TAT TTG CCA CAT AGG 3377 Pro Glu Tyr His Thr His Cys Glu Gly Arg Ala Tyr Leu Pro His Arg 130 135 140 ATG GGG AAG ACC CCT CCC ATG CTC AAT GTA CCA GAG CAC TTC AGA AGA 3425 Met Gly Lys Thr Pro Pro Met Leu Asn Val Pro Glu His Phe Arg Arg 145 150 155 160 CCA TTC AAT ATA GGT CTT TAC AAG GGA ACG ATT GAG CTC ACA ATG ACC 3473 Pro Phe Asn He Gly Leu Tyr Lys Gly Thr He Glu Leu Thr Met Thr 165 170 175 ATC TAC GAT GAT GAG TCA CTG GAA GCA GCT CCT ATG ATC TGG GAT CAT 3521 He Tyr Asp Asp Glu Ser Leu Glu Ala Ala Pro Met He Trp Asp His 180 185 190 TTC AAT TCT TCC AAA TTT TCT GAT TTC AGA GAG AAG GCC TTA ATG TTT 3569 Phe Asn Ser Ser Lys Phe Ser Asp Phe Arg Glu Lys Ala Leu Met Phe 195 200 205 GGC CTG ATT GTC GAG AAA AAG GCA TCT GGA GCG TGG GTC CTG GAT TCT 3617 Gly Leu He Val Glu Lys Lys Ala Ser Gly Ala Trp Val Leu Asp Ser 210 215 220 ATC AGC CAC TTC AAA TGA GCTAGTCTAA CTTCTAGCTT CTGAACAATC 3665 He Ser His Phe Lys 225 CCCGGTTTAC TCAGTCTCTC CTAATTCCAG CCTCTCGAAC AACTAATATC CTGTCTTTTC 3725 TATCCCTATG AAAAAAACTA ACAGAGATCG ATCTGTTTAC GCGTCACT ATG AAG TGC 3782 Met Lys Cys 1 CTT TTG TAC TTA GCC TTT TTA TTC ATT GGG GTG AAT TGC AAG TTC ACC 3830 Leu Leu Tyr Leu Ala Phe Leu Phe He Gly Val Asn Cys Lys Phe Thr 5 10 15 ATA GTT TTT CCA CAC AAC CAA AAA GGA AAC TGG AAA AAT GTT CCT TCT 3878 He Val Phe Pro His Asn Gin Lys Gly Asn Trp Lys Asn Val Pro Ser 20 25 30 35 AAT TAC CAT TAT TGC CCG TCA AGC TCA GAT TTA AAT TGG CAT AAT GAC 3926 Asn Tyr His Tyr Cys Pro Ser Ser Ser Asp Leu Asn Trp His Asn Asp 40 45 50 TTA ATA GGC ACA GCC ATA CAA GTC AAA ATG CCC AAG AGT CAC AAG GCT 3974 Leu He Gly Thr Ala He Gin Val Lys Met Pro Lys Ser His Lys Ala 55 60 65 ATT CAA GCA GAC GGT TGG ATG TGT CAT GCT TCC AAA TGG GTC ACT ACT 4022 He Gin Ala Asp Gly Trp Met Cys His Ala Ser Lys Trp Val Thr Thr 70 75 80 TGT GAT TTC CGC TGG TAT GGA CCG AAG TAT ATA ACA CAG TCC ATC CGA 4070 Cys Asp Phe Arg Trp Tyr Gly Pro Lys Tyr He Thr Gin Ser He Arg 85 90 95 TCC TTC ACT CCA TCT GTA GAA CAA TGC AAG GAA AGC ATT GAA CAA ACG 4118 Ser Phe Thr Pro Ser Val Glu Gin Cys Lys Glu Ser He Glu Gin Thr 100 105 110 115 AAA CAA GGA ACT TGG CTG AAT CCA GGC TTC CCT CCT CAA AGT TGT GGA 4166 Lys Gin Gly Thr Trp Leu Asn Pro Gly Phe Pro Pro Gin Ser Cys Gly 120 125 130 TAT GCA ACT GTG ACG GAT GCC GAA GCA GTG ATT GTC CAG GTG ACT CCT 4214 Tyr Ala Thr Val Thr Asp Ala Glu Ala Val He Val Gin Val Thr Pro 135 140 145 CAC CAT GTG CTG GTT GAT GAA TAC ACA GGA GAA TGG GTT GAT TCA CAG 4262 His His Val Leu Val Asp Glu Tyr Thr Gly Glu Trp Val Asp Ser Gin 150 155 160 TTC ATC AAC GGA AAA TGC AGC AAT TAC ATA TGC CCC ACT GTC CAT AAC 4310 Phe He Asn Gly Lys Cys Ser Asn Tyr He Cys Pro Thr Val His Asn 165 170 175 TCT ACA ACC TGG CAT TCT GAC TAT AAG GTC AAA GGG CTA TGT GAT TCT 4358 Ser Thr Thr Trp His Ser Asp Tyr Lys Val Lys Gly Leu Cys Asp Ser 180 185 190 195 AAC CTC ATT TCC ATG GAC ATC ACC TTC TTC TCA GAG GAC GGA GAG CTA 4406 Asn Leu He Ser Met Asp He Thr Phe Phe Ser Glu Asp Gly Glu Leu 200 205 210 TCA TCC CTG GGA AAG GAG GGC ACA GGG TTC AGA AGT AAC TAC TTT GCT 4454 Ser Ser Leu Gly Lys Glu Gly Thr Gly Phe Arg Ser Asn Tyr Phe Ala 215 220 225 TAT GAA ACT GGA GGC AAG GCC TGC AAA ATG CAA TAC TGC AAG CAT TGG 4502 Tyr Glu Thr Gly Gly Lys Ala Cys Lys Met Gin Tyr Cys Lys His Trp 230 235 240 GGA GTC AGA CTC CCA TCA GGT GTC TGG TTC GAG ATG GCT GAT AAG GAT 4550 Gly Val Arg Leu Pro Ser Gly Val Trp Phe Glu Met Ala Asp Lys Asp 245 250 255 CTC TTT GCT GCA GCC AGA TTC CCT GAA TGC CCA GAA GGG TCA AGT ATC 4598 Leu Phe Ala Ala Ala Arg Phe Pro Glu Cys Pro Glu Gly Ser Ser He 260 265 270 275 TCT GCT CCA TCT CAG ACC TCA GTG GAT GTA AGT CTA ATT CAG GAC GTT 4646 Ser Ala Pro Ser Gin Thr Ser Val Asp Val Ser Leu He Gin Asp Val 280 285 290 GAG AGG ATC TTG GAT TAT TCC CTC TGC CAA GAA ACC TGG AGC AAA ATC 4694 Glu Arg He Leu Asp Tyr Ser Leu Cys Gin Glu Thr Trp Ser Lys He 295 300 305 AGA GCG GGT CTT CCA ATC TCT CCA GTG GAT CTC AGC TAT CTT GCT CCT 4742 Arg Ala Gly Leu Pro He Ser Pro Val Asp Leu Ser Tyr Leu Ala Pro 310 315 320 AAA AAC CCA GGA ACC GGT CCT GCT TTC ACC ATA ATC AAT GGT ACC CTA 4790 Lys Asn Pro Gly Thr Gly Pro Ala Phe Thr He He Asn Gly Thr Leu 325 330 335 AAA TAC TTT GAG ACC AGA TAC ATC AGA GTC GAT ATT GCT GCT CCA ATC 4838 Lys Tyr Phe Glu Thr Arg Tyr He Arg Val Asp He Ala Ala Pro He 340 345 350 355 CTC TCA AGA ATG GTC GGA ATG ATC AGT GGA ACT ACC ACA GAA AGG GAA 4886 Leu Ser Arg Met Val Gly Met He Ser Gly Thr Thr Thr Glu Arg Glu 360 365 370 CTG TGG GAT GAC TGG GCA CCA TAT GAA GAC GTG GAA ATT GGA CCC AAT 4934 Leu Trp Asp Asp Trp Ala Pro Tyr Glu Asp Val Glu He Gly Pro Asn 375 380 385 GGA GTT CTG AGG ACC AGT TCA GGA TAT AAG TTT CCT TTA TAC ATG ATT 4982 Gly Val Leu Arg Thr Ser Ser Gly Tyr Lys Phe Pro Leu Tyr Met He 390 395 400 GGA CAT GGT ATG TTG GAC TCC GAT CTT CAT CTT AGC TCA AAG GCT CAG 5030 Gly His Gly Met Leu Asp Ser Asp Leu His Leu Ser Ser Lys Ala Gin 405 410 415 GTG TTC GAA CAT CCT CAC ATT CAA GAC GCT GCT TCG CAA CTT CCT GAT 5078 Val Phe Glu His Pro His He Gin Asp Ala Ala Ser Gin Leu Pro Asp 420 425 430 435 GAT GAG AGT TTA TTT TTT GGT GAT ACT GGG CTA TCC AAA AAT CCA ATC 5126 Asp Glu Ser Leu Phe Phe Gly Asp Thr Gly Leu Ser Lys Asn Pro He 440 445 450 GAG CTT GTA GAA GGT TGG TTC AGT AGT TGG AAA AGC TCT ATT GCC TCT 5174 Glu Leu Val Glu Gly Trp Phe Ser Ser Trp Lys Ser Ser He Ala Ser 455 460 465 TTT TTC TTT ATC ATA GGG TTA ATC ATT GGA CTA TTC TTG GTT CTC CGA 5222 Phe Phe Phe He He Gly Leu He He Gly Leu Phe Leu Val Leu Arg 470 475 480 GTT GGT ATC CAT CTT TGC ATT AAA TTA AAG CAC ACC AAG AAA AGA CAG 5270 Val Gly He His Leu Cys He Lys Leu Lys His Thr Lys Lys Arg Gin 485 490 495 ATT TAT ACA GAC ATA GAG ATG AAC CGA CTT GGA AAG TAA CTCAAATCCT 5319 He Tyr Thr Asp He Glu Met Asn Arg Leu Gly Lys 500 505 510 GCTAGCCAGA TTCTTCATGT TTGGACCAAA TCAACTTGTG ATACCATGCT CAAAGAGGCC 5379 TCAATTATAT TTGAGTTTTT AATTTTTATG AAAAAAACTA ACAGCAATC ATG GAA 5434 Met Glu 1 GTC CAC GAT TTT GAG ACC GAC GAG TTC AAT GAT TTC AAT GAA GAT GAC 5482 Val His Asp Phe Glu Thr Asp Glu Phe Asn Asp Phe Asn Glu Asp Asp 5 10 15 TAT GCC ACA AGA GAA TTC CTG AAT CCC GAT GAG CGC ATG ACG TAC TTG 5530 Tyr Ala Thr Arg Glu Phe Leu Asn Pro Asp Glu Arg Met Thr Tyr Leu 20 25 30 AAT CAT GCT GAT TAC AAT TTG AAT TCT CCT CTA ATT AGT GAT GAT ATT 5578 Asn His Ala Asp Tyr Asn Leu Asn Ser Pro Leu He Ser Asp Asp He 35 40 45 50 GAC AAT TTG ATC AGG AAA TTC AAT TCT CTT CCG ATT CCC TCG ATG TGG 5626 Asp Asn Leu He Arg Lys Phe Asn Ser Leu Pro He Pro Ser Met Trp 55 60 65 GAT AGT AAG AAC TGG GAT GGA GTT CTT GAG ATG TTA ACA TCA TGT CAA 5674 Asp Ser Lys Asn Trp Asp Gly Val Leu Glu Met Leu Thr Ser Cys Gin 70 75 80 GCC AAT CCC ATC TCA ACA TCT CAG ATG CAT AAA TGG ATG GGA AGT TGG 5722 Ala Asn Pro He Ser Thr Ser Gin Met His Lys Trp Met Gly Ser Trp 85 90 95 TTA ATG TCT GAT AAT CAT GAT GCC AGT CAA GGG TAT AGT TTT TTA CAT 5770 Leu Met Ser Asp Asn His Asp Ala Ser Gin Gly Tyr Ser Phe Leu His 100 105 110 GAA GTG GAC AAA GAG GCA GAA ATA ACA TTT GAC GTG GTG GAG ACC TTC 5818 Glu Val Asp Lys Glu Ala Glu He Thr Phe Asp Val Val Glu Thr Phe 115 120 125 130 ATC CGC GGC TGG GGC AAC AAA CCA ATT GAA TAC ATC AAA AAG GAA AGA 5866 He Arg Gly Trp Gly Asn Lys Pro He Glu Tyr He Lys Lys Glu Arg 135 140 145 TGG ACT GAC TCA TTC AAA ATT CTC GCT TAT TTG TGT CAA AAG TTT TTG 5914 Trp Thr Asp Ser Phe Lys He Leu Ala Tyr Leu Cys Gin Lys Phe Leu 150 155 160 GAC TTA CAC AAG TTG ACA TTA ATC TTA AAT GCT GTC TCT GAG GTG GAA 5962 Asp Leu His Lys Leu Thr Leu He Leu Asn Ala Val Ser Glu Val Glu 165 170 175 TTG CTC AAC TTG GCG AGG ACT TTC AAA GGC AAA GTC AGA AGA AGT TCT 6010 Leu Leu Asn Leu Ala Arg Thr Phe Lys Gly Lys Val Arg Arg Ser Ser 180 185 190 CAT GGA ACG AAC ATA TGC AGG ATT AGG GTT CCC AGC TTG GGT CCT ACT 6058 His Gly Thr Asn He Cys Arg He Arg Val Pro Ser Leu Gly Pro Thr 195 200 205 210 TTT ATT TCA GAA GGA TGG GCT TAC TTC AAG AAA CTT GAT ATT CTA ATG 6106 Phe He Ser Glu Gly Trp Ala Tyr Phe Lys Lys Leu Asp He Leu Met 215 220 225 GAC CGA AAC TTT CTG TTA ATG GTC AAA GAT GTG ATT ATA GGG AGG ATG 6154 Asp Arg Asn Phe Leu Leu Met Val Lys Asp Val He He Gly Arg Met 230 235 240 CAA ACG GTG CTA TCC ATG GTA TGT AGA ATA GAC AAC CTG TTC TCA GAG 6202 Gin Thr Val Leu Ser Met Val Cys Arg He Asp Asn Leu Phe Ser Glu 245 250 255 CAA GAC ATC TTC TCC CTT CTA AAT ATC TAC AGA ATT GGA GAT AAA ATT 6250 Gin Asp He Phe Ser Leu Leu Asn He Tyr Arg He Gly Asp Lys He 260 265 270 GTG GAG AGG CAG GGA AAT TTT TCT TAT GAC TTG ATT AAA ATG GTG GAA 6298 Val Glu Arg Gin Gly Asn Phe Ser Tyr Asp Leu He Lys Met Val Glu 275 280 285 290 CCG ATA TGC AAC TTG AAG CTG ATG AAA TTA GCA AGA GAA TCA AGG CCT 6346 Pro He Cys Asn Leu Lys Leu Met Lys Leu Ala Arg Glu Ser Arg Pro 295 300 305 TTA GTC CCA CAA TTC CCT CAT TTT GAA AAT CAT ATC AAG ACT TCT GTT 6394 Leu Val Pro Gin Phe Pro His Phe Glu Asn His He Lys Thr Ser Val 310 315 320 GAT GAA GGG GCA AAA ATT GAC CGA GGT ATA AGA TTC CTC CAT GAT CAG 6442 Asp Glu Gly Ala Lys He Asp Arg Gly He Arg Phe Leu His Asp Gin 325 330 335 ATA ATG AGT GTG AAA ACA GTG GAT CTC ACA CTG GTG ATT TAT GGA TCG 6490 He Met Ser Val Lys Thr Val Asp Leu Thr Leu Val He Tyr Gly Ser 340 345 350 TTC AGA CAT TGG GGT CAT CCT TTT ATA GAT TAT TAC ACT GGA CTA GAA 6538 Phe Arg His Trp Gly His Pro Phe He Asp Tyr Tyr Thr Gly Leu Glu 355 360 365 370 AAA TTA CAT TCC CAA GTA ACC ATG AAG AAA GAT ATT GAT GTG TCA TAT 6586 Lys Leu His Ser Gin Val Thr Met Lys Lys Asp He Asp Val Ser Tyr 375 380 385 GCA AAA GCA CTT GCA AGT GAT TTA GCT CGG ATT GTT CTA TTT CAA CAG 6634 Ala Lys Ala Leu Ala Ser Asp Leu Ala Arg He Val Leu Phe Gin Gin 390 395 400 TTC AAT GAT CAT AAA AAG TGG TTC GTG AAT GGA GAC TTG CTC CCT CAT 6682 Phe Asn Asp His Lys Lys Trp Phe Val Asn Gly Asp Leu Leu Pro His 405 410 415 GAT CAT CCC TTT AAA AGT CAT GTT AAA GAA AAT ACA TGG CCC ACA GCT 6730 Asp His Pro Phe Lys Ser His Val Lys Glu Asn Thr Trp Pro Thr Ala 420 425 430 GCT CAA GTT CAA GAT TTT GGA GAT AAA TGG CAT GAA CTT CCG CTG ATT 6778 Ala Gin Val Gin Asp Phe Gly Asp Lys Trp His Glu Leu Pro Leu He 435 440 445 450 AAA TGT TTT GAA ATA CCC GAC TTA CTA GAC CCA TCG ATA ATA TAC TCT 6826 Lys Cys Phe Glu He Pro Asp Leu Leu Asp Pro Ser He He Tyr Ser 455 460 465 GAC AAA AGT CAT TCA ATG AAT AGG TCA GAG GTG TTG AAA CAT GTC CGA 6874 Asp Lys Ser His Ser Met Asn Arg Ser Glu Val Leu Lys His Val Arg 470 475 480 ATG AAT CCG AAC ACT CCT ATC CCT AGT AAA AAG GTG TTG CAG ACT ATG 6922 Met Asn Pro Asn Thr Pro He Pro Ser Lys Lys Val Leu Gin Thr Met 485 490 495 TTG GAC ACA AAG GCT ACC AAT TGG AAA GAA TTT CTT AAA GAG ATT GAT 6970 Leu Asp Thr Lys Ala Thr Asn Trp Lys Glu Phe Leu Lys Glu He Asp 500 505 510 GAG AAG GGC TTA GAT GAT GAT GAT CTA ATT ATT GGT CTT AAA GGA AAG 7018 Glu Lys Gly Leu Asp Asp Asp Asp Leu He He Gly Leu Lys Gly Lys 515 520 525 530 GAG AGG GAA CTG AAG TTG GCA GGT AGA TTT TTC TCC CTA ATG TCT TGG 7066 Glu Arg Glu Leu Lys Leu Ala Gly Arg Phe Phe Ser Leu Met Ser Trp 535 540 545 AAA TTG CGA GAA TAC TTT GTA ATT ACC GAA TAT TTG ATA AAG ACT CAT 7114 Lys Leu Arg Glu Tyr Phe Val He Thr Glu Tyr Leu He Lys Thr His 550 555 560 TTC GTC CCT ATG TTT AAA GGC CTG ACA ATG GCG GAC GAT CTA ACT GCA 7162 Phe Val Pro Met Phe Lys Gly Leu Thr Met Ala Asp Asp Leu Thr Ala 565 570 575 GTC ATT AAA AAG ATG TTA GAT TCC TCA TCC GGC CAA GGA TTG AAG TCA 7210 Val He Lys Lys Met Leu Asp Ser Ser Ser Gly Gin Gly Leu Lys Ser 580 585 590 TAT GAG GCA ATT TGC ATA GCC AAT CAC ATT GAT TAC GAA AAA TGG AAT 7258 Tyr Glu Ala He Cys He Ala Asn His He Asp Tyr Glu Lys Trp Asn 595 600 605 610 AAC CAC CAA AGG AAG TTA TCA AAC GGC CCA GTG TTC CGA GTT ATG GGC 7306 Asn His Gin Arg Lys Leu Ser Asn Gly Pro Val Phe Arg Val Met Gly 615 620 625 CAG TTC TTA GGT TAT CCA TCC TTA ATC GAG AGA ACT CAT GAA TTT TTT 7354 Gin Phe Leu Gly Tyr Pro Ser Leu He Glu Arg Thr His Glu Phe Phe 630 635 640 GAG AAA AGT CTT ATA TAC TAC AAT GGA AGA CCA GAC TTG ATG CGT GTT 7402 Glu Lys Ser Leu He Tyr Tyr Asn Gly Arg Pro Asp Leu Met Arg Val 645 650 655 CAC AAC AAC ACA CTG ATC AAT TCA ACC TCC CAA CGA GTT TGT TGG CAA 7450 His Asn Asn Thr Leu He Asn Ser Thr Ser Gin Arg Val Cys Trp Gin 660 665 670 GGA CAA GAG GGT GGA CTG GAA GGT CTA CGG CAA AAA GGA TGG ACT ATC 7498 Gly Gin Glu Gly Gly Leu Glu Gly Leu Arg Gin Lys Gly Trp Thr He 675 680 685 690 CTC AAT CTA CTG GTT ATT CAA AGA GAG GCT AAA ATC AGA AAC ACT GCT 7546 Leu Asn Leu Leu Val He Gin Arg Glu Ala Lys He Arg Asn Thr Ala 695 700 705 GTC AAA GTC TTG GCA CAA GGT GAT AAT CAA GTT ATT TGC ACA CAG TAT 7594 Val Lys Val Leu Ala Gin Gly Asp Asn Gin Val He Cys Thr Gin Tyr 710 715 720 AAA ACG AAG AAA TCG AGA AAC GTT GTA GAA TTA CAG GGT GCT CTC AAT 7642 Lys Thr Lys Lys Ser Arg Asn Val Val Glu Leu Gin Gly Ala Leu Asn 725 730 735 CAA ATG GTT TCT AAT AAT GAG AAA ATT ATG ACT GCA ATC AAA ATA GGG 7690 Gin Met Val Ser Asn Asn Glu Lys He Met Thr Ala He Lys He Gly 740 745 750 ACA GGG AAG TTA GGA CTT TTG ATA AAT GAC GAT GAG ACT ATG CAA TCT 7738 Thr Gly Lys Leu Gly Leu Leu He Asn Asp Asp Glu Thr Met Gin Ser 755 760 765 770 GCA GAT TAC TTG AAT TAT GGA AAA ATA CCG ATT TTC CGT GGA GTG ATT 7786 Ala Asp Tyr Leu Asn Tyr Gly Lys He Pro He Phe Arg Gly Val He 775 780 785 AGA GGG TTA GAG ACC AAG AGA TGG TCA CGA GTG ACT TGT GTC ACC AAT 7834 Arg Gly Leu Glu Thr Lys Arg Trp Ser Arg Val Thr Cys Val Thr Asn 790 795 800 GAC CAA ATA CCC ACT TGT GCT AAT ATA ATG AGC TCA GTT TCC ACA AAT 7882 Asp Gin He Pro Thr Cys Ala Asn He Met Ser Ser Val Ser Thr Asn 805 810 815 GCT CTC ACC GTA GCT CAT TTT GCT GAG AAC CCA ATC AAT GCC ATG ATA 7930 Ala Leu Thr Val Ala His Phe Ala Glu Asn Pro He Asn Ala Met He 820 825 830 CAG TAC AAT TAT TTT GGG ACA TTT GCT AGA CTC TTG TTG ATG ATG CAT 7978 Gin Tyr Asn Tyr Phe Gly Thr Phe Ala Arg Leu Leu Leu Met Met His 835 840 845 850 GAT CCT GCT CTT CGT CAA TCA TTG TAT GAA GTT CAA GAT AAG ATA CCG 8026 Asp Pro Ala Leu Arg Gin Ser Leu Tyr Glu Val Gin Asp Lys He Pro 855 860 865 GGC TTG CAC AGT TCT ACT TTC AAA TAC GCC ATG TTG TAT TTG GAC CCT 8074 Gly Leu His Ser Ser Thr Phe Lys Tyr Ala Met Leu Tyr Leu Asp Pro 870 875 880 TCC ATT GGA GGA GTG TCG GGC ATG TCT TTG TCC AGG TTT TTG ATT AGA • 8122 Ser He Gly Gly Val Ser Gly Met Ser Leu Ser Arg Phe Leu He Arg 885 890 895 GCC TTC CCA GAT CCC GTA ACA GAA AGT CTC TCA TTC TGG AGA TTC ATC 8170 Ala Phe Pro Asp Pro Val Thr Glu Ser Leu Ser Phe Trp Arg Phe He 900 905 910 CAT GTA CAT GCT CGA AGT GAG CAT CTG AAG GAG ATG AGT GCA GTA TTT 8218 His Val His Ala Arg Ser Glu His Leu Lys Glu Met Ser Ala Val Phe 915 920 925 930 GGA AAC CCC GAG ATA GCC AAG TTT CGA ATA ACT CAC ATA GAC AAG CTA 8266 Gly Asn Pro Glu He Ala Lys Phe Arg He Thr His He Asp Lys Leu 935 940 945 GTA GAA GAT CCA ACC TCT CTG AAC ATC GCT ATG GGA ATG AGT CCA GCG 8314 Val Glu Asp Pro Thr Ser Leu Asn He Ala Met Gly Met Ser Pro Ala 950 955 960 AAC TTG TTA AAG ACT GAG GTT AAA AAA TGC TTA ATC GAA TCA AGA CAA 8362 Asn Leu Leu Lys Thr Glu Val Lys Lys Cys Leu He Glu Ser Arg Gin 965 970 975 ACC ATC AGG AAC CAG GTG ATT AAG GAT GCA ACC ATA TAT TTG TAT CAT 8410 Thr He Arg Asn Gin Val He Lys Asp Ala Thr He Tyr Leu Tyr His 980 985 990 GAA GAG GAT CGG CTC AGA AGT TTC TTA TGG TCA ATA AAT CCT CTG TTC 8458 Glu Glu Asp Arg Leu Arg Ser Phe Leu Trp Ser He Asn Pro Leu Phe 995 1000 1005 1010 CCT AGA TTT TTA AGT GAA TTC AAA TCA GGC ACT TTT TTG GGA GTC GCA 8506 Pro Arg Phe Leu Ser Glu Phe Lys Ser Gly Thr Phe Leu Gly Val Ala 1015 1020 1025 GAC GGG CTC ATC AGT CTA TTT CAA AAT TCT CGT ACT ATT CGG AAC TCC 8554 Asp Gly Leu He Ser Leu Phe Gin Asn Ser Arg Thr He Arg Asn Ser 1030 1035 1040 TTT AAG AAA AAG TAT CAT AGG GAA TTG GAT GAT TTG ATT GTG AGG AGT 8602 Phe Lys Lys Lys Tyr His Arg Glu Leu Asp Asp Leu He Val Arg Ser 1045 1050 1055 GAG GTA TCC TCT TTG ACA CAT TTA GGG AAA CTT CAT TTG AGA AGG GGA 8650 Glu Val Ser Ser Leu Thr His Leu Gly Lys Leu His Leu Arg Arg Gly 1060 1065 1070 TCA TGT AAA ATG TGG ACA TGT TCA GCT ACT CAT GCT GAC ACA TTA AGA 8698 Ser Cys Lys Met Trp Thr Cys Ser Ala Thr His Ala Asp Thr Leu Arg 1075 1080 1085 1090 TAC AAA TCC TGG GGC CGT ACA GTT ATT GGG ACA ACT GTA CCC CAT CCA 8746 Tyr Lys Ser Trp Gly Arg Thr Val He Gly Thr Thr Val Pro His Pro 1095 1100 1105 TTA GAA ATG TTG GGT CCA CAA CAT CGA AAA GAG ACT CCT TGT GCA CCA 8794 Leu Glu Met Leu Gly Pro Gin His Arg Lys Glu Thr Pro Cys Ala Pro 1110 1115 1120 TGT AAC ACA TCA GGG TTC AAT TAT GTT TCT GTG CAT TGT CCA GAC GGG 8842 Cys Asn Thr Ser Gly Phe Asn Tyr Val Ser Val His Cys Pro Asp Gly 1125 1130 1135 ATC CAT GAC GTC TTT AGT TCA CGG GGA CCA TTG CCT GCT TAT CTA GGG 8890 He His Asp Val Phe Ser Ser Arg Gly Pro Leu Pro Ala Tyr Leu Gly 1140 1145 1150 TCT AAA ACA TCT GAA TCT ACA TCT ATT TTG CAG CCT TGG GAA AGG GAA 8938 Ser Lys Thr Ser Glu Ser Thr Ser He Leu Gin Pro Trp Glu Arg Glu 1155 1160 1165 1170 AGC AAA GTC CCA CTG ATT AAA AGA GCT ACA CGT CTT AGA GAT GCT ATC 8986 Ser Lys Val Pro Leu He Lys Arg Ala Thr Arg Leu Arg Asp Ala He 1175 1180 1185 TCT TGG TTT GTT GAA CCC GAC TCT AAA CTA GCA ATG ACT ATA CTT TCT 9034 Ser Trp Phe Val Glu Pro Asp Ser Lys Leu Ala Met Thr He Leu Ser 1190 1195 1200 AAC ATC CAC TCT TTA ACA GGC GAA GAA TGG ACC AAA AGG CAG CAT GGG 9082 Asn He His Ser Leu Thr Gly Glu Glu Trp Thr Lys Arg Gin His Gly 1205 1210 1215 TTC AAA AGA ACA GGG TCT GCC CTT CAT AGG TTT TCG ACA TCT CGG ATG 9130 Phe Lys Arg Thr Gly Ser Ala Leu His Arg Phe Ser Thr Ser Arg Met 1220 1225 1230 AGC CAT GGT GGG TTC GCA TCT CAG AGC ACT GCA GCA TTG ACC AGG TTG 9178 Ser His Gly Gly Phe Ala Ser Gin Ser Thr Ala Ala Leu Thr Arg Leu 1235 1240 1245 1250 ATG GCA ACT ACA GAC ACC ATG AGG GAT CTG GGA GAT CAG AAT TTC GAC 9226 Met Ala Thr Thr Asp Thr Met Arg Asp Leu Gly Asp Gin Asn Phe Asp 1255 1260 1265 TTT TTA TTC CAA GCA ACG TTG CTC TAT GCT CAA ATT ACC ACC ACT GTT 9274 Phe Leu Phe Gin Ala Thr Leu Leu Tyr Ala Gin He Thr Thr Thr Val 1270 1275 1280 GCA AGA GAC GGA TGG ATC ACC AGT TGT ACA GAT CAT TAT CAT ATT GCC 9322 Ala Arg Asp Gly Trp He Thr Ser Cys Thr Asp His Tyr His He Ala 1285 1290 1295 TGT AAG TCC TGT TTG AGA CCC ATA GAA GAG ATC ACC CTG GAC TCA AGT 9370 Cys Lys Ser Cys Leu Arg Pro He Glu Glu He Thr Leu Asp Ser Ser 1300 1305 1310 ATG GAC TAC ACG CCC CCA GAT GTA TCC CAT GTG CTG AAG ACA TGG AGG 9418 Met Asp Tyr Thr Pro Pro Asp Val Ser His Val Leu Lys Thr Trp Arg 1315 1320 1325 1330 AAT GGG GAA GGT TCG TGG GGA CAA GAG ATA AAA CAG ATC TAT CCT TTA 9466 Asn Gly Glu Gly Ser Trp Gly Gin Glu He Lys Gin He Tyr Pro Leu 1335 1340 1345 GAA GGG AAT TGG AAG AAT TTA GCA CCT GCT GAG CAA TCC TAT CAA GTC 9514 Glu Gly Asn Trp Lys Asn Leu Ala Pro Ala Glu Gin Ser Tyr Gin Val 1350 1355 1360 GGC AGA TGT ATA GGT TTT CTA TAT GGA GAC TTG GCG TAT AGA AAA TCT 9562 Gly Arg Cys He Gly Phe Leu Tyr Gly Asp Leu Ala Tyr Arg Lys Ser 1365 1370 1375 ACT CAT GCC GAG GAC AGT TCT CTA TTT CCT CTA TCT ATA CAA GGT CGT 9610 Thr His Ala Glu Asp Ser Ser Leu Phe Pro Leu Ser He Gin Gly Arg 1380 1385 1390 ATT AGA GGT CGA GGT TTC TTA AAA GGG TTG CTA GAC GGA TTA ATG AGA 9658 He Arg Gly Arg Gly Phe Leu Lys Gly Leu Leu Asp Gly Leu Met Arg 1395 1400 1405 1410 GCA AGT TGC TGC CAA GTA ATA CAC CGG AGA AGT CTG GCT CAT TTG AAG 9706 Ala Ser Cys Cys Gin Val He His Arg Arg Ser Leu Ala His Leu Lys 1415 1420 1425 AGG CCG GCC AAC GCA GTG TAC GGA GGT TTG ATT TAC TTG ATT GAT AAA 9754 Arg Pro Ala Asn Ala Val Tyr Gly Gly Leu He Tyr Leu He Asp Lys 1430 1435 1440 TTG AGT GTA TCA CCT CCA TTC CTT TCT CTT ACT AGA TCA GGA CCT ATT 9802 Leu Ser Val Ser Pro Pro Phe Leu Ser Leu Thr Arg Ser Gly Pro He 1445 1450 1455 AGA GAC GAA TTA GAA ACG ATT CCC CAC AAG ATC CCA ACC TCC TAT CCG 9850 Arg Asp Glu Leu Glu Thr He Pro His Lys He Pro Thr Ser Tyr Pro 1460 1465 1470 ACA AGC AAC CGT GAT ATG GGG GTG ATT GTC AGA AAT TAC TTC AAA TAC 9898 Thr Ser Asn Arg Asp Met Gly Val He Val Arg Asn Tyr Phe Lys Tyr 1475 1480 1485 1490 CAA TGC CGT CTA ATT GAA AAG GGA AAA TAC AGA TCA CAT TAT TCA CAA 9946 Gin Cys Arg Leu He Glu Lys Gly Lys Tyr Arg Ser His Tyr Ser Gin 1495 1500 1505 TTA TGG TTA TTC TCA GAT GTC TTA TCC ATA GAC TTC ATT GGA CCA TTC 9994 Leu Trp Leu Phe Ser Asp Val Leu Ser He Asp Phe He Gly Pro Phe 1510 1515 1520 TCT ATT TCC ACC ACC CTC TTG CAA ATC CTA TAC AAG CCA TTT TTA TCT 10042 Ser He Ser Thr Thr Leu Leu Gin He Leu Tyr Lys Pro Phe Leu Ser 1525 1530 1535 GGG AAA GAT AAG AAT GAG TTG AGA GAG CTG GCA AAT CTT TCT TCA TTG 10090 Gly Lys Asp Lys Asn Glu Leu Arg Glu Leu Ala Asn Leu Ser Ser Leu 1540 1545 1550 CTA AGA TCA GGA GAG GGG TGG GAA GAC ATA CAT GTG AAA TTC TTC ACC 10138 Leu Arg Ser Gly Glu Gly Trp Glu Asp He His Val Lys Phe Phe Thr 1555 1560 1565 1570 AAG GAC ATA TTA TTG TGT CCA GAG GAA ATC AGA CAT GCT TGC AAG TTC 10186 Lys Asp He Leu Leu Cys Pro Glu Glu He Arg His Ala Cys Lys Phe 1575 1580 1585 GGG ATT GCT AAG GAT AAT AAT AAA GAC ATG AGC TAT CCC CCT TGG GGA 10234 Gly He Ala Lys Asp Asn Asn Lys Asp Met Ser Tyr Pro Pro Trp Gly 1590 1595 1600 AGG GAA TCC AGA GGG ACA ATT ACA ACA ATC CCT GTT TAT TAT ACG ACC 10282 Arg Glu Ser Arg Gly Thr He Thr Thr He Pro Val Tyr Tyr Thr Thr 1605 1610 1615 ACC CCT TAC CCA AAG ATG CTA GAG ATG CCT CCA AGA ATC CAA AAT CCC 10330 Thr Pro Tyr Pro Lys Met Leu Glu Met Pro Pro Arg He Gin Asn Pro 1620 1625 1630 CTG CTG TCC GGA ATC AGG TTG GGC CAA TTA CCA ACT GGC GCT CAT TAT 10378 Leu Leu Ser Gly He Arg Leu Gly Gin Leu Pro Thr Gly Ala His Tyr 1635 1640 1645 1650 AAA ATT CGG AGT ATA TTA CAT GGA ATG GGA ATC CAT TAC AGG GAC TTC 10426 Lys He Arg Ser He Leu His Gly Met Gly He His Tyr Arg Asp Phe 1655 1660 1665 TTG AGT TGT GGA GAC GGC TCC GGA GGG ATG ACT GCT GCA TTA CTA CGA 10474 Leu Ser Cys Gly Asp Gly Ser Gly Gly Met Thr Ala Ala Leu Leu Arg 1670 1675 1680 GAA AAT GTG CAT AGC AGA GGA ATA TTC AAT AGT CTG TTA GAA TTA TCA 10522 Glu Asn Val His Ser Arg Gly He Phe Asn Ser Leu Leu Glu Leu Ser 1685 1690 1695 GGG TCA GTC ATG CGA GGC GCC TCT CCT GAG CCC CCC AGT GCC CTA GAA 10570 Gly Ser Val Met Arg Gly Ala Ser Pro Glu Pro Pro Ser Ala Leu Glu 1700 1705 1710 ACT TTA GGA GGA GAT AAA TCG AGA TGT GTA AAT GGT GAA ACA TGT TGG 10618 Thr Leu Gly Gly Asp Lys Ser Arg Cys Val Asn Gly Glu Thr Cys Trp 1715 1720 1725 1730 GAA TAT CCA TCT GAC TTA TGT GAC CCA AGG ACT TGG GAC TAT TTC CTC 10666 Glu Tyr Pro Ser Asp Leu Cys Asp Pro Arg Thr Trp Asp Tyr Phe Leu 1735 1740 1745 CGA CTC AAA GCA GGC TTG GGG CTT CAA ATT GAT TTA ATT GTA ATG GAT 10714 Arg Leu Lys Ala Gly Leu Gly Leu Gin He Asp Leu He Val Met Asp 1750 1755 1760 ATG GAA GTT CGG GAT TCT TCT ACT AGC CTG AAA ATT GAG ACG AAT GTT 10762 Met Glu Val Arg Asp Ser Ser Thr Ser Leu Lys He Glu Thr Asn Val 1765 1770 1775 AGA AAT TAT GTG CAC CGG ATT TTG GAT GAG CAA GGA GTT TTA ATC TAC 10810 Arg Asn Tyr Val His Arg He Leu Asp Glu Gin Gly Val Leu He Tyr 1780 1785 1790 AAG ACT TAT GGA ACA TAT ATT TGT GAG AGC GAA AAG AAT GCA GTA ACA 10858 Lys Thr Tyr Gly Thr Tyr He Cys Glu Ser Glu Lys Asn Ala Val Thr 1795 1800 1805 1810 ATC CTT GGT CCC ATG TTC AAG ACG GTC GAC TTA GTT CAA ACA GAA TTT 10906 He Leu Gly Pro Met Phe Lys Thr Val Asp Leu Val Gin Thr Glu Phe 1815 1820 1825 AGT AGT TCT CAA ACG TCT GAA GTA TAT ATG GTA TGT AAA GGT TTG AAG 10954 Ser Ser Ser Gin Thr Ser Glu Val Tyr Met Val Cys Lys Gly Leu Lys 1830 1835 1840 AAA TTA ATC GAT GAA CCC AAT CCC GAT TGG TCT TCC ATC AAT GAA TCC 11002 Lys Leu He Asp Glu Pro Asn Pro Asp Trp Ser Ser He Asn Glu Ser 1845 1850 1855 TGG AAA AAC CTG TAC GCA TTC CAG TCA TCA GAA CAG GAA TTT GCC AGA 11050 Trp Lys Asn Leu Tyr Ala Phe Gin Ser Ser Glu Gin Glu Phe Ala Arg 1860 1865 1870 GCA AAG AAG GTT AGT ACA TAC TTT ACC TTG ACA GGT ATT CCC TCC CAA 11098 Ala Lys Lys Val Ser Thr Tyr Phe Thr Leu Thr Gly He Pro Ser Gin 1875 1880 1885 1890 TTC ATT CCT GAT CCT TTT GTA AAC ATT GAG ACT ATG CTA CAA ATA TTC 11146 Phe He Pro Asp Pro Phe Val Asn He Glu Thr Met Leu Gin He Phe 1895 1900 1905 GGA GTA CCC ACG GGT GTG TCT CAT GCG GCT GCC TTA AAA TCA TCT GAT 11194 Gly Val Pro Thr Gly Val Ser His Ala Ala Ala Leu Lys Ser Ser Asp 1910 1915 1920 AGA CCT GCA GAT TTA TTG ACC ATT AGC CTT TTT TAT ATG GCG ATT ATA 11242 Arg Pro Ala Asp Leu Leu Thr He Ser Leu Phe Tyr Met Ala He He 1925 1930 1935 TCG TAT TAT AAC ATC AAT CAT ATC AGA GTA GGA CCG ATA CCT CCG AAC 11290 Ser Tyr Tyr Asn He Asn His He Arg Val Gly Pro He Pro Pro Asn 1940 1945 1950 CCC CCA TCA GAT GGA ATT GCA CAA AAT GTG GGG ATC GCT ATA ACT GGT 11338 Pro Pro Ser Asp Gly He Ala Gin Asn Val Gly He Ala He Thr Gly 1955 1960 1965 1970 ATA AGC TTT TGG CTG AGT TTG ATG GAG AAA GAC ATT CCA CTA TAT CAA 11386 He Ser Phe Trp Leu Ser Leu Met Glu Lys Asp He Pro Leu Tyr Gin 1975 1980 1985 CAG TGT TTA GCA GTT ATC CAG CAA TCA TTC CCG ATT AGG TGG GAG GCT 11434 Gin Cys Leu Ala Val He Gin Gin Ser Phe Pro He Arg Trp Glu Ala 1990 1995 2000 GTT TCA GTA AAA GGA GGA TAC AAG CAG AAG TGG AGT ACT AGA GGT GAT 11482 Val Ser Val Lys Gly Gly Tyr Lys Gin Lys Trp Ser Thr Arg Gly Asp 2005 2010 2015 GGG CTC CCA AAA GAT ACC CGA ACT TCA GAC TCC TTG GCC CCA ATC GGG 11530 Gly Leu Pro Lys Asp Thr Arg Thr Ser Asp Ser Leu Ala Pro He Gly 2020 2025 2030 AAC TGG ATC AGA TCT CTG GAA TTG GTC CGA AAC CAA GTT CGT CTA AAT 11578 Asn Trp He Arg Ser Leu Glu Leu Val Arg Asn Gin Val Arg Leu Asn 2035 2040 2045 2050 CCA TTC AAT GAG ATC TTG TTC AAT CAG CTA TGT CGT ACA GTG GAT AAT 11626 Pro Phe Asn Glu He Leu Phe Asn Gin Leu Cys Arg Thr Val Asp Asn 2055 2060 2065 CAT TTG AAA TGG TCA AAT TTG CGA AGA AAC ACA GGA ATG ATT GAA TGG 11674 His Leu Lys Trp Ser Asn Leu Arg Arg Asn Thr Gly Met He Glu Trp 2070 2075 2080 ATC AAT AGA CGA ATT TCA AAA GAA GAC CGG TCT ATA CTG ATG TTG AAG 11722 He Asn Arg Arg He Ser Lys Glu Asp Arg Ser He Leu Met Leu Lys 2085 2090 2095 AGT GAC CTA CAC GAG GAA AAC TCT TGG AGA GAT TAA AAAATCATGA 11768 Ser Asp Leu His Glu Glu Asn Ser Trp Arg Asp 2100 2105 GGAGACTCCA AACTTTAAGT ATGAAAAAAA CTTTGATCCT TAAGACCCTC TTGTGGTTTT 11828 TATTTTTTAT CTGGTTTTGT GGTCTTCGTG GGTCGGCATG GCATCTCCAC CTCCTCGCGG 11888 TCCGACCTGG GCATCCGAAG GAGGACGTCG TCCACTCGGA TGGCTAAGGG AGGGGCCCCC 11948 GCGGGGCTGC TAACAAAGCC CGAAAGGAAG CTGAGTTGGC TGCTGCCACC GCTGAGCAAT 12008 AACTAGCATA ACCCCTTGGG GCCTCTAAAC GGGTCTTGAG GGGTTTTTTG CTGAAAGGAG 12068 GAACTATATC CGGATCGAGA CCTCGATACT AGTGCGGTGG AGCTCCAGCT TTTGTTCCCT 12128 TTAGTGAGGG TTAATTTCGA GCTTGGCGTA ATCATGGTCA TAGCTGTTTC CTGTGTGAAA 12188 TTGTTATCCG CTCACAATTC CACACAACAT ACGAGCCGGA AGCATAAAGT GTAAAGCCTG 12248 GGGTGCCTAA TGAGTGAGCT AACTCACATT AATTGCGTTG CGCTCACTGC CCGCTTTCCA 12308 GTCGGGAAAC CTGTCGTGCC AGCTGCATTA ATGAATCGGC CAACGCGCGG GGAGAGGCGG 12368 TTTGCGTATT GGGCGCTCTT CCGCTTCCTC GCTCACTGAC TCGCTGCGCT CGGTCGTTCG 12428 GCTGCGGCGA GCGGTATCAG CTCACTCAAA GGCGGTAATA CGGTTATCCA CAGAATCAGG 12488 GGATAACGCA GGAAAGAACA TGTGAGCAAA AGGCCAGCAA AAGGCCAGGA ACCGTAAAAA 12548 GGCCGCGTTG CTGGCGTTTT TCCATAGGCT CCGCCCCCCT GACGAGCATC ACAAAAATCG 12608 ACGCTCAAGT CAGAGGTGGC GAAACCCGAC AGGACTATAA AGATACCAGG CGTTTCCCCC 12668 TGGAAGCTCC CTCGTGCGCT CTCCTGTTCC GACCCTGCCG CTTACCGGAT ACCTGTCCGC 12728 CTTTCTCCCT TCGGGAAGCG TGGCGCTTTC TCATAGCTCA CGCTGTAGGT ATCTCAGTTC 12788 GGTGTAGGTC GTTCGCTCCA AGCTGGGCTG TGTGCACGAA CCCCCCGTTC AGCCCGACCG 12848 CTGCGCCTTA TCCGGTAACT ATCGTCTTGA GTCCAACCCG GTAAGACACG ACTTATCGCC 12908 ACTGGCAGCA GCCACTGGTA ACAGGATTAG CAGAGCGAGG TATGTAGGCG GTGCTACAGA 12968 GTTCTTGAAG TGGTGGCCTA ACTACGGCTA CACTAGAAGG ACAGTATTTG GTATCTGCGC 13028 TCTGCTGAAG CCAGTTACCT TCGGAAAAAG AGTTGGTAGC TCTTGATCCG GCAAACAAAC 13088 CACCGCTGGT AGCGGTGGTT TTTTTGTTTG CAAGCAGCAG ATTACGCGCA GAAAAAAAGG 13148 ATCTCAAGAA GATCCTTTGA TCTTTTCTAC GGGGTCTGAC GCTCAGTGGA ACGAAAACTC 13208 ACGTTAAGGG ATTTTGGTCA TGAGATTATC AAAAAGGATC TTCACCTAGA TCCTTTTAAA 13268 TTAAAAATGA AGTTTTAAAT CAATCTAAAG TATATATGAG TAAACTTGGT CTGACAGTTA 13328 CCAATGCTTA ATCAGTGAGG CACCTATCTC AGCGATCTGT CTATTTCGTT CATCCATAGT 13388 TGCCTGACTC CCCGTCGTGT AGATAACTAC GATACGGGAG GGCTTACCAT CTGGCCCCAG 13448 TGCTGCAATG ATACCGCGAG ACCCACGCTC ACCGGCTCCA GATTTATCAG CAATAAACCA 13508 GCCAGCCGGA AGGGCCGAGC GCAGAAGTGG TCCTGCAACT TTATCCGCCT CCATCCAGTC 13568 TATTAATTGT TGCCGGGAAG CTAGAGTAAG TAGTTCGCCA GTTAATAGTT TGCGCAACGT 13628 TGTTGCCATT GCTACAGGCA TCGTGGTGTC ACGCTCGTCG TTTGGTATGG CTTCATTCAG 13688 CTCCGGTTCC CAACGATCAA GGCGAGTTAC ATGATCCCCC ATGTTGTGCA AAAAAGCGGT 13748 TAGCTCCTTC GGTCCTCCGA TCGTTGTCAG AAGTAAGTTG GCCGCAGTGT TATCACTCAT 13808 GGTTATGGCA GCACTGCATA ATTCTCTTAC TGTCATGCCA TCCGTAAGAT GCTTTTCTGT 13868 GACTGGTGAG TACTCAACCA AGTCATTCTG AGAATAGTGT ATGCGGCGAC CGAGTTGCTC 13928 TTGCCCGGCG TCAATACGGG ATAATACCGC GCCACATAGC AGAACTTTAA AAGTGCTCAT 13988 CATTGGAAAA CGTTCTTCGG GGCGAAAACT CTCAAGGATC TTACCGCTGT TGAGATCCAG 14048 TTCGATGTAA CCCACTCGTG CACCCAACTG ATCTTCAGCA TCTTTTACTT TCACCAGCGT 14108 TTCTGGGTGA GCAAAAACAG GAAGGCAAAA TGCCGCAAAA AAGGGAATAA GGGCGACACG 14168 GAAATGTTGA ATACTCATAC TCTTCCTTTT TCAATATTAT TGAAGCATTT ATCAGGGTTA 14228 TTGTCTCATG AGCGGATACA TATTTGAATG TATTTAGAAA AATAAACAAA TAGGGGTTCC 14288 GCGCACATTT CCCCGAAAAG TGC 14311 (2) INFORMATION FOR SEQ ID NO:2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 422 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Ser Val Thr Val Lys Arg He He Asp Asn Thr Val He Val Pro 1 5 10 15 Lys Leu Pro Ala Asn Glu Asp Pro Val Glu Tyr Pro Ala Asp Tyr Phe 20 25 30 Arg Lys Ser Lys Glu He Pro Leu Tyr He Asn Thr Thr Lys Ser Leu 35 40 45 Ser Asp Leu Arg Gly Tyr Val Tyr Gin Gly Leu Lys Ser Gly Asn Val 50 55 60 Ser He He His Val Asn Ser Tyr Leu Tyr Gly Ala Leu Lys Asp He 65 70 75 80 Arg Gly Lys Leu Asp Lys Asp Trp Ser Ser Phe Gly He Asn He Gly 85 90 95 Lys Ala Gly Asp Thr He Gly He Phe Asp Leu Val Ser Leu Lys Ala 100 105 110 Leu Asp Gly Val Leu Pro Asp Gly Val Ser Asp Ala Ser Arg Thr Ser 115 120 125 Ala Asp Asp Lys Trp Leu Pro Leu Tyr Leu Leu Gly Leu Tyr Arg Val 130 135 140 Gly Arg Thr Gin Met Pro Glu Tyr Arg Lys Lys Leu Met Asp Gly Leu 145 150 155 160 Thr Asn Gin Cys Lys Met He Asn Glu Gin Phe Glu Pro Leu Val Pro 165 170 175 Glu Gly Arg Asp He Phe Asp Val Trp Gly Asn Asp Ser Asn Tyr Thr 180 185 190 Lys He Val Ala Ala Val Asp Met Phe Phe His Met Phe Lys Lys His 195 200 205 Glu Cys Ala Ser Phe Arg Tyr Gly Thr He Val Ser Arg Phe Lys Asp 210 215 220 Cys Ala Ala Leu Ala Thr Phe Gly His Leu Cys Lys He Thr Gly Met 225 230 235 240 Ser Thr Glu Asp Val Thr Thr Trp He Leu Asn Arg Glu Val Ala Asp 245 250 255 Glu Met Val Gin Met Met Leu Pro Gly Gin Glu He Asp Lys Ala Asp 260 265 270 Ser Tyr Met Pro Tyr Leu He Asp Phe Gly Leu Ser Ser Lys Ser Pro 275 280 285 Tyr Ser Ser Val Lys Asn Pro Ala Phe His Phe Trp Gly Gin Leu Thr 290 295 300 Ala Leu Leu Leu Arg Ser Thr Arg Ala Arg Asn Ala Arg Gin Pro Asp 305 310 315 320 Asp He Glu Tyr Thr Ser Leu Thr Thr Ala Gly Leu Leu Tyr Ala Tyr 325 330 335 Ala Val Gly Ser Ser Ala Asp Leu Ala Gin Gin Phe Cys Val Gly Asp 340 345 350 Asn Lys Tyr Thr Pro Asp Asp Ser Thr Gly Gly Leu Thr Thr Asn Ala 355 360 365 Pro Pro Gin Gly Arg Asp Val Val Glu Trp Leu Gly Trp Phe Glu Asp 370 375 380 Gin Asn Arg Lys Pro Thr Pro Asp Met Met Gin Tyr Ala Lys Arg Ala 385 390 395 400 Val Met Ser Leu Gin Gly Leu Arg Glu Lys Thr He Gly Lys Tyr Ala 405 410 415 Lys Ser Glu Phe Asp Lys 420 (2) INFORMATION FOR SEQ ID NO:3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 265 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 : Met Asp Asn Leu Thr Lys Val Arg Glu Tyr Leu Lys Ser Tyr Ser Arg 1 5 10 15 Leu Asp Gin Ala Val Gly Glu He Asp Glu He Glu Ala Gin Arg Ala 20 25 30 Glu Lys Ser Asn Tyr Glu Leu Phe Gin Glu Asp Gly Val Glu Glu His 35 40 45 Thr Lys Pro Ser Tyr Phe Gin Ala Ala Asp Asp Ser Asp Thr Glu Ser 50 55 60 Glu Pro Glu He Glu Asp Asn Gin Gly Leu Tyr Ala Pro Asp Pro Glu 65 70 75 80 Ala Glu Gin Val Glu Gly Phe He Gin Gly Pro Leu Asp Asp Tyr Ala 85 90 95 Asp Glu Glu Val Asp Val Val Phe Thr Ser Asp Trp Lys Gin Pro Glu 100 105 110 Leu Glu Ser Asp Glu His Gly Lys Thr Leu Arg Leu Thr Ser Pro Glu 115 120 125 Gly Leu Ser Gly Glu Gin Lys Ser Gin Trp Leu Ser Thr He Lys Ala 130 135 140 Val Val Gin Ser Ala Lys Tyr Trp Asn Leu Ala Glu Cys Thr Phe Glu 145 150 155 160 Ala Ser Gly Glu Gly Val He Met Lys Glu Arg Gin He Thr Pro Asp 165 170 175 Val Tyr Lys Val Thr Pro Val Met Asn Thr His Pro Ser Gin Ser Glu 180 185 190 Ala Val Ser Asp Val Trp Ser Leu Ser Lys Thr Ser Met Thr Phe Gin 195 200 205 Pro Lys Lys Ala Ser Leu Gin Pro Leu Thr He Ser Leu Asp Glu Leu 210 215 220 Phe Ser Ser Arg Gly Glu Phe He Ser Val Gly Gly Asp Gly Arg Met 225 230 235 240 Ser His Lys Glu Ala He Leu Leu Gly Leu Arg Tyr Lys Lys Leu Tyr 245 250 255 Asn Gin Ala Arg Val Lys Tyr Ser Leu 260 265 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 229 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4 : Met Ser Ser Leu Lys Lys He Leu Gly Leu Lys Gly Lys Gly Lys Lys 1 5 10 15 Ser Lys Lys Leu Gly He Ala Pro Pro Pro Tyr Glu Glu Asp Thr Ser 20 25 30 Met Glu Tyr Ala Pro Ser Ala Pro He Asp Lys Ser Tyr Phe Gly Val 35 40 45 Asp Glu Met Asp Thr Tyr Asp Pro Asn Gin Leu Arg Tyr Glu Lys Phe 50 55 60 Phe Phe Thr Val Lys Met Thr Val Arg Ser Asn Arg Pro Phe Arg Thr 65 70 75 80 Tyr Ser Asp Val Ala Ala Ala Val Ser His Trp Asp His Met Tyr He 85 90 95 Gly Met Ala Gly Lys Arg Pro Phe Tyr Lys He Leu Ala Phe Leu Gly 100 105 110 Ser Ser Asn Leu Lys Ala Thr Pro Ala Val Leu Ala Asp Gin Gly Gin 115 120 125 Pro Glu Tyr His Thr His Cys Glu Gly Arg Ala Tyr Leu Pro His Arg 130 135 140 Met Gly Lys Thr Pro Pro Met Leu Asn Val Pro Glu His Phe Arg Arg 145 150 155 160 Pro Phe Asn He Gly Leu Tyr Lys Gly Thr He Glu Leu Thr Met Thr 165 170 175 He Tyr Asp Asp Glu Ser Leu Glu Ala Ala Pro Met He Trp Asp His 180 185 190 Phe Asn Ser Ser Lys Phe Ser Asp Phe Arg Glu Lys Ala Leu Met Phe 195 200 205 Gly Leu He Val Glu Lys Lys Ala Ser Gly Ala Trp Val Leu Asp Ser 210 215 220 He Ser His Phe Lys 225 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 511 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5 : Met Lys Cys Leu Leu Tyr Leu Ala Phe Leu Phe He Gly Val Asn Cys 1 5 10 15 Lys Phe Thr He Val Phe Pro His Asn Gin Lys Gly Asn Trp Lys Asn 20 25 30 Val Pro Ser Asn Tyr His Tyr Cys Pro Ser Ser Ser Asp Leu Asn Trp 35 40 45 His Asn Asp Leu He Gly Thr Ala He Gin Val Lys Met Pro Lys Ser 50 55 60 His Lys Ala He Gin Ala Asp Gly Trp Met Cys His Ala Ser Lys Trp 65 70 75 80 Val Thr Thr Cys Asp Phe Arg Trp Tyr Gly Pro Lys Tyr He Thr Gin 85 90 95 Ser He Arg Ser Phe Thr Pro Ser Val Glu Gin Cys Lys Glu Ser He 100 105 110 Glu Gin Thr Lys Gin Gly Thr Trp Leu Asn Pro Gly Phe Pro Pro Gin 115 120 125 Ser Cys Gly Tyr Ala Thr Val Thr Asp Ala Glu Ala Val He Val Gin 130 135 140 Val Thr Pro His His Val Leu Val Asp Glu Tyr Thr Gly Glu Trp Val 145 150 155 160 Asp Ser Gin Phe He Asn Gly Lys Cys Ser Asn Tyr He Cys Pro Thr 165 170 175 Val His Asn Ser Thr Thr Trp His Ser Asp Tyr Lys Val Lys Gly Leu 180 185 190 Cys Asp Ser Asn Leu He Ser Met Asp He Thr Phe Phe Ser Glu Asp 195 200 205 Gly Glu Leu Ser Ser Leu Gly Lys Glu Gly Thr Gly Phe Arg Ser Asn 210 215 220 Tyr Phe Ala Tyr Glu Thr Gly Gly Lys Ala Cys Lys Met Gin Tyr Cys 225 230 235 240 Lys His Trp Gly Val Arg Leu Pro Ser Gly Val Trp Phe Glu Met Ala 245 250 255 Asp Lys Asp Leu Phe Ala Ala Ala Arg Phe Pro Glu Cys Pro Glu Gly 260 265 270 Ser Ser He Ser Ala Pro Ser Gin Thr Ser Val Asp Val Ser Leu He 275 280 285 Gin Asp Val Glu Arg He Leu Asp Tyr Ser Leu Cys Gin Glu Thr Trp 290 295 300 Ser Lys He Arg Ala Gly Leu Pro He Ser Pro Val Asp Leu Ser Tyr 305 310 315 320 Leu Ala Pro Lys Asn Pro Gly Thr Gly Pro Ala Phe Thr He He Asn 325 330 335 Gly Thr Leu Lys Tyr Phe Glu Thr Arg Tyr He Arg Val Asp He Ala 340 345 350 Ala Pro He Leu Ser Arg Met Val Gly Met He Ser Gly Thr Thr Thr 355 360 365 Glu Arg Glu Leu Trp Asp Asp Trp Ala Pro Tyr Glu Asp Val Glu He 370 375 380 Gly Pro Asn Gly Val Leu Arg Thr Ser Ser Gly Tyr Lys Phe Pro Leu 385 390 395 400 Tyr Met He Gly His Gly Met Leu Asp Ser Asp Leu His Leu Ser Ser 405 410 415 Lys Ala Gin Val Phe Glu His Pro His He Gin Asp Ala Ala Ser Gin 420 425 430 Leu Pro Asp Asp Glu Ser Leu Phe Phe Gly Asp Thr Gly Leu Ser Lys 435 440 445 Asn Pro He Glu Leu Val Glu Gly Trp Phe Ser Ser Trp Lys Ser Ser 450 455 460 He Ala Ser Phe Phe Phe He He Gly Leu He He Gly Leu Phe Leu 465 470 475 480 Val Leu Arg Val Gly He His Leu Cys He Lys Leu Lys His Thr Lys 485 490 495 Lys Arg Gin He Tyr Thr Asp He Glu Met Asn Arg Leu Gly Lys 500 505 510 (2) INFORMATION FOR SEQ ID NO:6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2109 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Met Glu Val His Asp Phe Glu Thr Asp Glu Phe Asn Asp Phe Asn Glu 1 5 10 15 Asp Asp Tyr Ala Thr Arg Glu Phe Leu Asn Pro Asp Glu Arg Met Thr 20 25 30 Tyr Leu Asn His Ala Asp Tyr Asn Leu Asn Ser Pro Leu He Ser Asp 35 40 45 Asp He Asp Asn Leu He Arg Lys Phe Asn Ser Leu Pro He Pro Ser 50 55 60 Met Trp Asp Ser Lys Asn Trp Asp Gly Val Leu Glu Met Leu Thr Ser 65 70 75 80 Cys Gin Ala Asn Pro He Ser Thr Ser Gin Met His Lys Trp Met Gly 85 90 95 Ser Trp Leu Met Ser Asp Asn His Asp Ala Ser Gin Gly Tyr Ser Phe 100 105 110 Leu His Glu Val Asp Lys Glu Ala Glu He Thr Phe Asp Val Val Glu 115 120 125 Thr Phe He Arg Gly Trp Gly Asn Lys Pro He Glu Tyr He Lys Lys 130 135 140 Glu Arg Trp Thr Asp Ser Phe Lys He Leu Ala Tyr Leu Cys Gin Lys 145 150 155 160 Phe Leu Asp Leu His Lys Leu Thr Leu He Leu Asn Ala Val Ser Glu 165 170 175 Val Glu Leu Leu Asn Leu Ala Arg Thr Phe Lys Gly Lys Val Arg Arg 180 185 190 Ser Ser His Gly Thr Asn He Cys Arg He Arg Val Pro Ser Leu Gly 195 200 205 Pro Thr Phe He Ser Glu Gly Trp Ala Tyr Phe Lys Lys Leu Asp He 210 215 220 Leu Met Asp Arg Asn Phe Leu Leu Met Val Lys Asp Val He He Gly 225 230 235 240 Arg Met Gin Thr Val Leu Ser Met Val Cys Arg He Asp Asn Leu Phe 245 250 255 Ser Glu Gin Asp He Phe Ser Leu Leu Asn He Tyr Arg He Gly Asp 260 265 270 Lys He Val Glu Arg Gin Gly Asn Phe Ser Tyr Asp Leu He Lys Met 275 280 285 Val Glu Pro He Cys Asn Leu Lys Leu Met Lys Leu Ala Arg Glu Ser 290 295 300 Arg Pro Leu Val Pro Gin Phe Pro His Phe Glu Asn His He Lys Thr 305 310 315 320 Ser Val Asp Glu Gly Ala Lys He Asp Arg Gly He Arg Phe Leu His 325 330 335 Asp Gin He Met Ser Val Lys Thr Val Asp Leu Thr Leu Val He Tyr 340 345 350 Gly Ser Phe Arg His Trp Gly His Pro Phe He Asp Tyr Tyr Thr Gly 355 360 365 Leu Glu Lys Leu His Ser Gin Val Thr Met Lys Lys Asp He Asp Val 370 375 380 Ser Tyr Ala Lys Ala Leu Ala Ser Asp Leu Ala Arg He Val Leu Phe 385 390 395 400 Gin Gin Phe Asn Asp His Lys Lys Trp Phe Val Asn Gly Asp Leu Leu 405 410 415 Pro His Asp His Pro Phe Lys Ser His Val Lys Glu Asn Thr Trp Pro 420 425 430 Thr Ala Ala Gin Val Gin Asp Phe Gly Asp Lys Trp His Glu Leu Pro 435 440 445 Leu He Lys Cys Phe Glu He Pro Asp Leu Leu Asp Pro Ser He He 450 455 460 Tyr Ser Asp Lys Ser His Ser Met Asn Arg Ser Glu Val Leu Lys His 465 470 475 480 Val Arg Met Asn Pro Asn Thr Pro He Pro Ser Lys Lys Val Leu Gin 485 490 495 Thr Met Leu Asp Thr Lys Ala Thr Asn Trp Lys Glu Phe Leu Lys Glu 500 505 510 He Asp Glu Lys Gly Leu Asp Asp Asp Asp Leu He He Gly Leu Lys 515 520 525 Gly Lys Glu Arg Glu Leu Lys Leu Ala Gly Arg Phe Phe Ser Leu Met 530 535 540 Ser Trp Lys Leu Arg Glu Tyr Phe Val He Thr Glu Tyr Leu He Lys 545 550 555 560 Thr His Phe Val Pro Met Phe Lys Gly Leu Thr Met Ala Asp Asp Leu 565 570 575 Thr Ala Val He Lys Lys Met Leu Asp Ser Ser Ser Gly Gin Gly Leu 580 585 590 Lys Ser Tyr Glu Ala He Cys He Ala Asn His He Asp Tyr Glu Lys 595 600 605 Trp Asn Asn His Gin Arg Lys Leu Ser Asn Gly Pro Val Phe Arg Val 610 615 620 Met Gly Gin Phe Leu Gly Tyr Pro Ser Leu He Glu Arg Thr His Glu 625 630 635 640 Phe Phe Glu Lys Ser Leu He Tyr Tyr Asn Gly Arg Pro Asp Leu Met 645 650 655 Arg Val His Asn Asn Thr Leu He Asn Ser Thr Ser Gin Arg Val Cys 660 665 670 Trp Gin Gly Gin Glu Gly Gly Leu Glu Gly Leu Arg Gin Lys Gly Trp 675 680 685 Thr He Leu Asn Leu Leu Val He Gin Arg Glu Ala Lys He Arg Asn 690 695 700 Thr Ala Val Lys Val Leu Ala Gin Gly Asp Asn Gin Val He Cys Thr 705 710 715 720 Gin Tyr Lys Thr Lys Lys Ser Arg Asn Val Val Glu Leu Gin Gly Ala 725 730 735 Leu Asn Gin Met Val Ser Asn Asn Glu Lys He Met Thr Ala He Lys 740 745 750 He Gly Thr Gly Lys Leu Gly Leu Leu He Asn Asp Asp Glu Thr Met 755 760 765 Gin Ser Ala Asp Tyr Leu Asn Tyr Gly Lys He Pro He Phe Arg Gly 770 775 780 Val He Arg Gly Leu Glu Thr Lys Arg Trp Ser Arg Val Thr Cys Val 785 790 795 800 Thr Asn Asp Gin He Pro Thr Cys Ala Asn He Met Ser Ser Val Ser 805 810 815 Thr Asn Ala Leu Thr Val Ala His Phe Ala Glu Asn Pro He Asn Ala 820 825 830 Met He Gin Tyr Asn Tyr Phe Gly Thr Phe Ala Arg Leu Leu Leu Met 835 840 845 Met His Asp Pro Ala Leu Arg Gin Ser Leu Tyr Glu Val Gin Asp Lys 850 855 860 He Pro Gly Leu His Ser Ser Thr Phe Lys Tyr Ala Met Leu Tyr Leu 865 870 875 880 Asp Pro Ser lie Gly Gly Val Ser Gly Met Ser Leu Ser Arg Phe Leu 885 890 895 He Arg Ala Phe Pro Asp Pro Val Thr Glu Ser Leu Ser Phe Trp Arg 900 905 910 Phe He His Val His Ala Arg Ser Glu His Leu Lys Glu Met Ser Ala 915 920 925 Val Phe Gly Asn Pro Glu He Ala Lys Phe Arg He Thr His He Asp 930 935 940 Lys Leu Val Glu Asp Pro Thr Ser Leu Asn He Ala Met Gly Met Ser 945 950 955 960 Pro Ala Asn Leu Leu Lys Thr Glu Val Lys Lys Cys Leu He Glu Ser 965 970 975 Arg Gin Thr He Arg Asn Gin Val He Lys Asp Ala Thr He Tyr Leu 980 985 990 Tyr His Glu Glu Asp Arg Leu Arg Ser Phe Leu Trp Ser He Asn Pro 995 1000 1005 Leu Phe Pro Arg Phe Leu Ser Glu Phe Lys Ser Gly Thr Phe Leu Gly 1010 1015 1020 Val Ala Asp Gly Leu He Ser Leu Phe Gin Asn Ser Arg Thr He Arg 1025 1030 1035 1040 Asn Ser Phe Lys Lys Lys Tyr His Arg Glu Leu Asp Asp Leu He Val 1045 1050 1055 Arg Ser Glu Val Ser Ser Leu Thr His Leu Gly Lys Leu His Leu Arg 1060 1065 1070 Arg Gly Ser Cys Lys Met Trp Thr Cys Ser Ala Thr His Ala Asp Thr 1075 1080 1085 Leu Arg Tyr Lys Ser Trp Gly Arg Thr Val He Gly Thr Thr Val Pro 1090 1095 1100 His Pro Leu Glu Met Leu Gly Pro Gin His Arg Lys Glu Thr Pro Cys 1105 1110 1115 1120 Ala Pro Cys Asn Thr Ser Gly Phe Asn Tyr Val Ser Val His Cys Pro 1125 1130 1135 Asp Gly He His Asp Val Phe Ser Ser Arg Gly Pro Leu Pro Ala Tyr 1140 1145 1150 Leu Gly Ser Lys Thr Ser Glu Ser Thr Ser He Leu Gin Pro Trp Glu 1155 1160 1165 Arg Glu Ser Lys Val Pro Leu He Lys Arg Ala Thr Arg Leu Arg Asp 1170 1175 1180 Ala He Ser Trp Phe Val Glu Pro Asp Ser Lys Leu Ala Met Thr He 1185 1190 1195 1200 Leu Ser Asn He His Ser Leu Thr Gly Glu Glu Trp Thr Lys Arg Gin 1205 1210 1215 His Gly Phe Lys Arg Thr Gly Ser Ala Leu His Arg Phe Ser Thr Ser 1220 1225 1230 Arg Met Ser His Gly Gly Phe Ala Ser Gin Ser Thr Ala Ala Leu Thr 1235 1240 1245 Arg Leu Met Ala Thr Thr Asp Thr Met Arg Asp Leu Gly Asp Gin Asn 1250 1255 1260 Phe Asp Phe Leu Phe Gin Ala Thr Leu Leu Tyr Ala Gin He Thr Thr 1265 1270 1275 1280 Thr Val Ala Arg Asp Gly Trp He Thr Ser Cys Thr Asp His Tyr His 1285 1290 1295 He Ala Cys Lys Ser Cys Leu Arg Pro He Glu Glu He Thr Leu Asp 1300 1305 1310 Ser Ser Met Asp Tyr Thr Pro Pro Asp Val Ser His Val Leu Lys Thr 1315 1320 1325 Trp Arg Asn Gly Glu Gly Ser Trp Gly Gin Glu He Lys Gin He Tyr 1330 1335 1340 Pro Leu Glu Gly Asn Trp Lys Asn Leu Ala Pro Ala Glu Gin Ser Tyr 1345 1350 1355 1360 Gin Val Gly Arg Cys He Gly Phe Leu Tyr Gly Asp Leu Ala Tyr Arg 1365 1370 1375 Lys Ser Thr His Ala Glu Asp Ser Ser Leu Phe Pro Leu Ser He Gin 1380 1385 1390 Gly Arg He Arg Gly Arg Gly Phe Leu Lys Gly Leu Leu Asp Gly Leu 1395 1400 1405 Met Arg Ala Ser Cys Cys Gin Val He His Arg Arg Ser Leu Ala His 1410 1415 1420 Leu Lys Arg Pro Ala Asn Ala Val Tyr Gly Gly Leu He Tyr Leu He 1425 1430 1435 1440 Asp Lys Leu Ser Val Ser Pro Pro Phe Leu Ser Leu Thr Arg Ser Gly 1445 1450 1455 Pro He Arg Asp Glu Leu Glu Thr He Pro His Lys He Pro Thr Ser 1460 1465 1470 Tyr Pro Thr Ser Asn Arg Asp Met Gly Val He Val Arg Asn Tyr Phe 1475 1480 1485 Lys Tyr Gin Cys Arg Leu He Glu Lys Gly Lys Tyr Arg Ser His Tyr 1490 1495 1500 Ser Gin Leu Trp Leu Phe Ser Asp Val Leu Ser He Asp Phe He Gly 1505 1510 1515 1520 Pro Phe Ser He Ser Thr Thr Leu Leu Gin He Leu Tyr Lys Pro Phe 1525 1530 1535 Leu Ser Gly Lys Asp Lys Asn Glu Leu Arg Glu Leu Ala Asn Leu Ser 1540 1545 1550 Ser Leu Leu Arg Ser Gly Glu Gly Trp Glu Asp He His Val Lys Phe 1555 1560 1565 Phe Thr Lys Asp He Leu Leu Cys Pro Glu Glu He Arg His Ala Cys 1570 1575 1580 Lys Phe Gly He Ala Lys Asp Asn Asn Lys Asp Met Ser Tyr Pro Pro 1585 1590 1595 1600 Trp Gly Arg Glu Ser Arg Gly Thr He Thr Thr He Pro Val Tyr Tyr 1605 1610 1615 Thr Thr Thr Pro Tyr Pro Lys Met Leu Glu Met Pro Pro Arg He Gin 1620 1625 1630 Asn Pro Leu Leu Ser Gly He Arg Leu Gly Gin Leu Pro Thr Gly Ala 1635 1640 1645 His Tyr Lys He Arg Ser He Leu His Gly Met Gly He His Tyr Arg 1650 1655 1660 Asp Phe Leu Ser Cys Gly Asp Gly Ser Gly Gly Met Thr Ala Ala Leu 1665 1670 1675 1680 Leu Arg Glu Asn Val His Ser Arg Gly He Phe Asn Ser Leu Leu Glu 1685 1690 1695 Leu Ser Gly Ser Val Met Arg Gly Ala Ser Pro Glu Pro Pro Ser Ala 1700 1705 1710 Leu Glu Thr Leu Gly Gly Asp Lys Ser Arg Cys Val Asn Gly Glu Thr 1715 1720 1725 Cys Trp Glu Tyr Pro Ser Asp Leu Cys Asp Pro Arg Thr Trp Asp Tyr 1730 1735 1740 Phe Leu Arg Leu Lys Ala Gly Leu Gly Leu Gin He Asp Leu He Val 1745 1750 1755 1760 Met Asp Met Glu Val Arg Asp Ser Ser Thr Ser Leu Lys He Glu Thr 1765 1770 1775 Asn Val Arg Asn Tyr Val His Arg He Leu Asp Glu Gin Gly Val Leu 1780 1785 1790 He Tyr Lys Thr Tyr Gly Thr Tyr He Cys Glu Ser Glu Lys Asn Ala 1795 1800 1805 Val Thr He Leu Gly Pro Met Phe Lys Thr Val Asp Leu Val Gin Thr 1810 1815 1820 Glu Phe Ser Ser Ser Gin Thr Ser Glu Val Tyr Met Val Cys Lys Gly 1825 1830 1835 1840 Leu Lys Lys Leu He Asp Glu Pro Asn Pro Asp Trp Ser Ser He Asn 1845 1850 1855 Glu Ser Trp Lys Asn Leu Tyr Ala Phe Gin Ser Ser Glu Gin Glu Phe 1860 1865 1870 Ala Arg Ala Lys Lys Val Ser Thr Tyr Phe Thr Leu Thr Gly He Pro 1875 1880 1885 Ser Gin Phe He Pro Asp Pro Phe Val Asn He Glu Thr Met Leu Gin 1890 1895 1900 He Phe Gly Val Pro Thr Gly Val Ser His Ala Ala Ala Leu Lys Ser 1905 1910 1915 1920 Ser Asp Arg Pro Ala Asp Leu Leu Thr He Ser Leu Phe Tyr Met Ala 1925 1930 1935 He He Ser Tyr Tyr Asn He Asn His He Arg Val Gly Pro He Pro 1940 1945 1950 Pro Asn Pro Pro Ser Asp Gly He Ala Gin Asn Val Gly He Ala He 1955 1960 1965 Thr Gly He Ser Phe Trp Leu Ser Leu Met Glu Lys Asp He Pro Leu 1970 1975 1980 Tyr Gin Gin Cys Leu Ala Val He Gin Gin Ser Phe Pro He Arg Trp 1985 1990 1995 2000 Glu Ala Val Ser Val Lys Gly Gly Tyr Lys Gin Lys Trp Ser Thr Arg 2005 2010 2015 Gly Asp Gly Leu Pro Lys Asp Thr Arg Thr Ser Asp Ser Leu Ala Pro 2020 2025 2030 He Gly Asn Trp He Arg Ser Leu Glu Leu Val Arg Asn Gin Val Arg 2035 2040 2045 Leu Asn Pro Phe Asn Glu He Leu Phe Asn Gin Leu Cys Arg Thr Val 2050 2055 2060 Asp Asn His Leu Lys Trp Ser Asn Leu Arg Arg Asn Thr Gly Met He 2065 2070 2075 2080 Glu Trp He Asn Arg Arg He Ser Lys Glu Asp Arg Ser He Leu Met 2085 2090 2095 Leu Lys Ser Asp Leu His Glu Glu Asn Ser Trp Arg Asp 2100 2105 (2 ) INFORMATION FOR SEQ ID NO : 7 : ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH: 14311 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7 : GCACTTTTCG GGGAAATGTG CGCGGAACCC CTATTTGTTT ATTTTTCTAA ATACATTCAA 60 ATATGTATCC GCTCATGAGA CAATAACCCT GATAAATGCT TCAATAATAT TGAAAAAGGA 120 AGAGTATGAG TATTCAACAT TTCCGTGTCG CCCTTATTCC CTTTTTTGCG GCATTTTGCC 180 TTCCTGTTTT TGCTCACCCA GAAACGCTGG TGAAAGTAAA AGATGCTGAA GATCAGTTGG 240 GTGCACGAGT GGGTTACATC GAACTGGATC TCAACAGCGG TAAGATCCTT GAGAGTTTTC 300 GCCCCGAAGA ACGTTTTCCA ATGATGAGCA CTTTTAAAGT TCTGCTATGT GGCGCGGTAT 360 TATCCCGTAT TGACGCCGGG CAAGAGCAAC TCGGTCGCCG CATACACTAT TCTCAGAATG 420 ACTTGGTTGA GTACTCACCA GTCACAGAAA AGCATCTTAC GGATGGCATG ACAGTAAGAG 480 AATTATGCAG TGCTGCCATA ACCATGAGTG ATAACACTGC GGCCAACTTA CTTCTGACAA 540 CGATCGGAGG ACCGAAGGAG CTAACCGCTT TTTTGCACAA CATGGGGGAT CATGTAACTC 600 GCCTTGATCG TTGGGAACCG GAGCTGAATG AAGCCATACC AAACGACGAG CGTGACACCA 660 CGATGCCTGT AGCAATGGCA ACAACGTTGC GCAAACTATT AACTGGCGAA CTACTTACTC 720 TAGCTTCCCG GCAACAATTA ATAGACTGGA TGGAGGCGGA TAAAGTTGCA GGACCACTTC 780 TGCGCTCGGC CCTTCCGGCT GGCTGGTTTA TTGCTGATAA ATCTGGAGCC GGTGAGCGTG 840 GGTCTCGCGG TATCATTGCA GCACTGGGGC CAGATGGTAA GCCCTCCCGT ATCGTAGTTA 900 TCTACACGAC GGGGAGTCAG GCAACTATGG ATGAACGAAA TAGACAGATC GCTGAGATAG 960 GTGCCTCACT GATTAAGCAT TGGTAACTGT CAGACCAAGT TTACTCATAT ATACTTTAGA 1020 TTGATTTAAA ACTTCATTTT TAATTTAAAA GGATCTAGGT GAAGATCCTT TTTGATAATC 1080 TCATGACCAA AATCCCTTAA CGTGAGTTTT CGTTCCACTG AGCGTCAGAC CCCGTAGAAA 1140 AGATCAAAGG ATCTTCTTGA GATCCTTTTT TTCTGCGCGT AATCTGCTGC TTGCAAACAA 1200 AAAAACCACC GCTACCAGCG GTGGTTTGTT TGCCGGATCA AGAGCTACCA ACTCTTTTTC 1260 CGAAGGTAAC TGGCTTCAGC AGAGCGCAGA TACCAAATAC TGTCCTTCTA GTGTAGCCGT 1320 AGTTAGGCCA CCACTTCAAG AACTCTGTAG CACCGCCTAC ATACCTCGCT CTGCTAATCC 1380 TGTTACCAGT GGCTGCTGCC AGTGGCGATA AGTCGTGTCT TACCGGGTTG GACTCAAGAC 1440 GATAGTTACC GGATAAGGCG CAGCGGTCGG GCTGAACGGG GGGTTCGTGC ACACAGCCCA 1500 GCTTGGAGCG AACGACCTAC ACCGAACTGA GATACCTACA GCGTGAGCTA TGAGAAAGCG 1560 CCACGCTTCC CGAAGGGAGA AAGGCGGACA GGTATCCGGT AAGCGGCAGG GTCGGAACAG 1620 GAGAGCGCAC GAGGGAGCTT CCAGGGGGAA ACGCCTGGTA TCTTTATAGT CCTGTCGGGT 1680 TTCGCCACCT CTGACTTGAG CGTCGATTTT TGTGATGCTC GTCAGGGGGG CGGAGCCTAT 1740 GGAAAAACGC CAGCAACGCG GCCTTTTTAC GGTTCCTGGC CTTTTGCTGG CCTTTTGCTC 1800 ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC GCCTTTGAGT 1860 GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG CGAGTCAGTG AGCGAGGAAG 1920 CGGAAGAGCG CCCAATACGC AAACCGCCTC TCCCCGCGCG TTGGCCGATT CATTAATGCA 1980 GCTGGCACGA CAGGTTTCCC GACTGGAAAG CGGGCAGTGA GCGCAACGCA ATTAATGTGA 2040 GTTAGCTCAC TCATTAGGCA CCCCAGGCTT TACACTTTAT GCTTCCGGCT CGTATGTTGT 2100 GTGGAATTGT GAGCGGATAA CAATTTCACA CAGGAAACAG CTATGACCAT GATTACGCCA 2160 AGCTCGAAAT TAACCCTCAC TAAAGGGAAC AAAAGCTGGA GCTCCACCGC ACTAGTATCG 2220 AGGTCTCGAT CCGGATATAG TTCCTCCTTT CAGCAAAAAA CCCCTCAAGA CCCGTTTAGA 2280 GGCCCCAAGG GGTTATGCTA GTTATTGCTC AGCGGTGGCA GCAGCCAACT CAGCTTCCTT 2340 TCGGGCTTTG TTAGCAGCCC CGCGGGGGCC CCTCCCTTAG CCATCCGAGT GGACGACGTC 2400 CTCCTTCGGA TGCCCAGGTC GGACCGCGAG GAGGTGGAGA TGCCATGCCG ACCCACGAAG 2460 ACCACAAAAC CAGATAAAAA ATAAAAACCA CAAGAGGGTC TTAAGGATCA AAGTTTTTTT 2520 CATACTTAAA GTTTGGAGTC TCCTCATGAT TTTTTAATCT CTCCAAGAGT TTTCCTCGTG 2580 TAGGTCACTC TTCAACATCA GTATAGACCG GTCTTCTTTT GAAATTCGTC TATTGATCCA 2640 TTCAATCATT CCTGTGTTTC TTCGCAAATT TGACCATTTC AAATGATTAT CCACTGTACG 2700 ACATAGCTGA TTGAACAAGA TCTCATTGAA TGGATTTAGA CGAACTTGGT TTCGGACCAA 2760 TTCCAGAGAT CTGATCCAGT TCCCGATTGG GGCCAAGGAG TCTGAAGTTC GGGTATCTTT 2820 TGGGAGCCCA TCACCTCTAG TACTCCACTT CTGCTTGTAT CCTCCTTTTA CTGAAACAGC 2880 CTCCCACCTA ATCGGGAATG ATTGCTGGAT AACTGCTAAA CACTGTTGAT ATAGTGGAAT 2940 GTCTTTCTCC ATCAAACTCA GCCAAAAGCT TATACCAGTT ATAGCGATCC CCACATTTTG 3000 TGCAATTCCA TCTGATGGGG GGTTCGGAGG TATCGGTCCT ACTCTGATAT GATTGATGTT 3060 ATAATACGAT ATAATCGCCA TATAAAAAAG GCTAATGGTC AATAAATCTG CAGGTCTATC 3120 AGATGATTTT AAGGCAGCCG CATGAGACAC ACCCGTGGGT ACTCCGAATA TTTGTAGCAT 3180 AGTCTCAATG TTTACAAAAG GATCAGGAAT GAATTGGGAG GGAATACCTG TCAAGGTAAA 3240 GTATGTACTA ACCTTCTTTG CTCTGGCAAA TTCCTGTTCT GATGACTGGA ATGCGTACAG 3300 GTTTTTCCAG GATTCATTGA TGGAAGACCA ATCGGGATTG GGTTCATCGA TTAATTTCTT 3360 CAAACCTTTA CATACCATAT ATACTTCAGA CGTTTGAGAA CTACTAAATT CTGTTTGAAC 3420 TAAGTCGACC GTCTTGAACA TGGGACCAAG GATTGTTACT GCATTCTTTT CGCTCTCACA 3480 AATATATGTT CCATAAGTCT TGTAGATTAA AACTCCTTGC TCATCCAAAA TCCGGTGCAC 3540 ATAATTTCTA ACATTCGTCT CAATTTTCAG GCTAGTAGAA GAATCCCGAA CTTCCATATC 3600 CATTACAATT AAATCAATTT GAAGCCCCAA GCCTGCTTTG AGTCGGAGGA AATAGTCCCA 3660 AGTCCTTGGG TCACATAAGT CAGATGGATA TTCCCAACAT GTTTCACCAT TTACACATCT 3720 CGATTTATCT CCTCCTAAAG TTTCTAGGGC ACTGGGGGGC TCAGGAGAGG CGCCTCGCAT 3780 GACTGACCCT GATAATTCTA ACAGACTATT GAATATTCCT CTGCTATGCA CATTTTCTCG 3840 TAGTAATGCA GCAGTCATCC CTCCGGAGCC GTCTCCACAA CTCAAGAAGT CCCTGTAATG 3900 GATTCCCATT CCATGTAATA TACTCCGAAT TTTATAATGA GCGCCAGTTG GTAATTGGCC 3960 CAACCTGATT CCGGACAGCA GGGGATTTTG GATTCTTGGA GGCATCTCTA GCATCTTTGG 4020 GTAAGGGGTG GTCGTATAAT AAACAGGGAT TGTTGTAATT GTCCCTCTGG ATTCCCTTCC 4080 CCAAGGGGGA TAGCTCATGT CTTTATTATT ATCCTTAGCA ATCCCGAACT TGCAAGCATG 4140 TCTGATTTCC TCTGGACACA ATAATATGTC CTTGGTGAAG AATTTCACAT GTATGTCTTC 4200 CCACCCCTCT CCTGATCTTA GCAATGAAGA AAGATTTGCC AGCTCTCTCA ACTCATTCTT 4260 ATCTTTCCCA GATAAAAATG GCTTGTATAG GATTTGCAAG AGGGTGGTGG AAATAGAGAA 4320 TGGTCCAATG AAGTCTATGG ATAAGACATC TGAGAATAAC CATAATTGTG AATAATGTGA 4380 TCTGTATTTT CCCTTTTCAA TTAGACGGCA TTGGTATTTG AAGTAATTTC TGACAATCAC 4440 CCCCATATCA CGGTTGCTTG TCGGATAGGA GGTTGGGATC TTGTGGGGAA TCGTTTCTAA 4500 TTCGTCTCTA ATAGGTCCTG ATCTAGTAAG AGAAAGGAAT GGAGGTGATA CACTCAATTT 4560 ATCAATCAAG TAAATCAAAC CTCCGTACAC TGCGTTGGCC GGCCTCTTCA AATGAGCCAG 4620 ACTTCTCCGG TGTATTACTT GGCAGCAACT TGCTCTCATT AATCCGTCTA GCAACCCTTT 4680 TAAGAAACCT CGACCTCTAA TACGACCTTG TATAGATAGA GGAAATAGAG AACTGTCCTC 4740 GGCATGAGTA GATTTTCTAT ACGCCAAGTC TCCATATAGA AAACCTATAC ATCTGCCGAC 4800 TTGATAGGAT TGCTCAGCAG GTGCTAAATT CTTCCAATTC CCTTCTAAAG GATAGATCTG 4860 TTTTATCTCT TGTCCCCACG AACCTTCCCC ATTCCTCCAT GTCTTCAGCA CATGGGATAC 4920 ATCTGGGGGC GTGTAGTCCA TACTTGAGTC CAGGGTGATC TCTTCTATGG GTCTCAAACA 4980 GGACTTACAG GCAATATGAT AATGATCTGT ACAACTGGTG ATCCATCCGT CTCTTGCAAC 5040 AGTGGTGGTA ATTTGAGCAT AGAGCAACGT TGCTTGGAAT AAAAAGTCGA AATTCTGATC 5100 TCCCAGATCC CTCATGGTGT CTGTAGTTGC CATCAACCTG GTCAATGCTG CAGTGCTCTG 5160 AGATGCGAAC CCACCATGGC TCATCCGAGA TGTCGAAAAC CTATGAAGGG CAGACCCTGT 5220 TCTTTTGAAC CCATGCTGCC TTTTGGTCCA TTCTTCGCCT GTTAAAGAGT GGATGTTAGA 5280 AAGTATAGTC ATTGCTAGTT TAGAGTCGGG TTCAACAAAC CAAGAGATAG CATCTCTAAG 5340 ACGTGTAGCT CTTTTAATCA GTGGGACTTT GCTTTCCCTT TCCCAAGGCT GCAAAATAGA 5400 TGTAGATTCA GATGTTTTAG ACCCTAGATA AGCAGGCAAT GGTCCCCGTG AACTAAAGAC 5460 GTCATGGATC CCGTCTGGAC AATGCACAGA AACATAATTG AACCCTGATG TGTTACATGG 5520 TGCACAAGGA GTCTCTTTTC GATGTTGTGG ACCCAACATT TCTAATGGAT GGGGTACAGT 5580 TGTCCCAATA ACTGTACGGC CCCAGGATTT GTATCTTAAT GTGTCAGCAT GAGTAGCTGA 5640 ACATGTCCAC ATTTTACATG ATCCCCTTCT CAAATGAAGT TTCCCTAAAT GTGTCAAAGA 5700 GGATACCTCA CTCCTCACAA TCAAATCATC CAATTCCCTA TGATACTTTT TCTTAAAGGA 5760 GTTCCGAATA GTACGAGAAT TTTGAAATAG ACTGATGAGC CCGTCTGCGA CTCCCAAAAA 5820 AGTGCCTGAT TTGAATTCAC TTAAAAATCT AGGGAACAGA GGATTTATTG ACCATAAGAA 5880 ACTTCTGAGC CGATCCTCTT CATGATACAA ATATATGGTT GCATCCTTAA TCACCTGGTT 5940 CCTGATGGTT TGTCTTGATT CGATTAAGCA TTTTTTAACC TCAGTCTTTA ACAAGTTCGC 6000 TGGACTCATT CCCATAGCGA TGTTCAGAGA GGTTGGATCT TCTACTAGCT TGTCTATGTG 6060 AGTTATTCGA AACTTGGCTA TCTCGGGGTT TCCAAATACT GCACTCATCT CCTTCAGATG 6120 CTCACTTCGA GCATGTACAT GGATGAATCT CCAGAATGAG AGACTTTCTG TTACGGGATC 6180 TGGGAAGGCT CTAATCAAAA ACCTGGACAA AGACATGCCC GACACTCCTC CAATGGAAGG 6240 GTCCAAATAC AACATGGCGT ATTTGAAAGT AGAACTGTGC AAGCCCGGTA TCTTATCTTG 6300 AACTTCATAC AATGATTGAC GAAGAGCAGG ATCATGCATC ATCAACAAGA GTCTAGCAAA 6360 TGTCCCAAAA TAATTGTACT GTATCATGGC ATTGATTGGG TTCTCAGCAA AATGAGCTAC 6420 GGTGAGAGCA TTTGTGGAAA CTGAGCTCAT TATATTAGCA CAAGTGGGTA TTTGGTCATT 6480 GGTGACACAA GTCACTCGTG ACCATCTCTT GGTCTCTAAC CCTCTAATCA CTCCACGGAA 6540 AATCGGTATT TTTCCATAAT TCAAGTAATC TGCAGATTGC ATAGTCTCAT CGTCATTTAT 6600 CAAAAGTCCT AACTTCCCTG TCCCTATTTT GATTGCAGTC ATAATTTTCT CATTATTAGA 6660 AACCATTTGA TTGAGAGCAC CCTGTAATTC TACAACGTTT CTCGATTTCT TCGTTTTATA 6720 CTGTGTGCAA ATAACTTGAT TATCACCTTG TGCCAAGACT TTGACAGCAG TGTTTCTGAT 6780 TTTAGCCTCT CTTTGAATAA CCAGTAGATT GAGGATAGTC CATCCTTTTT GCCGTAGACC 6840 TTCCAGTCCA CCCTCTTGTC CTTGCCAACA AACTCGTTGG GAGGTTGAAT TGATCAGTGT 6900 GTTGTTGTGA ACACGCATCA AGTCTGGTCT TCCATTGTAG TATATAAGAC TTTTCTCAAA 6960 AAATTCATGA GTTCTCTCGA TTAAGGATGG ATAACCTAAG AACTGGCCCA TAACTCGGAA 7020 CACTGGGCCG TTTGATAACT TCCTTTGGTG GTTATTCCAT TTTTCGTAAT CAATGTGATT 7080 GGCTATGCAA ATTGCCTCAT ATGACTTCAA TCCTTGGCCG GATGAGGAAT CTAACATCTT 7140 TTTAATGACT GCAGTTAGAT CGTCCGCCAT TGTCAGGCCT TTAAACATAG GGACGAAATG 7200 AGTCTTTATC AAATATTCGG TAATTACAAA GTATTCTCGC AATTTCCAAG ACATTAGGGA 7260 GAAAAATCTA CCTGCCAACT TCAGTTCCCT CTCCTTTCCT TTAAGACCAA TAATTAGATC 7320 ATCATCATCT AAGCCCTTCT CATCAATCTC TTTAAGAAAT TCTTTCCAAT TGGTAGCCTT 7380 TGTGTCCAAC ATAGTCTGCA ACACCTTTTT ACTAGGGATA GGAGTGTTCG GATTCATTCG 7440 GACATGTTTC AACACCTCTG ACCTATTCAT TGAATGACTT TTGTCAGAGT ATATTATCGA 7500 TGGGTCTAGT AAGTCGGGTA TTTCAAAACA TTTAATCAGC GGAAGTTCAT GCCATTTATC 7560 TCCAAAATCT TGAACTTGAG CAGCTGTGGG CCATGTATTT TCTTTAACAT GACTTTTAAA 7620 GGGATGATCA TGAGGGAGCA AGTCTCCATT CACGAACCAC TTTTTATGAT CATTGAACTG 7680 TTGAAATAGA ACAATCCGAG CTAAATCACT TGCAAGTGCT TTTGCATATG ACACATCAAT 7740 ATCTTTCTTC ATGGTTACTT GGGAATGTAA TTTTTCTAGT CCAGTGTAAT AATCTATAAA 7800 AGGATGACCC CAATGTCTGA ACGATCCATA AATCACCAGT GTGAGATCCA CTGTTTTCAC 7860 ACTCATTATC TGATCATGGA GGAATCTTAT ACCTCGGTCA ATTTTTGCCC CTTCATCAAC 7920 AGAAGTCTTG ATATGATTTT CAAAATGAGG GAATTGTGGG ACTAAAGGCC TTGATTCTCT 7980 TGCTAATTTC ATCAGCTTCA AGTTGCATAT CGGTTCCACC ATTTTAATCA AGTCATAAGA 8040 AAAATTTCCC TGCCTCTCCA CAATTTTATC TCCAATTCTG TAGATATTTA GAAGGGAGAA 8100 GATGTCTTGC TCTGAGAACA GGTTGTCTAT TCTACATACC ATGGATAGCA CCGTTTGCAT 8160 CCTCCCTATA ATCACATCTT TGACCATTAA CAGAAAGTTT CGGTCCATTA GAATATCAAG 8220 TTTCTTGAAG TAAGCCCATC CTTCTGAAAT AAAAGTAGGA CCCAAGCTGG GAACCCTAAT 8280 CCTGCATATG TTCGTTCCAT GAGAACTTCT TCTGACTTTG CCTTTGAAAG TCCTCGCCAA 8340 GTTGAGCAAT TCCACCTCAG AGACAGCATT TAAGATTAAT GTCAACTTGT GTAAGTCCAA 8400 AAACTTTTGA CACAAATAAG CGAGAATTTT GAATGAGTCA GTCCATCTTT CCTTTTTGAT 8460 GTATTCAATT GGTTTGTTGC CCCAGCCGCG GATGAAGGTC TCCACCACGT CAAATGTTAT 8520 TTCTGCCTCT TTGTCCACTT CATGTAAAAA ACTATACCCT TGACTGGCAT CATGATTATC 8580 AGACATTAAC CAACTTCCCA TCCATTTATG CATCTGAGAT GTTGAGATGG GATTGGCTTG 8640 ACATGATGTT AACATCTCAA GAACTCCATC CCAGTTCTTA CTATCCCACA TCGAGGGAAT 8700 CGGAAGAGAA TTGAATTTCC TGATCAAATT GTCAATATCA TCACTAATTA GAGGAGAATT 8760 CAAATTGTAA TCAGCATGAT TCAAGTACGT CATGCGCTCA TCGGGATTCA GGAATTCTCT 8820 TGTGGCATAG TCATCTTCAT TGAAATCATT GAACTCGTCG GTCTCAAAAT CGTGGACTTC 8880 CATGATTGCT GTTAGTTTTT TTCATAAAAA TTAAAAACTC AAATATAATT GAGGCCTCTT 8940 TGAGCATGGT ATCACAAGTT GATTTGGTCC AAACATGAAG AATCTGGCTA GCAGGATTTG 9000 AGTTACTTTC CAAGTCGGTT CATCTCTATG TCTGTATAAA TCTGTCTTTT CTTGGTGTGC 9060 TTTAATTTAA TGCAAAGATG GATACCAACT CGGAGAACCA AGAATAGTCC AATGATTAAC 9120 CCTATGATAA AGAAAAAAGA GGCAATAGAG CTTTTCCAAC TACTGAACCA ACCTTCTACA 9180 AGCTCGATTG GATTTTTGGA TAGCCCAGTA TCACCAAAAA ATAAACTCTC ATCATCAGGA 9240 AGTTGCGAAG CAGCGTCTTG AATGTGAGGA TGTTCGAACA CCTGAGCCTT TGAGCTAAGA 9300 TGAAGATCGG AGTCCAACAT ACCATGTCCA ATCATGTATA AAGGAAACTT ATATCCTGAA 9360 CTGGTCCTCA GAACTCCATT GGGTCCAATT TCCACGTCTT CATATGGTGC CCAGTCATCC 9420 CACAGTTCCC TTTCTGTGGT AGTTCCACTG ATCATTCCGA CCATTCTTGA GAGGATTGGA 9480 GCAGCAATAT CGACTCTGAT GTATCTGGTC TCAAAGTATT TTAGGGTACC ATTGATTATG 9540 GTGAAAGCAG GACCGGTTCC TGGGTTTTTA GGAGCAAGAT AGCTGAGATC CACTGGAGAG 9600 ATTGGAAGAC CCGCTCTGAT TTTGCTCCAG GTTTCTTGGC AGAGGGAATA ATCCAAGATC 9660 CTCTCAACGT CCTGAATTAG ACTTACATCC ACTGAGGTCT GAGATGGAGC AGAGATACTT 9720 GACCCTTCTG GGCATTCAGG GAATCTGGCT GCAGCAAAGA GATCCTTATC AGCCATCTCG 9780 AACCAGACAC CTGATGGGAG TCTGACTCCC CAATGCTTGC AGTATTGCAT TTTGCAGGCC 9840 TTGCCTCCAG TTTCATAAGC AAAGTAGTTA CTTCTGAACC CTGTGCCCTC CTTTCCCAGG 9900 GATGATAGCT CTCCGTCCTC TGAGAAGAAG GTGATGTCCA TGGAAATGAG GTTAGAATCA 9960 CATAGCCCTT TGACCTTATA GTCAGAATGC CAGGTTGTAG AGTTATGGAC AGTGGGGCAT 10020 ATGTAATTGC TGCATTTTCC GTTGATGAAC TGTGAATCAA CCCATTCTCC TGTGTATTCA 10080 TCAACCAGCA CATGGTGAGG AGTCACCTGG ACAATCACTG CTTCGGCATC CGTCACAGTT 10140 GCATATCCAC AACTTTGAGG AGGGAAGCCT GGATTCAGCC AAGTTCCTTG TTTCGTTTGT 10200 TCAATGCTTT CCTTGCATTG TTCTACAGAT GGAGTGAAGG ATCGGATGGA CTGTGTTATA 10260 TACTTCGGTC CATACCAGCG GAAATCACAA GTAGTGACCC ATTTGGAAGC ATGACACATC 10320 CAACCGTCTG CTTGAATAGC CTTGTGACTC TTGGGCATTT TGACTTGTAT GGCTGTGCCT 10380 ATTAAGTCAT TATGCCAATT TAAATCTGAG CTTGACGGGC AATAATGGTA ATTAGAAGGA 10440 ACATTTTTCC AGTTTCCTTT TTGGTTGTGT GGAAAAACTA TGGTGAACTT GCAATTCACC 10500 CCAATGAATA AAAAGGCTAA GTACAAAAGG CACTTCATAG TGACGCGTAA ACAGATCGAT 10560 CTCTGTTAGT TTTTTTCATA GGGATAGAAA AGACAGGATA TTAGTTGTTC GAGAGGCTGG 10620 AATTAGGAGA GACTGAGTAA ACCGGGGATT GTTCAGAAGC TAGAAGTTAG ACTAGCTCAT 10680 TTGAAGTGGC TGATAGAATC CAGGACCCAC GCTCCAGATG CCTTTTTCTC GACAATCAGG 10740 CCAAACATTA AGGCCTTCTC TCTGAAATCA GAAAATTTGG AAGAATTGAA ATGATCCCAG 10800 ATCATAGGAG CTGCTTCCAG TGACTCATCA TCGTAGATGG TCATTGTGAG CTCAATCGTT 10860 CCCTTGTAAA GACCTATATT GAATGGTCTT CTGAAGTGCT CTGGTACATT GAGCATGGGA 10920 GGGGTCTTCC CCATCCTATG TGGCAAATAA GCCCTGCCTT CGCAGTGAGT GTGATACTCT 10980 GGTTGACCTT GATCTGCCAA TACCGCTGGA GTGGCCTTTA GATTAGAAGA ACCCAAAAAA 11040 GCCAAGATTT TGTAGAAGGG ACGTTTCCCT GCCATTCCGA TGTACATGTG ATCCCAATGG 11100 GATACAGCGG CTGCCACATC TGAGTATGTT CTGAACGGAC GATTAGATCT AACCGTCATT 11160 TTCACTGTAA AGAAGAATTT CTCATATCTT AATTGATTCG GATCATAGGT GTCCATCTCG 11220 TCAACTCCAA AATAGGATTT GTCAATTGGA GCGCTCGGAG CATACTCCAT GCTAGTGTCC 11280 TCTTCATAAG GGGGTGGTGC GATCCCTAAT TTCTTAGATT TCTTACCTTT CCCCTTCAGA 11340 CCGAGAATCT TCTTTAAGGA ACTCATGATG AATGGATTGG GATAACACTT AGATCGTGAT 11400 ATCTGTTACT TTTTTTCATA GTCTACAGAG AATATTTGAC TCTCGCCTGA TTGTACAACT 11460 TTTTGTATCT CAGGCCGAGC AGGATGGCCT CTTTATGAGA CATTCGTCCG TCACCTCCGA 11520 CAGAGATGAA CTCTCCTCTA GATGAGAACA ATTCATCCAA GGATATGGTG AGAGGCTGAA 11580 GACTTGCTTT CTTGGGTTGG AAAGTCATGG ATGTCTTTGA GAGAGACCAA ACATCTGATA 11640 CTGCTTCTGA TTGGGACGGA TGTGTGTTCA TCACTGGAGT GACCTTATAT ACATCCGGAG 11700 TTATCTGGCG CTCCTTCATA ATGACCCCTT CTCCCGATGC TTCAAATGTG CACTCTGCCA 11760 GATTCCAGTA TTTGGCACTT TGCACGACTG CTTTAATCGT CGAAAGCCAC TGGGATTTCT 11820 GCTCTCCACT TAAACCCTCT GGCGATGTCA ACCGTAAGGT CTTTCCATGC TCGTCAGATT 11880 CAAGCTCAGG CTGTTTCCAG TCCGAAGTAA ATACAACATC CACTTCCTCA TCTGCATAGT 11940 CATCTAAAGG CCCCTGTATA AAGCCTTCAA CTTGCTCAGC TTCTGGATCT GGTGCATACA 12000 AACCTTGATT GTCTTCAATT TCTGGTTCAG ATTCTGTGTC AGAATCATCT GCTGCCTGAA 12060 AATAAGAGGG CTTAGTATGC TCTTCCACTC CATCCTCTTG GAACAACTCA TAATTGGACT 12120 TTTCAGCTCG TTGTGCTTCG ATCTCATCTA TCTCTCCTAC CGCCTGATCC AGACGAGAAT 12180 AGGACTTGAG ATACTCACGA ACTTTTGTGA GATTATCCAT GATATCTGTT AGTTTTTTTC 12240 ATATGTAGCA TAATATATAA TAGGTGATCT GAGAATTATA GGGTCATTTG TCAAATTCTG 12300 ACTTAGCATA CTTGCCAATT GTCTTCTCTC TTAGGCCTTG CAGTGACATG ACTGCTCTTT 12360 TCGCATACTG CATCATATCA GGAGTCGGTT TTCTGTTTTG ATCTTCAAAC CATCCGAGCC 12420 ATTCGACCAC ATCTCTGCCT TGTGGCGGTG CATTAGTCGT CAATCCTCCG GTACTATCAT 12480 CTGGAGTGTA TTTGTTATCT CCAACACAAA ACTGTTGTGC CAAGTCGGCA GAGGATCCTA 12540 CTGCATAAGC GTACAACAAA CCTGCTGTAG TAAGAGATGT ATACTCAATG TCATCAGGCT 12600 GTCGGGCATT CCTTGCTCTG GTGGATCTGA GCAGAAGAGC TGTCAATTGC CCCCAGAAGT 12660 GGAAGGCAGG GTTTTTGACG GAAGAATATG GAGACTTAGA AGACAATCCA AAGTCGATCA 12720 AATAAGGCAT GTATGAATCG GCCTTGTCAA TTTCTTGGCC TGGAAGCATC ATTTGGACCA 12780 TTTCATCTGC AACTTCTCGG TTCAAGATCC AGGTCGTTAC ATCTTCTGTA GACATTCCGG 12840 TTATTTTGCA GAGGTGTCCA AATGTTGCCA ATGCAGCACA ATCTTTGAAT CTGGAAACAA 12900 TAGTTCCGTA TCTGAACGAG GCACATTCAT GTTTTTTGAA CATGTGGAAG AACATGTCCA 12960 CTGCAGCGAC AATTTTTGTG TAATTACTGT CATTTCCCCA CACATCAAAA ATGTCACGAC 13020 CTTCTGGCAC AAGAGGTTCA AACTGTTCAT TGATCATTTT GCATTGATTT GTCAGCCCAT 13080 CCATGAGCTT TTTTCTGTAT TCAGGCATTT GTGTTCTGCC CACTCTGTAT AAGCCAAGTA 13140 GATACAAAGG CAACCATTTG TCATCTGCGC TGGTTCTGGA AGCATCCGAT ACTCCATCTG 13200 GAAGTACGCC GTCCAGGGCT TTCAAGGATA CAAGGTCAAA TATTCCGATT GTATCCCCTG 13260 CTTTCCCGAT GTTTATTCCG AAACTTGACC AATCTTTATC CAACTTACCC CGGATGTCCT 13320 TTAATGCTCC ATACAAGTAG CTGTTGACAT GTATGATTGA TACATTTCCG GATTTGAGGC 13380 CTTGGTAGAC ATATCCTCTT AGATCTGACA AACTTTTTGT AGTATTGATG TAAAGAGGAA 13440 TCTCCTTTGA TTTTCTGAAG TAATCTGCCG GGTATTCCAC TGGATCCTCA TTTGCAGGAA 13500 GTTTTGGAAC TATGACTGTG TTGTCAATGA TTCTCTTGAC TGTAACAGAC ATTTTGATTA 13560 CTGTTAAAGT TTCTCCTGAG CCTTTTAATG ATAATAATGG TTTGTTTGTC TTCGTCCCTA 13620 TAGTGAGTCG TATTACAACT CGAGGGGGGG CCCGGTACCC AATTCGCCCT ATAGTGAGTC 13680 GTATTACAAT TCACTGGCCG TCGTTTTACA ACGTCGTGAC TGGGAAAACC CTGGCGTTAC 13740 CCAACTTAAT CGCCTTGCAG CACATCCCCC TTTCGCCAGC TGGCGTAATA GCGAAGAGGC 13800 CCGCACCGAT CGCCCTTCCC AACAGTTGCG CAGCCTGAAT GGCGAATGGG ACGCGCCCTG 13860 TAGCGGCGCA TTAAGCGCGG CGGGTGTGGT GGTTACGCGC AGCGTGACCG CTACACTTGC 13920 CAGCGCCCTA GCGCCCGCTC CTTTCGCTTT CTTCCCTTCC TTTCTCGCCA CGTTCGCCGG 13980 CTTTCCCCGT CAAGCTCTAA ATCGGGGGCT CCCTTTAGGG TTCCGATTTA GTGCTTTACG 14040 GCACCTCGAC CCCAAAAAAC TTGATTAGGG TGATGGTTCA CGTAGTGGGC CATCGCCCTG 14100 ATAGACGGTT TTTCGCCCTT TGACGTTGGA GTCCACGTTC TTTAATAGTG GACTCTTGTT 14160 CCAAACTGGA ACAACACTCA ACCCTATCTC GGTCTATTCT TTTGATTTAT AAGGGATTTT 14220 GCCGATTTCG GCCTATTGGT TAAAAAATGA GCTGATTTAA CAAAAATTTA ACGCGAATTT 14280 TAACAAAATA TTAACGCTTA CAATTTAGGT G 14311 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8 : TTGTAATACG ACTCACTATA GGG 23 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS:. (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9 : TTGTAATACG ACTCACTATA GGG 23 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 50 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: ACGAAGACAA ACAAACCATT ATTATCATTA AAAGGCTCAG GAGAAACTTT 50 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 136 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GGCTGCTAAC AAAGCCCGAA AGGAAGCTGA GTTGGCTGCT GCCACCGCTG AGCAATAACT 60 AGCATAACCC CTTGGGGCCT CTAAACGGGT CTTGAGGGGT TTTTTGCTGA AAGGAGGAAC 120 TATATCCGGA TCGAGA 136 (2) INFORMATION FOR SEQ ID NO:12 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 83 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: GGGTCGGCAT GGCATCTCCA CCTCCTCGCG GTCCGACCTG GGCATCCGAA GGAGGACGTC 60 GTCCACTCGG ATGGCTAAGG GAG 83 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 630 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: TTGTAGAAGG TTGGTTCAGT AGTTGGAAAA GCTCTATTGC CTCTTTTTTC TTTATCATAG 60 GGTTAATCAT TGGACTATTC TTGGTTCTCC GAGTTGGTAT CCATCTTTGC ATTAAATTAA 120 AGCACACCAA GAAAAGACAG ATTTATACAG ACATAGAGAT GAACCGACTT GGAAAGTAAC 180 TCAAATCCTG CTAGCTATGA AAAAAACTAA CAGATATCCA ACCCGGGAGC TAGTTGCGGC 240 CGCCTAGCAG ATTCTTCATG TTTGGACCAA ATCAACTTGT GATACCATGC TCAAAGAGGC 300 CTCAATTATA TTTGAGTTTT TAATTTTTAT GAAAAAAACT AACAGCAATC ATGGAAGTCC 360 ACGATTTTGA GACCGACGAG TTCAATGATT TCAATGAAGA TGACTATGCC ACAAGAGAAT 420 TCCTGAATCC CGATGAGCGC ATGACGTACT TGAATCATGC TGATTACAAT TTGAATTCTC 480 CTCTAATTAG TGATGATATT GACAATTTGA TCAGGAAATT CAATTCTCTT CCGATTCCCT 540 CGATGTGGGA TAGTAAGAAC TGGGATGGAG TTCTTGAGAT GTTAACATCA TGTCAAGCCA 600 ATCCCATCTC AACATCTCAG ATGCATAAAT 630 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 630 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: ATTTATGCAT CTGAGATGTT GAGATGGGAT TGGCTTGACA TGATGTTAAC ATCTCAAGAA 60 CTCCATCCCA GTTCTTACTA TCCCACATCG AGGGAATCGG AAGAGAATTG AATTTCCTGA 120 TCAAATTGTC AATATCATCA CTAATTAGAG GAGAATTCAA ATTGTAATCA GCATGATTCA 180 AGTACGTCAT GCGCTCATCG GGATTCAGGA ATTCTCTTGT GGCATAGTCA TCTTCATTGA 240 AATCATTGAA CTCGTCGGTC TCAAAATCGT GGACTTCCAT GATTGCTGTT AGTTTTTTTC 300 ATAAAAATTA AAAACTCAAA TATAATTGAG GCCTCTTTGA GCATGGTATC ACAAGTTGAT 360 TTGGTCCAAA CATGAAGAAT CTGCTAGGCG GCCGCAACTA GCTCCCGGGT TGGATATCTG 420 TTAGTTTTTT TCATAGCTAG CAGGATTTGA GTTACTTTCC AAGTCGGTTC ATCTCTATGT 480 CTGTATAAAT CTGTCTTTTC TTGGTGTGCT TTAATTTAAT GCAAAGATGG ATACCAACTC 540 GGAGAACCAA GAATAGTCCA ATGATTAACC CTATGATAAA GAAAAAAGAG GCAATAGAGC 600 TTTTCCAACT ACTGAACCAA CCTTCTACAA 630 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: UCAGGAGAAA C 11 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: 5' Gppp (B) LOCATION: 1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: AACAGUAAUC 10 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: GAUUACUGUU AAAGUUUCUC CUGA 24 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: polyA (B) LOCATION: 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: GCUACAUAUG 10 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: 5' Gppp (B) LOCATION: 1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: AACAGAUAUC 10 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: GAUAUCUGUU AGUUUUUUUC AUAUGUAGC 29 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: polyA (B) LOCATION: 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: GUAGACUAUG 10 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: 5' Gppp (B) LOCATION: 1 (x ) SEQUENCE DESCRIPTION: SEQ ID NO:22: AACAGAUAUC 10 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: GAUAUCUGUU ACUUUUUUUC AUAGUCUAC 29 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: polyA (B) LOCATION: 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: UAUCCCUAUG 10 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: 5' Gppp (B) LOCATION: 1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: AACAGAGAUC 10 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: GAUCUCUGUU AGUUUUUUUC AUAGGGAUA 29 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: polyA (B) LOCATION: 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: AAUUUUUAUG 10 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: 5' Gppp (B) LOCATION: 1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: AACAGCAAUC 10 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: GAUUGCUGUU AGUUUUUUUC AUAAAAAUU 29 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: polyA (B) LOCATION: 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: UUUAAGUAUG 10 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: AGGAUCAAAG UUUUUUUCAU ACUUAAA 27 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: CATTCAAGAC GCTGCTTCGC AACTTCC 27 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: CATGAATGTT AACATCTCAA GA 22 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: RNA (ix) FEATURE: (A) NAME/KEY: miscellaneous feature (B) LOCATION: 11..12 (D) OTHER INFORMATION: Intergenic dinucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: GAUNNCUGUU ANUUUUUUUC AUA 23 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: UAUGAAAAAA A 11 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: RNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: UUUUUUUCAU A 11 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: TATGAAAAAA A 11 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 59 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: CCGGCTCGAG TTGTAATACG ACTCACTATA GGGACGAAGA CAAACAAACC ATTATTATC 59 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: GAACTCTCCT CTAGATGAGA AC 22 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: AGGTCGGACC GCGAGGAGGT GGAGATGCCA TGCCGACCCA CGAAGACCAC AAAACCAG 58 (2) INFORMATION FOR SEQ ID NO:41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: ATGTTGAAGA GTGACCTACA CG 22

Claims: WHAT IS CLAIMED IS: 1. A recombinant replicable vesiculovirus, the genome of which comprises a foreign RNA sequence. 2. The vesiculovirus of claim 1 in which an RNA sequence complementary to said foreign RNA sequence encodes a peptide or protein that is expressed in a suitable host infected by the virus. 3. The vesiculovirus of claim 1 in which the peptide or protein is antigenic or immunogenic. 4. The vesiculovirus of claim 2 in which the peptide or protein displays the antigenicity or immunogenicity of an antigen of a pathogenic microorganism. 5. The vesiculovirus of claim 4 in which the pathogenic microorganism is a virus. 6. The vesiculovirus of claim 4 in which the pathogenic microorganism is a bacterium. 7. The vesiculovirus of claim 4 in which the pathogenic microorganism is a parasite. 8. The vesiculovirus of claim 4 in which the pathogenic microorganism is a human pathogen. 9. The vesiculovirus of claim 4 in which the pathogenic microorganism is a non-human pathogen. 10. The vesiculovirus of claim 2 in which the peptide or protein displays the antigenicity or immunogenicity of a tumor specific or tumor associated antigen. 11. Plasmid pVSVFL(+) , as deposited with the ATCC and assigned accession number 97134. 12. A nucleic acid comprising the DNA sequence of plasmid pVSVFL(- ) as depicted in Figure 1 from nucleotide numbers 623-12088 (a portion of SEQ ID NO:l), in which a region nonessential for vesiculovirus replication has been inserted into or replaced by foreign DNA. 13. A host cell containing the recombinant vesiculovirus of claim 1. 14. A method of producing a recombinant vesiculovirus comprising culturing a cell containing (a) a recombinant nucleic acid that can be transcribed to produce an RNA molecule comprising a vesiculovirus antigenomic (+) RNA, in which a region of the RNA nonessential for replication of the vesiculovirus has been inserted into or replaced by a foreign RNA sequence; (b) a second recombinant nucleic acid encoding a vesiculovirus N protein; (c) a third recombinant nucleic acid encoding a vesiculovirus L protein; and (d) a fourth recombinant nucleic acid encoding a vesiculovirus P protein; whereby the first recombinant nucleic acid is transcribed in the cell to produce said RNA molecule, and the N, L and P proteins are expressed in the cell, and a recombinant replicable vesiculovirus is produced that has a genome that is the complement of said antigenomic RNA comprising said foreign RNA sequence. 15. The method according to claim 14 in which the cell is a mammalian cell. 16. The method according to claim 14 in which the first recombinant nucleic acid comprises a first promoter sequence which controls the expression of the RNA molecule in the cell; the second recombinant nucleic acid comprises a second promoter sequence which controls the expression of the N protein in the cell; the third recombinant nucleic acid comprises a third promoter sequence which controls the expression of the P protein in the cell; and the fourth recombinant nucleic acid comprises a fourth promoter sequence which controls the expression of the L protein in the cell. 17. The method according to claim 14 in which said RNA molecule further comprises a ribozyme sequence immediately downstream of said antigenomic (+) RNA, that cleaves at the 3' terminus of the antigenomic (+) RNA. 18. The method according to claim 14 in which the first recombinant nucleic acid is a DNA plasmid vector comprising the following operatively linked components: (a) a promoter; (b) a DNA sequence that can be transcribed under the control of the promoter in the cell to produce said RNA molecule; and (c) a transcription termination signal. 19. The method according to claim 14 or 18 in which the second recombinant nucleic acid is a DNA plasmid vector comprising the following operatively linked components: (a) a promoter which controls the expression of the N protein; (b) a translation initiation signal; (c) a DNA sequence encoding the N protein; and (d) a transcription termination signal; and in which the third recombinant nucleic acid is a DNA plasmid vector comprising the following operatively linked components: (a) a promoter which controls the expression of the P protein; (b) a translation initiation signal; (c) a DNA sequence encoding the P protein; and (d) a transcription termination signal; and and in which the fourth recombinant nucleic acid is a DNA plasmid vector comprising the following operatively linked components: (a) a promoter which controls the expression of the L protein; (b) a translation initiation signal; (c) a DNA sequence encoding the L protein; and (d) a transcription termination signal. 20. The method according to claim 17 in which the first recombinant nucleic acid is a DNA plasmid vector comprising the following operatively linked components: (a) a promoter; (b) a DNA sequence that can be transcribed under the control of the promoter in the cell to produce said RNA molecule; and (c) a transcription termination signal. 21. The method according to claim 19 in which the first recombinant nucleic acid, the second recombinant nucleic acid, the third recombinant nucleic acid, and the fourth recombinant nucleic acid, each further comprises a selectable marker. 22. The method according to claim 14 in which the second, third and fourth recombinant nucleic acids form part of a single recombinant nucleic acid. 23. The method according to claim 16 in which the first, second, third and fourth promoter sequences are RNA polymerase promoter sequences for the same RNA polymerase, and in which the cell also contains a cytoplasmic source of said RNA polymerase. 24. The method according to claim 23 in which the cytoplasmic source of said RNA polymerase is a recombinant vaccinia virus expressing said RNA polymerase in the cell. 25. A method of producing a recombinant vesiculovirus comprising culturing a mammalian cell containing: (a) a first DNA plasmid vector comprising the following operatively linked components: (i) a bacteriophage RNA polymerase promoter; (ii) a first DNA sequence that is transcribed in the cell to produce an RNA molecule comprising (A) a vesiculovirus antigenomic (+) RNA in which a region of the RNA nonessential for replication of the vesiculovirus has been inserted into or replaced by a foreign RNA sequence, and (B) a ribozyme sequence immediately downstream of said antigenomic (+) RNA, that cleaves at the 3' terminus of the antigenomic RNA; and (iii) a transcription termination signal for the RNA polymerase; (b) a second DNA plasmid vector comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter; (ii) a second DNA sequence encoding an N protein of the vesiculovirus; and (iii) a second transcription termination signal for the RNA polymerase; (c) a third DNA plasmid vector comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter; (ii) a third DNA sequence encoding a P protein of the vesiculovirus; and (iii) a third transcription termination signal for the RNA polymerase; (d) a fourth DNA plasmid vector comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter; (ii) a fourth DNA sequence encoding an L protein of the vesiculovirus; and (iii) a fourth transcription termination signal for the RNA polymerase; and (e) a recombinant vaccinia virus comprising a sequence encoding the bacteriophage RNA polymerase; whereby in said cell the first DNA sequence is transcribed to produce said RNA molecule, the N, P, and L proteins and the bacteriophage RNA polymerase are expressed, and a recombinant replicable vesiculovirus is produced that has a genome that is the complement of said antigenomic RNA comprising said foreign RNA sequence. 26. The method according to claim 25 in which the ribozyme sequence is the sequence of the hepatitis delta virus ribozyme, and the bacteriophage RNA polymerase is the T7 RNA polymerase. 27. The method according to claim 14 in which the foreign RNA sequence is the complement of a sequence encoding a protein or peptide that is immunogenic or antigenic. 28. The method according to claim 25 in which the foreign RNA sequence is the complement of a sequence encoding a protein or peptide that is immunogenic or antigenic. 29. The method according to claim 27 or 28 in which the protein or peptide displays the antigenicity or immunogenicity of an antigen of a pathogenic microorganism. 30. The method according to claim 27 or 28 in which the protein or peptide displays the antigenicity or immunogenicity of a tumor specific antigen. 31. The method according to claim 25 which further comprises before step (a) the step of introducing said first, second, third and fourth plasmid vectors and said recombinant vaccinia virus into said cell. 32. A host cell comprising (a) a recombinant nucleic acid that can be transcribed to produce an RNA molecule comprising a vesiculovirus antigenomic (+) RNA, in which a region of the RNA nonessential for replication of the vesiculovirus has been inserted into or replaced by a foreign RNA sequence; (b) a second recombinant nucleic acid encoding a vesiculovirus N protein; (c) a third recombinant nucleic acid encoding a vesiculovirus L protein; and (d) a fourth recombinant nucleic acid encoding a vesiculovirus P protein. 33. A host cell comprising: (a) a first DNA plasmid vector comprising the following operatively linked components: (i) a bacteriophage RNA polymerase promoter; (ii) a first DNA sequence that is transcribed in the cell to produce an RNA molecule comprising (A) a vesiculovirus antigenomic (+) RNA in which a region of the RNA nonessential for replication of the vesiculovirus has been inserted into or replaced by a foreign RNA sequence, and (B) a ribozyme sequence immediately downstream of said antigenomic (+) RNA, that cleaves at the 3' terminus of the antigenomic RNA; and (iii) a transcription termination signal for the RNA polymerase; (b) a second DNA plasmid vector comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter; (ii) a second DNA sequence encoding an N protein of the vesiculovirus; and (iii) a second transcription termination signal for the RNA polymerase; (c) a third DNA plasmid vector comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter; (ii) a third DNA sequence encoding a P protein of the vesiculovirus; and (iii) a third transcription termination signal for the RNA polymerase; (d) a fourth DNA plasmid vector comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter; (ii) a fourth DNA sequence encoding an L protein of the vesiculovirus; and (iii) a fourth transcription termination signal for the RNA polymerase; and (e) a recombinant vaccinia virus comprising a sequence encoding the bacteriophage RNA polymerase; whereby in said cell the first DNA sequence is transcribed to produce said RNA molecule, the N, P, and L proteins and the bacteriophage RNA polymerase are expressed, and a recombinant replicable vesiculovirus is produced that has a genome that is the complement of said antigenomic RNA comprising said foreign RNA sequence. 34. A vaccine formulation comprising an effective immunizing amount of the vesiculovirus of claim 3; and a pharmaceutically acceptable carrier. 35. A vaccine formulation comprising an effective immunizing amount of the recombinant vesiculovirus of claim 4; and a pharmaceutically acceptable carrier. 36. A vaccine formulation comprising an effective immunizing amount of the recombinant vesiculovirus of claim 10; and a pharmaceutically acceptable carrier. 37. A vaccine formulation comprising an effective immunizing amount of a first recombinant vesiculovirus of claim 3; an effective immunizing amount of a second recombinant vesiculovirus of claim 3; and a pharmaceutically acceptable carrier; in which said peptide or protein expressed by the first and second recombinant vesiculoviruses are different. 38. The vaccine formulation of claim 37 in which the peptide or protein expressed by the first recombinant vesiculovirus displays the antigenicity or immunogenicity of an antigen of a first pathogenic microorganism, and the peptide or protein expressed by the second recombinant vesiculovirus displays the antigenicity or immunogenicity of an antigen of a second, different pathogenic microorganism. 39. A method of treating or preventing a disease or disorder in a subject comprising administering to the subject an effective immunizing amount of the recombinant vesiculovirus of claim 3. 40. A method of treating or preventing a disease or disorder in a subject caused by infection by a pathogenic microorganism comprising administering to the subject an effective immunizing amount of the recombinant vesiculovirus of claim 4. 41. A method of treating or preventing a subject having a tumor comprising administering to the subject an effective immunizing amount of the recombinant vesiculovirus of claim 10. 42. The method according to claim 39 in which the subject is a human. 43. The method according to claim 39 in which the subject is a non-human animal. 44. A kit comprising in one or more containers (a) a first recombinant nucleic acid that can be transcribed in a host cell to produce an RNA molecule comprising a vesiculovirus antigenomic (+) RNA, in which a region of the RNA nonessential for replication of the vesiculovirus has been inserted into or replaced by a foreign RNA sequence; (b) a second recombinant nucleic acid encoding and capable of expressing in the host cell a vesiculovirus N protein; (c) a third recombinant nucleic acid encoding and capable of expressing in the host cell a vesiculovirus L protein; and (d) a fourth recombinant nucleic acid encoding and capable of expressing in the host cell a vesiculovirus P protein. 45. A kit comprising in one or more containers (a) a first recombinant nucleic acid that can be transcribed in a host cell to produce an RNA molecule comprising a vesiculovirus antigenomic (+) RNA; (b) a second recombinant nucleic acid encoding and capable of expressing in the host cell a vesiculovirus N protein; (c) a third recombinant nucleic acid encoding and capable of expressing in the host cell a vesiculovirus L protein; and (d) a fourth recombinant nucleic acid encoding and capable of expressing in the host cell a vesiculovirus P protein. 46. A kit comprising in one or more containers (a) a recombinant nucleic acid that can be transcribed to produce an RNA molecule comprising a vesiculovirus antigenomic (+) RNA; and (b) a host cell that recombinantly expresses vesiculovirus N, P, and L proteins. 47. The kit of claim 45 in which said first recombinant nucleic acid further comprises a polylinker in a region that is transcribed to produce said RNA molecule, said region being nonessential for replication of the vesiculovirus. 48. The kit according to claim 45 in which the second recombinant nucleic acid is a DNA plasmid vector comprising the following operatively linked components: (a) a promoter which controls the expression of the N protein; (b) a translation initiation signal; (c) a DNA sequence encoding the N protein; and (d) a transcription termination signal; and in which the third recombinant nucleic acid is a DNA plasmid vector comprising the following operatively linked components: (a) a promoter which controls the expression of the P protein; (b) a translation initiation signal; (c) a DNA sequence encoding the P protein; and (d) a transcription termination signal and in which the fourth recombinant nucleic acid is a DNA plasmid vector comprising the following operatively linked components: (a) a promoter which controls the expression of the L protein; (b) a translation initiation signal; (c) a DNA sequence encoding the L protein; and (d) a transcription termination signal; and in which the first recombinant nucleic acid is a DNA plasmid vector comprising the following operatively linked components: (a) a promoter; (b) a DNA sequence that can be transcribed under the control of the promoter in the cell to produce said RNA molecule, said RNA molecule further comprising a ribozyme sequence immediately downstream of said antigenomic (+) RNA, that cleaves at the 3 ' terminus of the antigenomic (+) RNA, said DNA comprising a polylinker in a region that is transcribed to produce said RNA molecule, said region being nonessential for replication of the vesiculovirus; and (c) a transcription termination signal. 49. The kit of claim 48 in which the promoter is an RNA polymerase promoter, and in which the cell also contains a cytoplasmic source of said RNA polymerase. 50. A kit comprising (a) in a first container a first DNA plasmid vector comprising the following operatively linked components: (i) a bacteriophage RNA polymerase promoter; (ii) a first DNA sequence that can be transcribed in a cell to produce an RNA molecule comprising (A) a vesiculovirus antigenomic (+) RNA in which a region of the RNA nonessential for replication of the vesiculovirus has been inserted into or replaced by a foreign RNA sequence, and (B) a ribozyme sequence immediately downstream of said antigenomic (+) RNA, that cleaves at the 3' terminus of the antigenomic RNA; and (iii) a transcription termination signal for the RNA polymerase; (b) in a second container a second DNA plasmid vector comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter; (ii) a second DNA sequence encoding an N protein of the vesiculovirus; and (iii) a second transcription termination signal for the RNA polymerase; (c) in a third container a third DNA plasmid vector comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter; (ii) a third DNA sequence encoding a P protein of the vesiculovirus; and (iii) a third transcription termination signal for the RNA polymerase; (d) in a fourth container a fourth DNA plasmid vector comprising the following operatively linked components: (i) the bacteriophage RNA polymerase promoter; (ii) a fourth DNA sequence encoding an L protein of the vesiculovirus; and (iii) a fourth transcription termination signal for the RNA polymerase; and (e) in a fifth container a recombinant vaccinia virus comprising a sequence encoding the bacteriophage RNA polymerase. 51. A kit comprising in a container an effective immunizing amount of the vesiculovirus of claim 3. 52. The vesiculovirus of claim 1 which is a vesicular stomatitis virus. 53. The vesiculovirus of claim 4 in which the peptide or protein displays the antigenicity or immunogenicity of an envelope glycoprotein of a virus other than a vesiculovirus. 54. The vesiculovirus of claim 53 in which the envelope glycoprotein is an envelope glycoprotein of a Human Immunodeficiency Virus. 55. The vesiculovirus of claim 53 in which the peptide or protein is incorporated into the vesiculovirus envelope. 56. The vesiculovirus of claim 53 in which the peptide or protein is expressed as a fusion protein comprising the cytoplasmic domain of a vesiculovirus G protein. 57. The vesiculovirus of claim 56 in which the native G protein of the vesiculovirus is not expressed. 58. The vesiculovirus of claim 56 in which the native G protein of the vesiculovirus is also expressed. 59. The vesiculovirus of claim 3 in which a second RNA sequence complementary to said foreign RNA sequence encodes a second peptide or protein that is expressed in the suitable host, in which the first peptide or protein and the second peptide or protein display different antigenicity or immunogenicity. 60. An inactivated recombinant vesiculovirus that is the product of a method comprising inactivating a recombinant replicable vesiculovirus, the genome of which comprises a foreign RNA sequence, in which an RNA sequence complementary to said foreign RNA sequence encodes a peptide or protein that is expressed in a suitable host infected by the recombinant replicable vesiculovirus, and in which the peptide or protein is antigenic or immunogenic. 61. The vesiculovirus of claim 60 in which the peptide or protein displays the antigenicity or immunogenicity of an antigen of a pathogenic microorganism. 62. The vesiculovirus of claim 60 in which the peptide or protein displays the antigenicity or immunogenicity of a tumor specific or tumor associated antigen. 63. The vesiculovirus of claim 60 in which a second RNA sequence complementary to said foreign RNA sequence encodes a second peptide or protein that is expressed in the suitable host, in which the first peptide or protein and the second peptide or protein display different antigenicity or immunogenicity. 64. The vesiculovirus of claim 60 in which the peptide or protein displays the antigenicity or immunogenicity of an envelope glycoprotein of a virus other than a vesiculovirus. 65. The vesiculovirus of claim 64 in which the envelope glycoprotein is an envelope glycoprotein of a Human Immunodeficiency Virus. 66. The vesiculovirus of claim 64 in which the peptide or protein is incorporated into the vesiculovirus envelope. 67. The vesiculovirus of claim 64 in which the peptide or protein is expressed as a fusion protein comprising the cytoplasmic domain of a vesiculovirus G protein. 68. A vaccine formulation comprising an effective immunizing amount of the vesiculovirus of claim 60; and a pharmaceutically acceptable carrier. 69. A vaccine formulation comprising an effective immunizing amount of the vesiculovirus of claim 64; and a pharmaceutically acceptable carrier. 70. A vaccine formulation comprising an effective immunizing amount of the vesiculovirus of claim 66; and a pharmaceutically acceptable carrier. 71. A method of treating or preventing a disease or disorder in a subject comprising administering to the subject an effective immunizing amount of the inactivated recombinant vesiculovirus of claim 60. 72. A kit comprising in a container an effective immunizing amount of the inactivated recombinant vesiculovirus of claim 60. 73. A method for producing a peptide or protein comprising culturing a cell containing the recombinant replicable vesiculovirus of claim 2 in said suitable host; and recovering the expressed peptide or protein. 74. A method for producing an inactivated virus vaccine comprising inactivating a recombinant replicable vesiculovirus, the genome of which comprises a foreign RNA sequence, in which an RNA sequence complementary to said foreign RNA sequence encodes a peptide or protein that is expressed in a suitable host infected by the recombinant replicable vesiculovirus, and in which the peptide or protein is antigenic or immunogenic. International Application No: PCT/ MICROORGANISMS Optional Sheet in connection with the microorganism referred to on page T__, lines 15-35 of the description ' A. IDENTIFICATION OF DEPOSIT ' Further deposits are identified on an additional sheet Name of depositary institution ' American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, MD 20852 US Date of deposit ' May 2, 1995 Accession Number ' 97134 B. ADDITIONAL INDICATIONS ' (leave blank if not applicable) This information is continued on a separate attached sheet C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE ' i^^^ _ τ M ___ p __ iam) D. SEPARATE FURNISHING OF INDICATIONS ' (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later ' {Specify the general nature of the indications e g , "Accession Number of Deposit") E. ETa τ Tihis sheet was received with the International application when filed (to be checked by the receiving Office) (Authorized Officer) D The date of receipt (from the applicant) by the International Bureau " (Authorized Officer) Form PCT/RO/134 (January 1981 )

Inventors: ROSE JOHN K, ROSE, JOHN, K.
Applicants: ROSE JOHN K, UNIV YALE, ROSE, JOHN, K., YALE UNIVERSITY
Application year: 1996
Main classification: A61K39
IPC codes: A61K39, A61P31, C07K14, C07K16, C12N7, C12N15